



IN THE DISTRICT COURT OF CLEVELAND COUNTY
STATE OF OKLAHOMA

Document split into multiple parts

STATE OF OKLAHOMA, ex rel.,)
MIKE HUNTER,)
ATTORNEY GENERAL OF OKLAHOMA,)

PART C

Plaintiff,)

vs.)

Case No. CJ-2017-816
Judge Thad Balkman

- (1) PURDUE PHARMA L.P.;)
- (2) PURDUE PHARMA, INC.;)
- (3) THE PURDUE FREDERICK COMPANY;)
- (4) TEVA PHARMACEUTICALS USA, INC.;)
- (5) CEPHALON, INC.;)
- (6) JOHNSON & JOHNSON;)
- (7) JANSSEN PHARMACEUTICALS, INC;)
- (8) ORTHO-MCNEIL-JANSSEN)
PHARMACEUTICALS, INC., n/k/a)
JANSSEN PHARMACEUTICALS;)
- (9) JANSSEN PHARMACEUTICA, INC.,)
n/k/a JANSSEN PHARMACEUTICALS, INC.;)
- (10) ALLERGAN, PLC, f/k/a ACTAVIS PLC,)
f/k/a ACTAVIS, INC., f/k/a WATSON)
PHARMACEUTICALS, INC.;)
- (11) WATSON LABORATORIES, INC.;)
- (12) ACTAVIS LLC; and)
- (13) ACTAVIS PHARMA, INC.,)
f/k/a WATSON PHARMA, INC.,)

Defendants.)

STATE OF OKLAHOMA } S.S.
CLEVELAND COUNTY }

FILED

MAY 23 2019

In the office of the
Court Clerk MARILYN WILLIAMS

PRETRIAL CONFERENCE ORDER

S-0975	Appropriate Opioid Pharmacotherapy for Chronic Pain Management - A								
S-0976	Multimedia CME Program Email	OKEPERT-00013098 JAN-MS-00826110							PRE; R; H; AU; LF PRE; R; H; AU; LF
S-0977	PriCara Pain Cycle 1 2010 Business Acumen Workshop	JAN-OK-00135646							AU; H; PRE; R; LF
S-0978	Chronic Pain Management: Dependence, Tolerance, Addiction, Abuse and Misuse (Redline)	JAN-MS-00411487							12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0979	Metadata page	JAN-MS-00411487							AU; H; PRE; R; LF
S-0980	Executive Summary - Chronic Pain Scientific Advisory Board	JAN-MS-00654435							12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0981	APS Activities PowerPoint	JAN-MS-00271169							PRE; R; H; AU; LF
S-0982	Director of Stakeholders- Business Plan	JAN-MS-00408676							First Amendment; AU; H; PRE; R; LF Nuisance Statute's Safe-harbor; Preemption; R; PRE; CON; CU; AU; H; PRE; R; LF
S-0983	Defendants Johnson & Johnson, Janssen Pharmaceuticals, Inc., Ortho-McNeil-Janssen Pharmaceuticals, Inc. and Janssen Pharmaceutica, Inc.'s Written Responses and Objections to Topics 17 and 43 in Plaintiffs' Amended Notices of Videotapes 3230(5) Depositions								
S-0984	Nucynta Advocacy, Policy, Quality Activities	JAN-MS-0000409779							R 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0985	Teva List of Schedule II Drugs Developed/Sold								AU; H; PRE; R; LF 12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0986	Teva List of Schedule III-V Opioid-Related Products								AU; H; R 12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0987	FDA U.S. Food & Drug Administration Letter- ANDA Tentative Approval	TEVA_OK_13727811							H; R 12 O.S. 2401, 2402; 12 O.S. 2802

S-0988	A Pain Primer - A Reference for the Rest of Us - TEVA_OK00116240 - TEVA_OK00116250	TEVA_OK00116240	TEVA_OK00116250	Williams 1	AU; H; R; LF; J-MIL-12	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0989	10/17/2005 E-mail Chain From M. Napolitano to P. Castagno, M. Geandreau - TEVA_OK_03810009 - TEVA_OK_03810010	TEVA_OK_03810009	TEVA_OK_03810010	Williams 2	AU; H; R; LF; J-MIL-12	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0990	Guilty Plea Agreement - TEVA_OK_01322516 - TEVA_OK_01322528	TEVA_OK_01322516	TEVA_OK_01322528	Williams 3	H; AU; LF; PO; T-MIL-5	
S-0991	Making Pain Talk Painless - A Guide to Help You Talk with Your Doctor About Pain Management - TEVA_OK_00116233 - TEVA_OK_00116236	TEVA_OK_00116233	TEVA_OK_00116236	Williams 4	AU; H; R; LF; J-MIL-12	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0992	4/9/2004 E-mail Chain - from A. Pyfer to various recipients - TEVA_OK_00785480 - TEVA_OK_00785481	TEVA_OK_00785480	TEVA_OK_00785481	Williams 5	AU; H; R; LF	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-0993	8/15/2006 Cephalon memo - Re_Actiq Sales/Marketing - TEVA_OK_06514598 - TEVA_OK_0654602	TEVA_OK_06514598	TEVA_OK_0654602	Williams 6	H; R; AU; LF; J-MIL-12	12 O.S. 2401, 2402; 12 O.S. 2802
S-0994	Training Tool - TEVA_OK_00116639 - TEVA_OK_00116644	TEVA_OK_00116639	TEVA_OK_00116644	Williams 7	H; R; AU; LF	12 O.S. 2401, 2402; 12 O.S. 2802
S-0995	3/12/2003 PPT slides - Actiq Sales Training - TEVA_OK_05250196 - TEVA_OK_05250242	TEVA_OK_05250196	TEVA_OK_05250242	Williams 8	H; R; AU; LF	12 O.S. 2401, 2402; 12 O.S. 2802
S-0996	9/13/2004 E-mail from N. Shanfelt to Sales Reps. - TEVA_OK_08080018 - TEVA_OK_08080019	TEVA_OK_08080018	TEVA_OK_08080019	Williams 9	H; R; AU; LF	12 O.S. 2401, 2402; 12 O.S. 2802
S-0997	4/22/2005 Cephalon Memo Re_Actiq Segmentation - TEVA_OK_07434010 - TEVA_OK_07434013	TEVA_OK_07434010	TEVA_OK_07434013	Williams 10	H; R; AU; LF	12 O.S. 2401, 2402; 12 O.S. 2802
S-0998	2004 Actiq Marketing Plan	TEVA_OK_00637645	TEVA_OK_00637702	Williams 11	H; R; AU; LF	12 O.S. 2401, 2402; 12 O.S. 2802
S-0999	Cephalon - Employee Self-Appraisal	TEVA_OK00606384	TEVA_OK_00606386	Williams 12	H; R; AU; LF	12 O.S. 2401, 2402; 12 O.S. 2802

S-1000	12/15/2003 Letter Re_Actiq Consultant Meeting - TEVA_OK_0523977 - TEVA_OK_0523980	TEVA_OK_0523977	TEVA_OK_0523980	Williams 13	H; R; AU; LF	12 O.S. 2401, 2402; 12 O.S. 2802
S-1001	Pain Franchise Quarterly Staff Meeting	TEVA_OK_13727304		Williams 14	H; R; AU; LF	12 O.S. 2401, 2402; 12 O.S. 2802
S-1002	Notice			Hassler 1	R; PRE; CU	
S-1003	Chart for Topic 31			Hassler 2	H; R	12 O.S. 2401, 2402; 12 O.S. 2802
S-1004	2004 Actiq Marketing Plan	TEVA_OK_00094427		Hassler 3	H; R; AU; LF	12 O.S. 2401, 2402; 12 O.S. 2802
S-1005	Marketing Plan for 2007 for Femtora	TEVA_OK_0041036		Hassler 4	H; R; AU; LF	12 O.S. 2401, 2402; 12 O.S. 2802
S-1006	Actiq Managed Care Report, 2005	TEVA_OK_04999840		Hassler 5	AU; R; H; LF	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901
S-1007	Actiq Managed Care Report State Lev, March 2004, Actiq State Quarterly Percentage	TEVA_OK_04970821		Hassler 6	AU; R; H; LF	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901
S-1008	Third-party Payor Report for Area 6530, Q3, 2003	TEVA_OK_06825794		Hassler 7	AU; H; R; LF	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1009	National Account Manager April 2008 Monthly Update	TEVA_OK_01020241		Hassler 8	AU; H; R; LF	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1010	Formulary Status Update for Texas, Oklahoma and Louisiana updated August 15th, 2007	TEVA_OK_00597353		Hassler 9	AU; H; R; LF	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1011	Teva's CNS 2012-2014 Work Plan, November 7, 2011	TEVA_OK_03740390		Hassler 10	H; R; AU; LF	12 O.S. 2401, 2402; 12 O.S. 2802
S-1012	Email dated 8-7-2012 from B. Mauk to J. Jacobs	TEVA_OK_067204510		Hassler 11	AU; H; R; LF	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1013	Chart for Topic 17 and 43			Hassler 12	H; R	12 O.S. 2401, 2402; 12 O.S. 2802
S-1014	Deposition Transcript of Phil Cramer, Excerpt			Kyle 1	R; INC; H	12 O.S. 2401, 2402
S-1015	Rough Draft Transcript, Deposition of Kimberly Deem-Eshleman, Excerpt			Kyle 2	First Amendment; AU; H; R; PRE; CON; CU; INC; IC	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1016	Deposition Transcript of Russell Portenoy, M.D.			Kyle 3	Discovery Violations; J-MIL-14	

S-1017	Rough Draft Deposition Transcript of Kimberly Deem-Eshleman, Excerpt				Kyle 4	Discovery Violations; AU; H; INC	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1018	Deposition Transcript of John Hassler, Excerpt				Kyle 5	Discovery Violations; INC; H	
S-1019	Kyle Binder				Kyle 6	Discovery Violations; AU; H; LF	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1020	Kyle Binder				Kyle 7	AU; H; LF	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1021	Systematic Review of the Efficacy and Safety of Long-Term Opioid Therapy in the Management of Chronic Noncancer Pain, POK003056941-3057086				Kyle 8	Discovery Violations; AU; H; R; PRE; CON; CU; LF; T-MIL-4	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1022	5/29/97 E-mail, M. Friedman to M. Cullen, Re_ onyplms.doc - bates nos. PDD9316506216- 9316506218, PDD1741655572-1741655574				Kyle 9	AU; H; R; PRE; CON; CU; LF; T-MIL-4	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1023	Counseling Your Patients and Their Families Regarding the Use of Opioids to Relieve Pain, PDD1502303673-1502303688, PKY180112565-180112580				Kyle 10	Discovery Violations; First Amendment; AU; H; R; PRE; CON; CU; LF; T-MIL-4	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1024	Doctor Who Wrote 1980 Letter On Painkillers Regrets That It Fed The Opioid Crisis,				Kyle 11	H; PRE; R; LF; AU	12 O.S. 2802
S-1025	A 1980 Letter on the Risk of Opioid Addiction				Kyle 12	H; PRE; R; LF; AU	12 O.S. 2802
S-1026	Dispelling the Myths About Opioids, PDD1502312091-1502312119, PKY180120983-180121011				Kyle 13	First Amendment; AU; H; R; PRE; CON; CU; LF; T-MIL-4	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1027	Responsible Opioid Prescribing, Scott M. Fishman, MD, Excerpt				Kyle 14	First Amendment; R; PRE; CON; CU; H; PRE; R; INC	12 O.S. 2403; 12 O.S. 2802
S-1028	How You Can Be a Partner Against Pain and Gain Control Over Your Own Pain, PDD1502312156-1900726340, PKY180121048-182172557				Kyle 15	First Amendment; R; PRE; CON; CU; AU; H; R; PRE; LF; T-MIL-4	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802

S-1029	Call Note	PDD1900726340	PDD1900726340	Kyle 16	R; PRE; CON; CU; AU; H; PRE; LF; T-MIL-4	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1030	Partners Against Pain, PDD890144993-8901045017	PDD890144993-8901045017		Kyle 17	First Amendment; AU; H; R; PRE; CON; CU; LF; T-MIL-4	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1031	I Got My Life Back, Part I, PKY183261902-183261912	PKY183261902-183261912		Kyle 18	Judicial Estoppel; R; PRE; CON; CU; AU; H; R; PRE; LF; T-MIL-4	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1032	8/8/2012 Email from M. Beatriz to Chen, Christine and others - bates nos. JAN-MS-00336316	JAN-MS-00336316		DeMiro 1	AU; H; PRE; R; LF	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1033	3/7/2012 Email from F. DeMiro to L. Furguson and others - bates nos. JAN-MS-00253230 through 231	JAN-MS-00253230	231	DeMiro 2	AU; H; PRE; R; LF	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1034	Decile.ten communications - Nucynta 2010 Speaker Training- East Tapentadol PriCara Division of Ortho-McNeil-Janssen Pharmaceuticals, Inc. 5/13/2011 Email from F. DeMiro to K. Hofbeck, H. Park and others Re_eDatail Project - bates nos. JAN-MS-00255374	JAN-MS-00339240	249	DeMiro 3	AU; H; PRE; R; LF	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1035	12/08/2010 Memo- to J. Christensen, F. DeMiro from J. Kennedy, J. Statham Re_ Summary of PriCara Tapentadol Public Relations Activities November 2010 - bates nos. JAN-MS-00007432 through 433	JAN-MS-00255374		DeMiro 4	AU; H; PRE; R; LF	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1036	7/15/2011 Consulting Agreement- to American Pain Foundation and F. DeMiro and T. Sloan. - bates nos. JAN-MS-0000255 through 263	JAN-MS-00007432	433	DeMiro 5	AU; H; PRE; R; LF	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1037	1/10/2011 Email to J. Christensen from F. DeMiro Re_ Funding decision for "Let's Talk Pain" Coalition partners - bates nos. JAN-MS-00007434 through 435	JAN-MS-0000255	263	DeMiro 6	First Amendment; AU; H; PRE; R; LF	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1038		JAN-MS-00007434	435	DeMiro 7	First Amendment; AU; H; PRE; R; LF	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802

S-1039	8/23/2010 Email to F. DeMiro from J. Statham Re_LTP and Prescribe Responsibly 8/23/2010 pptx - bates no. JAN-MS-0082470	JAN-MS-0082470		DeMiro 8	First Amendment; AU; H; PRE; R; LF	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1040	2011- Tapentadol ER/Tapentadol IR (Purchase Order)	JAN-MS-00000264	266	DeMiro 9	First Amendment; AU; H; PRE; R; LF; J-MIL-12	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1041	7/23/2010 Email from R. Hohn to D. Lin, W. Foster, F. DeMiro, M. Griffin Re_ National Pain Awareness month	JAN-MS-00920608		DeMiro 10	First Amendment; AU; H; PRE; R; LF	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1042	12/19/2012 Amendment to Consulting Agreement between Janssen Pharmaceuticals, Inc. and Ms. Lennie Duensing of the American Academy of Pain Management	JAN-MS-00000267	272	DeMiro 11	First Amendment; AU; H; PRE; R; LF	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1043	12/5/2012 Nucynta & Nucynta ER 2012 Business Plan - Tactic Review - bates nos. JAN-MS-01119969	JAN-MS-01119969		DeMiro 12	First Amendment; H; R; PRE; LF; AU	12 O.S. 2401, 2402; 12 O.S. 2802
S-1044	Johnson & Johnson Code of Business Conduct - Live our Credo, Know Our Code PPT			Mashett 1	AU; H; R; PRE; CON; CU; LF	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1045	Chart of Rates of Opioid Sales, OD Deaths, and Treatment, 1999-2010 by the CDC			Mashett 2	AU; H; R; PRE; CON; CU; LF; PR/AU; T-MIL-1, SUM	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1046	"The Tasmanian Poppy Industry: A Case Study of the Application of Science and Technology" by A. J. Fist			Mashett 3	Nuisance Statute's Safe-harbor; AU; H; PRE; R; LF	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1047	5/30/03 Email from Mike Kindergarten to Rick Blockinger - Subject: Noramco Attachments: TOAC.ppt - Bates# JAN-MS-00725218	JAN-MS-00725218		Mashett 4	PRE; R; H; LF; AU; J-MIL-4	
S-1048	October 2015 Noramco World Wide Narcotics Franchise PowerPoint Slide Deck - Bates# JAN-OK-00149992 - JAN-OK-00150068	JAN-OK-00149992	JAN-OK-00150068	Mashett 5	PRE; R; H; LF; AU; J-MIL-4	
S-1049	Noramco Controlled Substance Active Ingredients for the Pharmaceutical Industry			Mashett 6	Nuisance Statute's Safe-harbor; AU; H; PRE; R; LF; J-MIL-4	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1050	Spreadsheet of Drug Manufacturers, Drugs, and APIs Created by Plaintiff's Counsel			Mashett 7	Nuisance Statute's Safe-harbor; AU; H; PRE; R; LF; J-MIL-4; SUM	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802

S-1051	Noramco Sales Report December 2000 Index	NORAMCO00000001		Mashett 8	PRE; R; H; LF; AU; J-MIL-4	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1052	Noramco Sales Report December 2001 Index	NORAMCO00000002		Mashett 9	Nuisance Statute's Safe-harbor; AU; H; PRE; R; LF; J-MIL-4	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1053	Noramco Sales Report December 2002 Index	NORAMCO00000003		Mashett 10	Nuisance Statute's Safe-harbor; AU; H; PRE; R; LF; J-MIL-4	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1054	Noramco Sales Report December 2003 Index	NORAMCO00000004		Mashett 11	Nuisance Statute's Safe-harbor; AU; H; R; PRE; LF; J-MIL-4	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1055	Noramco Sales Report December 2004 Index	NORAMCO00000005		Mashett 12	Nuisance Statute's Safe-harbor; AU; H; PRE; R; LF; J-MIL-4	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1056	Noramco Sales Report December 2005 Index	NORAMCO00000006		Mashett 13	Nuisance Statute's Safe-harbor; AU; H; PRE; R; LF; J-MIL-4	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1057	Noramco Sales Report December 2006 Index	NORAMCO00000007		Mashett 14	Nuisance Statute's Safe-harbor; AU; H; PRE; R; LF; J-MIL-4	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1058	Noramco Sales Report December 2007 Index	NORAMCO00000008		Mashett 15	Nuisance Statute's Safe-harbor; R; PRE; H; LF; AU; J-MIL-4	12 O.S. 2401, 2402
S-1059	Noramco Sales Report December 2008 Index	NORAMCO00000009		Mashett 16	Nuisance Statute's Safe-harbor; AU; H; PRE; R; LF; J-MIL-4	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1060	Noramco Sales Report December 2009 Index	NORAMCO00000010		Mashett 17	Nuisance Statute's Safe-harbor; AU; H; R; PRE; LF; J-MIL-4	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1061	Noramco Sales Report December 2011 Index	NORAMCO00000012		Mashett 18	Nuisance Statute's Safe-harbor; AU; H; PRE; R; LF; J-MIL-4	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1062	Noramco Sales Report December 2012 Index	NORAMCO00000013		Mashett 19	Nuisance Statute's Safe-harbor; AU; H; PRE; R; LF; J-MIL-4	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1063	Noramco Sales Report December 2013 Index	NORAMCO00000014		Mashett 20	Nuisance Statute's Safe-harbor; AU; H; PRE; R; LF; J-MIL-4	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1064	Noramco Sales Report December 2014 Index	NORAMCO00000015		Mashett 21	Nuisance Statute's Safe-harbor; AU; H; PRE; R; LF; J-MIL-4	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1065	Noramco Sales Report December 2015 Index	NORAMCO00000016		Mashett 22	Nuisance Statute's Safe-harbor; AU; H; PRE; R; LF; J-MIL-4	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1066	Noramco Sales Report December 2016 Index	NORAMCO00000017		Mashett 23	Nuisance Statute's Safe-harbor; AU; H; PRE; R; LF; J-MIL-4	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1067	GAO Report to Congressional Requesters - December 2003 Prescription Drugs - OxyContin Abuse and Diversion and Efforts to Address the Problem			Mashett 24	H; R; PRE; CON; CU; AU; LF; PR/AU; T-MIL-1, SUM	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2802

S-1068	5/10/07 Statement of United States Attorney John Brownlee on the Guilty Plea of the Purdue Frederick Company and its Executives for Illegally Misbranding OxyContin			Mashett 25	R; PRE; CON; CU; AU; H; PRE; LF; T-MIL-4	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1069	Business Dealings with Other Opioid Manufacturers Prepared Based on a Reasonable Investigation Conducted as of the Deposition of Frank Mashett on January 30, 2019			Mashett 26	AU; H; R; PRE; CON; CU; SUM	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1070	USA v. Cephalon, Inc. - Government's Memorandum for Entry of Plea and Sentencing			Mashett 27	AU; H; R; PRE; CON; CU; PO, T-MIL-5	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1071	Groundhog - Top 5 Customers - Janssen Document - Bates# JAN-OK-00150475	JAN-OK-00150475		Mashett 28	AU; H; PRE; R; LF	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1072	Ultram & Line Extensions - GLCP Executive Summary USA - Bates# JAN-MS-00456505 - JAN-MS- 00456509	JAN-MS-00456505	JAN-MS-00456509	Mashett 29	PRE; CON; CU; AU; H; R; LF	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1073	Ron Kuntz (G01-340) Project Rose Open PowerPoint	JAN-MS-01002292		Mashett 30	R; PRE; CON; CU; AU; H; PRE; LF	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1074	Notice of Deposition			Hassler 1	R; PRE; CU	
S-1075	Sales and Marketing Expenditure - Chart for Topics 17 & 43 (based on Bates #s TEVA_OK_02321353 & TEVA_OK_01218820			Hassler 2	R; PRE; CON; CU; AU; H; PRE	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1076	Information from Finance Team - chart in response to Topic 18 (based on Bates #s TEVA_OK_003300696 & TEVA_OK_02321353)			Hassler 3	R; PRE; CON; CU; AU; H; PRE	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1077	Table of Clinical Studies	TEVA_OK_08952668		Hassler 4	Judicial Estoppel; R; PRE; CON; CU; AU; H; R; LF	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1078	Fentora Product Spend 2008 Budget	TEVA_OK_00046276		Hassler 5	R; PRE; CON; CU; AU; H; PRE; LF	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1079	November 4, 2013 E-mail	TEVA_OK_02237905		Hassler 6	R; PRE; CON; CU; AU; H; PRE; LF	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802

S-1080	GMA Function	TEVA_OK_06825794		Hassler 7	R; PRE; CON; CU; AU; H; PRE; LF	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1081	2017 Brand Planning	TEVA_OK_02599842		Hassler 8	R; PRE; CON; CU; AU; H; PRE; LF	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1082	Training Guide	TEVA_OK_00028230		Hassler 9	R; PRE; CON; CU; AU; H; PRE; LF	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1083	Reimbursement Process and Procedure Guide	TEVA_OK_00510198		Hassler 10	H; R; AU; LF	12 O.S. 2401, 2402; 12 O.S. 2802
S-1084	October 2004 Rob Host Monthly Update	TEVA_OK_06598017		Hassler 11	AU; H; R; LF	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1085	2005 Actiq Marketing Plan	TEVA_OK_00094427		Hassler 12	AU; H; R; LF	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1086	May 23, 2005 Email	TEVA_OK_00598841		Hassler 13	AU; H; LF	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1087	Medicaid Document	TEVA_OK_00585606		Hassler 14	AU; H; R; LF	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1088	Formulary Status Update	TEVA_OK_00586856		Hassler 15	AU; H; R; LF	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1089	Actiq 2002 Marketing Plan	TEVA_OK_03187758		Hassler 16	AU; H; R; LF	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1090	Teva Code of Conduct			Hassler 17	AU; H; R	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1091	9/25/13 Email	TEVA_OK_03073209		Hassler 18	AU; H; LF	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1092	Minutes of a Meeting of Board	PDD9316315973	PDD9316315978	Hassler 19	AU; H; R; PRE; CON; CU; LF; T-MIL-4	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1093	"Purdue Sales" Oxycodone ER Generic Q&A	POK003278476		Hassler 20	AU; H; R; PRE; CON; CU; LF; T-MIL-4	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802

S-1094	Distribution and Supply Agreement	TEVA_OK-03321424		Hassler 21	AU; H; R; LF; PRE; T-MIL-4	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1095	Noramco World Wide Narcotics Franchise	JAN-OK-00149992		Hassler 22	PRE; R; H; LF; AU; J-MIL-4	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1096	"Sales" Purdue Memo	POK003276557		Hassler 23	AU; H; R; PRE; CON; CU; LF; T-MIL-4	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1097	Letter to Lecture Bureau Re: Diversion	PKY180336009	PKY180336010	Kyle 19	First Amendment; R; PRE; CON; CU; AU; H; R; PRE; LF; T-MIL-4	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1098	Annals of Internal Medicine Volume 78, Number 2			Kyle 20	Judicial Estoppel; R; PRE; CON; CU; H; PRE; R; LF; AU	12 O.S. 2403; 12 O.S. 2802
S-1099	Addiction Research Report - Risk factors for drug dependence among out-patients on opioid therapy in a large US health care system			Kyle 21	Judicial Estoppel; R; PRE; CON; CU; H; PRE; R; LF; AU	12 O.S. 2403; 12 O.S. 2802
S-1100	MedPage - Chronic Pain Fuels Boom in Opioids			Kyle 22	First Amendment; R; PRE; CON; CU; AU; H; PRE; R; LF	12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1101	Frequently Asked Questions About Actiq	TEVA_OK_07226345	TEVA_OK_07226353	Kyle 23	AU; H; R; LF	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1102	Original Article - Long-Term Use of Controlled-Release Oxycodone for Noncancer Pain: Results of a 3-year Registry Study			Kyle 24	First Amendment; Judicial Estoppel; R; PRE; CON; CU; H; PRE; J-MIL-14; LF; AU	12 O.S. 2403; 12 O.S. 2802
S-1103	Clinical Note - Opioid Pseudoaddiction - An Iatrogenic Syndrome	PKY183228610	PKY183228613	Kyle 25	H; AU; LF; R; PRE	
S-1104	Clinical Note - Opioid Pseudoaddiction - An Iatrogenic Syndrome			Kyle 26	First Amendment; Judicial Estoppel; R; PRE; CON; CU; AU; H; PRE; LF	12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1105	Proposed Target KOLs for PPR Communications	PPLP004268991		Kyle 27	First Amendment; AU; H; R; PRE; CON; CU; LF; J-MIL-7; T-MIL-4	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1106	The Truth About Pain Management	PKY183027554	PKY183027568	Kyle 28	First Amendment; Judicial Estoppel; R; PRE; CON; CU; AU; H; R; PRE; LF; J-MIL-7; T-MIL-4	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802

S-1107	Use of Opioids in Chronic Noncancer Pain	PKY181076347	PKY181076362	Kyle 29	First Amendment; AU; H; R; PRE; CON; CU; LF; J-MIL-7; T-MIL-4	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602; 12 O.S. 2901; 12 O.S. 2802
S-1108	NIH Archives - Continuing Concern Over Imported Pharmaceuticals			Kyle 30	First Amendment; R; PRE; CON; CU; H; PRE; R; AU; LF; J-MIL-7; T-MIL-4	12 O.S. 2403; 12 O.S. 2802
S-1109	Statement of United States Attorney John Brownlee on the Guilty Plea of the Purdue Frederick Company and its Executives for Illegally Misbranding Oxycontin			Kyle 31	R; PRE; CON; CU; H; PRE; AU; LF; J-MIL-7; T-MIL-4; J-MIL-1	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2802
S-1110	Partners Against Pain Website	PKY180131556	PKY180131569	Kyle 32	First Amendment; Judicial Estoppel; R; PRE; CON; CU; AU; H; R; PRE; LF; J-MIL-7; T-MIL-4	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602; 12 O.S. 2901; 12 O.S. 2802
S-1111	Pain Management: The 5th Vital Sign	PKY180797978	PKY180798059	Kyle 33	First Amendment; R; PRE; CON; CU; AU; H; R; PRE; LF	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602; 12 O.S. 2901; 12 O.S. 2802
S-1112	6-19-18 Draft Internal Document by Don Kyle President's Commission on Combating Drug Addiction and the Opioid Crisis (portion)	PPLPC30000156697	VPLPC30000156699	Kyle 34	R; PRE; CON; CU; AU; H; PRE; LF; J-MIL-7; T-MIL-4	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602; 12 O.S. 2901; 12 O.S. 2802
S-1113				Kyle 35	R; PRE; CON; CU; H; PRE; T-MIL-1	12 O.S. 2403; 12 O.S. 2802
S-1114	OxyContin Quick Conversion Guide	PPLP030000276059		Kyle 36	R; PRE; CON; CU; AU; H; PRE; LF; J-MIL-7; T-MIL-4	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602; 12 O.S. 2901; 12 O.S. 2802
S-1115	Top Gun Advertisement			Kyle 37	AU; H; R; PRE; LF; J-MIL-7; T-MIL-4	12 O.S. 2401, 2402; 12 O.S. 2602; 12 O.S. 2901; 12 O.S. 2802
S-1116	Overview of Public Affairs	PKY181306077	PKY181306097	Kyle 38	First Amendment; R; PRE; CON; CU; AU; H; R; PRE; LF; J-MIL-7; T-MIL-4	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602; 12 O.S. 2901; 12 O.S. 2802
S-1117	Public Relations Program - Pain: The 5th Vital Sign	PKY183052626	PKY183052629	Kyle 39	First Amendment; R; PRE; CON; CU; AU; H; R; PRE; LF; J-MIL-7; T-MIL-4	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602; 12 O.S. 2901; 12 O.S. 2802
S-1118	8-27-99 Email from Maurie Temple Re: Pain - The 5th Vital Sign	PKY180233461	PKY180233461	Kyle 40	First Amendment; R; PRE; CON; CU; AU; H; R; PRE; LF; J-MIL-7; T-MIL-4	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602; 12 O.S. 2901; 12 O.S. 2802
S-1119	Purdue Pharma Mailer	PKY180108987	PKY180108994	Kyle 41	First Amendment; R; PRE; CON; CU; AU; H; R; PRE; LF; J-MIL-7; T-MIL-4	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602; 12 O.S. 2901; 12 O.S. 2802

S-1120	Email String Re: PROP.	PPLP004325104	PPLP004325105	Kyle 42	First Amendment; R; PRE; CON; CU; AU; H; R; PRE; LF; J-MIL-7; T-MIL-4	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1121	US Patent - Kyle.			Kyle 43	R; PRE; CON; CU; H; PRE; AU; LF; J-MIL-7; T-MIL-4	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2802
S-1122	US Patent Udell, et al			Kyle 44	R; PRE; CON; CU; H; PRE; AU; LF; J-MIL-7; T-MIL-4	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2802
S-1123	8-12-99 Email from Stuart Baker to Michael Friedman and James Dolan with attachment	PKY181824236	PKY181824245	Kyle 45	R; PRE; CON; CU; AU; H; PRE; LF; J-MIL-7; T-MIL-4	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1124	Clinical Trials for OxyContin (Original and Reformulated)			Kyle 46	Judicial Estoppel; R; PRE; CON; CU; AU; H; R; PRE; LF; J-MIL-7; T-MIL-4	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1125	Post-Marketing OxyContin Epidemiology Study Program			Kyle 47	Judicial Estoppel; R; PRE; CON; CU; AU; H; R; PRE; LF; J-MIL-7; T-MIL-4	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1126	January 1996 FDA-approved labeling for OxyContin	PDD1501602953		Kyle 48	AU; H; R; PRE; CON; CU; LF; J-MIL-7; T-MIL-4	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1127	Boston Collaborative Drug Surveillance Program			Kyle 49	R; PRE; CON; CU; AU; H; PRE; LF	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1128	Cancer Pain Relief Article	8100237248	8100237287	Kyle 50	R; PRE; CON; CU; H; PRE; AU; LF	12 O.S. 2403; 12 O.S. 2802
S-1129	Cancer Pain Relief and Palliative Care			Kyle 51	R; PRE; CON; CU; H; PRE; AU; LF	12 O.S. 2403; 12 O.S. 2802
S-1130	The Management of Pain by John J.nBonica			Kyle 52	First Amendment; AU; H; LF	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1131	New Drug Application, Volume 105	POK000157097	POK000157200	Kyle 53	R; PRE; CON; CU; AU; H; PRE; LF	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1132	National Institute on Drug Abuse Research Report - Prescription Drugs: Abuse and Addiction			Kyle 54	R; PRE; CON; CU; H; PRE; AU; LF	12 O.S. 2403; 12 O.S. 2802
S-1133	Bonica's Management of Pain			Kyle 55	First Amendment; R; PRE; CON; CU; AU; H; PRE; LF	12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1134	JAMA Evidence Glossary			Kyle 56	R; PRE; CON; CU; H; PRE; AU; LF	12 O.S. 2403; 12 O.S. 2802
S-1135	Works in Progress - Oxycodone CR	PDD1701604291	PDD1701604295	Kyle 57	First Amendment; AU; H; R; PRE; CON; CU; LF	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802

S-1136	Long-Acting Opioids for Severe Chronic Daily Headache	PKY180680394	PKY180680409	Kyle 58	First Amendment; R; PRE; CON; CU; AU; H; R; PRE; LF; J-MIL-7; T-MIL-4	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1137	Budget Presentation- Marketing & Sales Department	PKY180235563	PKY180235633	Kyle 59	AU; H; R; PRE; CON; CU; LF; J-MIL-7; T-MIL-4; J-MIL-1	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1138	Deposition Notice			Colligen 1	R	
S-1139	6/1/12 E-mail to S. Brigner from A. Must Re_ State Section Materials - June 6 Meeting - bates nos. PPLP031000933917-918	PPLP031000933917-918		Colligen 2	First Amendment; AU; H; R; PRE; CON; CU; LF; J-MIL-7; T-MIL-4	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1140	3A- Topic 41 Reference Binder, 1 of 2			Colligen 3A	AU; H; R; PRE; CON; CU; J-MIL-2	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1141	3A- Topic 41 Reference Binder, 1 of 2			Colligen 3B	AU; H; R; PRE; CON; CU; J-MIL-2	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1142	2/25/14 E-mail from A. Nicole to R. Kuntz and others Re_ Oklahoma Pain/Opioid Legislation Movement Flag- bates no. JAN-MS-00984596	JAN-MS-00984596		Colligen 4	First Amendment; AU; H; LF; J-MIL-2	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1143	3/11/08 E-mail from L. Leonard to R. Kuntz and Attachment: Pain Policy Final PPT - bates no. JAN- MS-00442777	JAN-MS-00442777		Colligen 5	First Amendment; AU; H; LF; J-MIL-2	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1144	2/21/08 E-mail from G. Vorsanger to B. Moskovitz - bates nos. JAN-MS-02149085-02149094	JAN-MS-02149085-02149094		Colligen 6	First Amendment; AU; H; LF; J-MIL-2	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1145	2/19/08 E-mail from G. Vorsanger to M. Quinn, S. Zalensky and others Re_ Nebraska - Tramadol legislation - bates nos. JAN-MS-02149093-02149094	JAN-MS-02149093-02149094		Colligen 7	First Amendment; AU; H; LF; J-MIL-2	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1146	DUR Board, Wednesday, 4/11/12 Minutes	OKG00013637		Colligen 8	AU; H; LF; J-MIL-2	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1147	4/6/12 E-mail from W. Russell to E. Anderson - bates nos. JAN-OK-00134927-00134928	JAN-OK-00134927-00134928		Colligen 9	AU; H; LF; J-MIL-2	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1148	Our Credo, Johnson & Johnson			Colligen 10	AU; H; R; LF	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802

S-1149	Memo dated 7-16-1990 from R. Kaiko to P. Goldenheim, M. Friedman and R. Sackler	PDD9316718973	PDD9316718975	Hassler 25	Preemption; AU; H; R; PRE; CON; CU; LF; J-MIL-7; T-MIL-4	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1150	Tealink Newsletter	PDD9316703679	PDD9316703690	Hassler 26	AU; H; R; PRE; CON; CU; LF; J-MIL-7; T-MIL-4	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1151	Email chain including an email dated 6-2-1997 from M. Cullen	PKY181422992	PKY181422994	Hassler 27	AU; H; R; PRE; CON; CU; LF; J-MIL-7; T-MIL-4	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1152	Email dated 5-28-1997 from R. Sackler to M. Friedman	PKY183238391		Hassler 28	AU; H; R; PRE; CON; CU; LF; J-MIL-7; T-MIL-4	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1153	Actiq Master Plan from November 16, 2000	TEVA_OK_00094174		Hassler 29	AU; H; R; LF	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1154	Testimony of P. Goldenheim before the Senate Committee	PKY181425353	PKY181425358	Hassler 30	AU; H; R; PRE; CON; CU; LF; J-MIL-7; T-MIL-4	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1155	GAO Report			Hassler 31	AU; H; R; LF; PRE; J-MIL-7; T-MIL-4	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1156	Statement of U.S. Attorney John Brownlee			Hassler 32	AU; H; R; PRE; CON; CU; LF; J-MIL-7; T-MIL-4	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1157	Canister of Johnson & Johnson Baby Powder			KDE 1	Inadmissible Character Evidence; R; PRE; CON; CU; AU; H; R; PRE; LF; J-MIL-13; SCOPE	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1158	Bottle of Johnson & Johnson's Baby Shampoo			KDE 2	AU; H; R; PRE; LF; J-MIL-13; CON; SCOPE	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1159	Johnson & Johnson Code of Business Conduct			KDE 3	AU; H; R; PRE; LF	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1160	Excerpt from 12/18/19 Deposition of Kimberly-Deem Eshleman			KDE 4	H; INA	
S-1161	6/17/10 Email from Robyn Kohn to Kimberly-Deem Eshleman and Others Subject: RKDENUCYNATA ER Launce Governance Market Access61710.pptx	JAN-MS-00330383		KDE 5	First Amendment; AU; H; R; PRE; LF	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802

S-1162	4/10/08 Email from Lynn Leonard to Ron Kuntz - Subject: GCT pres. - PR, McNeil Employees - Subject: Re: Non Branded Round 2 - Final Report Review	JAN-MS-00500562	KDE 6	R; H; PRE; LF; AU	
S-1163	11/30/07 Email from Christina Belza to Ortho-McNeil Employees - Subject: Re: Action Plan - Unbranded Campaign	JAN-MS-02565580&JAN-MS-02565581	KDE 7	H; R; PRE; LF; AU	12 O.S. 2802
S-1164	9/26/2011 Imagine the Possibilities Pain Coalition PowerPoint Presentation	JAN-MS-01135718	KDE 8	R; PRE; CON; CU; AU; H; PRE; LF	12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1165	11/1/01 Email from Robyn Kohn to Tricia Haertlein - Subject: Meeting 2 outputsRkohn 111.pptx	JAN-MS-00939970	KDE 9	PRE; CON; CU; AU; H; R; LF	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1166	Imagine the Possibilities Pain Coalition - Directors	JAN-MS-00940011	KDE 10	PRE; CON; CU; AU; H; R; LF	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1167	12/12/11 Email from Penney Cowan to Robyn Kohn - Subject: RE: Growing Pains	JAN-MS-00402851	KDE 11	PRE; CON; CU; AU; H; R; LF	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1168	Growing Pains Website Screenshot "Accept the Pain"	JAN-MS-00396378	KDE 12	First Amendment; PRE; CON; CU; AU; H; R; PRE; LF; J-MIL-5	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1169	Growing Pains Website Screenshot "Know Your Emotions"		KDE 13	First Amendment; PRE; CON; CU; AU; H; R; PRE; LF; J-MIL-5	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1170	Growing Pains Website Screenshot "Communicating to Others"		KDE 14	First Amendment; PRE; CON; CU; AU; H; R; PRE; LF; J-MIL-5	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1171	Growing Pains Website Screenshot "Family"		KDE 15	First Amendment; PRE; CON; CU; AU; H; R; PRE; LF; J-MIL-5	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1172	Growing Pains Website Screenshot "Parents"		KDE 16	First Amendment; PRE; CON; CU; AU; H; R; PRE; LF; J-MIL-5	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1173	Growing Pains Website Screenshot "Know Your Rights"		KDE 17	First Amendment; PRE; CON; CU; AU; H; R; PRE; LF; J-MIL-5	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1174	Growing Pains Website Screenshot "Assert Your Rights"		KDE 18	PRE; CON; CU; AU; H; R; LF; J-MIL-5	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1175	Growing Pains Website Screenshot "Know Your Rights"		KDE 19	PRE; CON; CU; AU; H; R; LF; J-MIL-5	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1176	Growing Pains Website Screenshot "Know Your Rights"		KDE 20	PRE; CON; CU; AU; H; R; LF; J-MIL-5	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802

S-1177	The Pulse - Opioid Epidemic in Central Oklahoma Youth				KDE 21	AU; H; R; PRE; LF; J-MIL-5	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1178	1/25/12 Email from Robyn Kohn to Malcom Monaghan and Lisa Ferguson - Subject: FW: Sen. Bernadette Sanchez introduces legislation on drug abuse	JAN-MS-00404945			KDE 22	First Amendment; R; PRE; CON; CU; AU; H; R; PRE; LF; J-MIL-2	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1179	Lennen & Newell, Inc. Advertising Letter from Nicholas Keesely to Manuel Yellen				KDE 23	PRE; CON; CU; AU; H; R; LF; J-MIL-5	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1180	Tobacco Company Marketing to Kids by Campaign for Tobacco-Free Kids				KDE 24	PRE; CON; CU; AU; H; R; LF; J-MIL-5	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1181	USA v. Philip Morris Judgment				KDE 25	PRE; CON; CU; AU; H; R; LF; J-MIL-5	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1182	Lucky Strike Ad - "Luckies, less irritating"				KDE 26	AU; H; R; PRE; CON; CU; LF; J-MIL-5	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1183	9/27/95 Purdue OxyContin Launch Plan	PKY180111098			KDE 27	AU; H; R; PRE; CON; CU; LF; J-MIL-7; T-MIL-4	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1184	9/22/04 Email from Gary Vorsanger to Janssen and Purdue Employees - Subject: FW: Oxycontin abuse; GAO Report	JAN-MS-02130028			KDE 28	AU; H; R; LF; PRE; J-MIL-7; T-MIL-4	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1185	Assumptions - Overview of Opioids in the market	PKY180199464			KDE 29	AU; H; R; PRE; CON; CU; LF; J-MIL-7; T-MIL-4	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1186	Nucynta Lexicon Research Questionnaire	JAN-MS-00484636			KDE 30	AU; H; R; PRE; LF	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1187	Pain Advocacy Coalition Kick-Off Meeting Summary and Contact Report for Meeting Held on February 22, 2008	JAN-MS-01239405			KDE 31	First Amendment; H; R; PRE; LF; AU; J-MIL-3	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1188	2/29/08 Email from Chris Handler to let's Talk Pain Coalition and Others - Subject: "Let's Talk Pain" Coalition Meeting Summary	JAN-MS-01239405			KDE 32	First Amendment; AU; H; R; PRE; LF; J-MIL-3	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802

S-1189	2011 Tapentadol Purchase Order 5/9/12 Email from Jeffrey Christensen to Robyn Kohn - Subject: Re: WASH POST-Senate Inquiry-DURAGESIC	JAN-MS-00000264		KDE 33	AU; H; R; PRE; LF; J-MIL-3	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1190		JAN-MS-00927417		KDE 34	First Amendment; AU; H; R; PRE; LF; J-MIL-3	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1191	Pain Brief Advocacy & Policy Monthly - 2011 E-mail from Lynn Leonard to Ron Kuntz; Subject: Pain Policy Final.ppf, with PowerPoint presentation	JAN-MS-00403640		KDE 35	First Amendment; PRE; CON; CU; AU; H; R; PRE; LF; J-MIL-3	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1192	E-mail Chain; Subject: October Conference - NASCA support	JAN-MS-00442777		Buel 1	First Amendment; AU; H; R; PRE; LF	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1193	E-mail Chain; Subject: August 27	JAN-MS-02970062		Buel 2	First Amendment; AU; H; J-MIL-2; T-MIL-10; LF	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1194	E-mail Chain; Subject: August 27	JAN-MS-02145054		Buel 3	First Amendment; AU; H; J-MIL-2; T-MIL-10	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1195	E-mail from SGA Update; Subject: State Government Affairs Update - January 2005	JAN-MS-00434088		Buel 4	First Amendment; Inadmissible Character Evidence; R; PRE; CON; CU; AU; H; R; PRE; J-MIL-2; T-MIL-10; LF	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1196	E-mail from Robyn Kohn to John Hoffman; Subject: Update & 2013 Advocacy Business Planning PAIN 82102.pptx, with PowerPoint Presentation	JAN-MS-00393084		Buel 5	First Amendment; PRE; CON; CU; AU; H; J-MIL-2; T-MIL-10; LF	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1197	E-mail Chain; Subject: Urgent Help in NM from pain care forum	JAN-MS-00926915		Buel 6	First Amendment; Judicial Estoppel; R; PRE; CON; CU; AU; H; R; PRE; J-MIL-2; T-MIL-10; LF	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1198	E-mail Chain; Subject: Article on Opioid bill E-mail Chain; Subject: NM Residents - Take action to stop SB 159 and protect access to pain care	JAN-MS-00263772		Buel 7	First Amendment; Judicial Estoppel; R; PRE; CON; CU; AU; H; R; PRE; J-MIL-2; T-MIL-10; LF; J-MIL7; T-MIL-4	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1199	E-mail Chain; Subject: Draft council recommendations for discussion Friday	SFC00007801		Buel 8	J-MIL-2; T-MIL-10; AU; LF; H	
S-1200		JAN-MS-02304317		Buel 9	First Amendment; R; PRE; CON; CU; H; R; PRE; J-MIL-2; T-MIL-10; AU; LF	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2802
S-1201	E-mail Chain; Subject: OpioidBestPractices.ppt	TWILLMAN037246		Buel 10	First Amendment; R; PRE; CON; CU; H; R; PRE; J-MIL-2; T-MIL-10; AU; LF	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2802

S-1202	E-mail Chain; Subject: For Transmittal to State Section	PPLPC031000168544	PPLPC031000168546	Buel11	First Amendment; AU; H; R; PRE; CON; CU; J-MIL-2; T-MIL-10; LF	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1203	E-mail from Bruce Colligen; Subject: Update: Connecticut Gross Receipts Tax on Controlled Substance and Narcotics Sales	JAN-MS-02964938		Buel12	First Amendment; R; PRE; CON; CU; AU; H; R; PRE; J-MIL-2; T-MIL-10; LF	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1204	E-mail chain; subject: NASPER Reauthorization	JAN-MS-00935073		Buel13	J-MIL-2; T-MIL-10; AU; LF; H	
S-1205	E-mail Chain; Subject: Sen. Bernadette Sanchez introduces legislation on drug abuse	JAN-MS-00404946		Buel14	First Amendment; R; PRE; CON; CU; AU; H; R; PRE; J-MIL-2; T-MIL-10; LF	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1206	E-mail chain; Subject: updated Directory	JAN-MS-00402849		Buel15	First Amendment; AU; H; LF; R; PRE	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1207	E-mail from Robyn Kohn to Tricia Haertlein; Subject; Meeting 2 OutputsRkohn 111.pptx, with PowerPoint Presentation	JAN-MS-00940011		Buel16	First Amendment; PRE; CON; CU; AU; H; R; PRE; LF	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1208	Key Decision, Action Items, and Follow-Up to 1/20/12 ITPPC Meeting	JAN-MS-00940141		Buel17	PRE; CON; CU; AU; H; LF; R	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1209	E-mail from Tricia Haertlein; Subject: Tapentadol Coalition - Mindy/Gary/Robyn meet	JAN-MS-00949251		Buel18	First Amendment; AU; H; LF; R; PRE	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1210	E-mail Chain; Subject; Pain Coalition 1/24 Meeting	JAN-MS-02496805		Buel19	First Amendment; AU; H; LF; R; PRE	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1211	E-mail from Mindy Hall; Subject: Meeting Output, with PowerPoint Presentation	JAN-MS-00939605		Buel20	PRE; CON; CU; AU; H; LF; R	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1212	Imagine The Possibilities Pain Coalition, May 2, 2012, Meeting 4 Output PowerPoint Presentation	JAN-MS-01480094		Buel21	PRE; CON; CU; AU; H; LF; R; J-MIL-5	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1213	Lucky Strike Ad - "Get Lucky"			KDE 36	AU; H; R; PRE; CON; CU; LF; J-MIL-5	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1214	7/23/10 Email from Robyn Kohn to J&J Employees - Subject: Re: National Pain Awareness Month	JAN-MS-00920608		KDE 37	AU; R; H; PRE; LF; J-MIL-3	12 O.S. 2602, 12 O.S. 2901
S-1215	Excerpt from the Deposition of Russell Portenoy, M.D. Taken on 1/24/19			KDE 38	Discovery Violations; First Amendment; AU; H; INC; J-MIL-14	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802

S-1216	PAINS Project Packet	JAN-MS-00397451			KDE 39	First Amendment; AU; H; R; PRE; LF; J-MIL-3	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1217	8/22/12 Email from Robyn Kohn to John Hoffman - Subject: update & 2013 Advocacy Business Planning PAIN82102.pptx	JAN-MS-00393084			KDE 40	First Amendment; PRE; CON; CU; AU; H; R; PRE; LF; J-MIL-3; J-MIL-2	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1218	Pain Care Forum Participating Organizations	JAN-MS-00992093			KDE 41	R; H; PRE; LF; AU; J-MIL-3	
S-1219	PAINS Project 2012 Annual Meeting Invitees	JAN-MS-00411906			KDE 42	R; H; PRE; LF; AU; J-MIL-3	
S-1220	Oklahoma Injury Prevention Service "Opioid Services"				KDE 43	AU; H; LF; SUM	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1221	Rates of Opioid Sales, OD Deaths, and Treatment, 1999-2010 CDC Graph				KDE 44	AU; H; LF; SUM	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1222	Communications and External Affairs Committee April 24th Minutes/Action Items	PPLP004270640			KDE 45	AU; H; R; PRE; CON; CU; Privileged; J-MIL-2; J-MIL-3; J-MIL-7; T-MIL-4	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1223	11/4/11 CDC Morbidity and Mortality Weekly Report - Vital Signs: Overdoses of Prescription Opioid Pain Relievers - United States, 1999-2008				KDE 46	AU; H; LF; R; PRE; SUM	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1224	7/7/11 Email from Robyn Kohn to Bert Wickey and Others- Subject: Monthly Update Brief	JAN-MS-00403639			KDE 47	AU; H; J-MIL-3; LF	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1225	Duragesic Fentanyl Transdermal System 2003 Business Plan July 30, 2002	JAN-MS-00726351			KDE 48	AU; H; LF; R; PRE	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1226	1/18/01 Email from Tim Armundsen to James Harper and Others - Subject: FW: Janssen Marketing Program	POK003491024			KDE 49	First Amendment; AU; H; R; PRE; CON; CU; J-MIL-7; T-MIL-4; LF	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1227	3/28/11 Email from Laura Flannery to Kimberly Deem-Eshleman - Subject: Prescribe Responsibly Copy & Insert: Pain Resource Guide	JAN-MS-00320771			KDE 50	J-MIL-3	
S-1228	HSGAC Minority Staff Report "Fueling an Epidemic" - McCaskill Report				KDE 51	First Amendment; AU; H; J-MIL-3; LF; SUM	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802

S-1229	Johnson & Johnson Request for Proposal - RFP Number RFP06181 - Therapeutic Area	JAN-OK-00148064	KDE 52	AU; J-MIL-3	12 O.S. 2602, 12 O.S. 2901
S-1230	3/4/08 Email from Greg Panico to Gloria Vanderham - Subject: Landscape store	JAN-MS-00276405	KDE 53	AU; H; R; J-MIL-3; LF	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1231	Defendant Johnson & Johnson's Written Responses and Objections to Topic23 in Plaintiff's Amended Notices of Videotapes 3230(5) Depositions		KDE 54	R	
S-1232	Janssen's Contributions to Advocacy Organizations		KDE 55	First Amendment; AU; J-MIL-3	12 O.S. 2602, 12 O.S. 2901
S-1233	UW-Madison Pain & Policy Studies Group Funding Award Informaiton Cancer Pain Relief Newsletter Funding	WISPPSG00415633	KDE 56	First Amendment; AU; H; R; J-MIL-3; LF	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1234	Nucynta ER Train-the-Trainer August 29, 2011 Slide Deck	JAN-MS-00064792	KDE 57	AU; LF; R; PRE; H	
S-1235	Purdue Phase IV OxyContine Tablets Team Meeting Minutes	PPLP004030366	KDE 58	AU; H; R; PRE; CON; CU; LF; J-MIL-7; T-MIL-4	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1236	Nucynta & Nucynta ER 2012 Business Plan Slide Deck	JAN-MS-00010801	KDE 59	AU; LF; R; PRE; H	
S-1237	2/26 Email from Michelle Wanat to Gary Borsanger and Michael Paulik - Subject: RE: REMS	JAN-MS-02238368	KDE 60	AU; H; LF; R; PRE	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1238	Prioritization of the ER Incremental Spend Request	JAN-MS-00841384	KDE 61	AU; H; INC; LF; R; PRE	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1239	6/29/07 Email from Lynn Leonard to Haya Taitel and Others - Subject: Unbranded Tactical v1.ppt	JAN-MS-00442057	KDE 62	H; PRE; CON; CU; AU; LF; R	12 O.S. 2403; 12 O.S. 2802
S-1240	Janssen Non-Speaker Prescribers List	JAN-MS-02238372	KDE 60A	Inadmissible Character Evidence; R; PRE; CON; CU; H; AU; LF; R; PRE	12 O.S. 2802
S-1241	NUCYNTA Speakers Top 20 List Mutual Accountability for Pain - Driving Demand for Nucynta and Nucynta ER Slide Deck	JAN-MS-02238371	KDE 60B	Inadmissible Character Evidence; R; PRE; CON; CU; H; AU; LF; R; PRE	12 O.S. 2802
S-1242		JAN-MS-00937860	KDE 63	AU; LF; R; PRE; H	

S-1243	Mayday Fund's "A Call to Revolutionize Chronic Pain Care in America: An Opportunity in Health Care Reform"			KDE 64	AU; LF; R; PRE; H	12 O.S. 2602, 12 O.S. 2901
S-1244	11/14/12 Email from Robyn Kohn to Ron Kuntz - Subject: FW: PAINS Update	JAN-MS-00948094		KDE 65	J-MIL-3; AU; LF; H	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1245	Pain Action Initiative: A National Strategy - Tampa Report	JAN-MS-00921033		KDE 66	First Amendment; R; PRE; CON; CU; AU; H; R; PRE; J-MIL-3; LF	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1246	Memo to the Duragesic Sales Force Market Update and Strategic Focus, Etc.	JAN-MS-00311782		KDE 67	H; R; AU; LF; PRE	12 O.S. 2401, 2402; 12 O.S. 2802
S-1247	Pain, Finding Relief, Pain Management for Older Adults Guidebook			KDE 68	First Amendment; Inadmissible Character Evidence; R; PRE; CON; CU; H; AU; LF; R; PRE	12 O.S. 2802
S-1248	12/6/10 Email from Bonnie Weissfeld to David Gerould - Subject: Permission to Reproduce APF Materials - Attachment: Target Chronic Pain Notebook	JAN-MS-00329344		KDE 69	J-MIL-3; AU; LF; H	
S-1249	12/6/10 Email from Bonnie Weissfeld to David Gerould - Subject: Permission to Reproduce APF Materials - Attachment: Target Chronic Pain Provider Card	JAN-MS-00329331		KDE 70	J-MIL-3; AU; LF; H	
S-1250	12/6/10 Email from Bonnie Weissfeld to David Gerould - Subject: Permission to Reproduce APF Materials - Attachment: Top 10 Tips: Making the Most of Your Medical Visits (tip sheet)	JAN-MS-00250471		KDE 71	J-MIL-3; AU; LF; H	
S-1251	3/4/11 Email from Kimberly Deem-Eshleman to Michelle Wanat - Subject: Prescribe Responsibility Platform Inserts Permissions	JAN-MS-00318705		KDE 72	First Amendment; H; J-MIL-3; AU; LF	12 O.S. 2802
S-1252	3/15/02 Email from Brad Gray - Subject: Duragesic Disease Modeling Update	JAN-MS-00481545		KDE 73	AU; H; R; LF; PRE	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802

S-1253	Duragesic Disease Modeling Workshop 2 Takeaways Synthesis Document March 14, 2002	JAN-MS-00481547		KDE 74	AU; H; R; LF; PRE	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1254	3/19/10 Email from Mary Griffin to Kimberly Deem-Eshleman - Subject: Deck for Tuesday	JAN-MS-00330059		KDE 75	Inadmissible Character Evidence; R; PRE; CON; CU; H; AU; LF; R; PRE	12 O.S. 2802
S-1255	Porter & Jick Letter to the Editor - Addition Rare in Patients Treated with Narcotics			KDE 76	R; PRE; CON; CU; AU; H; PRE; SCOPE; LF	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1256	Excerpt from the First Amended Complaint Filed in Commonwealth of Massachusetts v. Purdue Pharma			KDE 77	R; PRE; CON; CU; H; PRE; AU; LF; J-MIL-7; T-MIL-4; INC; SCOPE	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2802
S-1257	J&J Pharmaceuticals Group Global Strategy Presentation	JAN-MS-00305511		KDE 78	AU; H; R; LF; PRE	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1258	Curriculum Vitae of Lynn Webster, MD			Webster 1	H; R	12 O.S. 2401, 2402; 12 O.S. 2802
S-1259	Memo dated July 16, 1990	PDD9316718973-8975)		Webster 2	AU; H; R; PRE; CON; CU; A; LF; T-MIL-4; J-MIL-7	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1260	Tealink article	PDD9316703679-3690		Webster 3	AU; H; R; PRE; CON; CU; A; LF; T-MIL-4; J-MIL-7	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1261	Email string	PKY183238394-395		Webster 4	AU; H; R; PRE; CON; CU; A; LF; T-MIL-4; J-MIL-7	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1262	Email string	PKY181422992-2994		Webster 5	AU; H; R; PRE; CON; CU; A; LF; T-MIL-4; J-MIL-7	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1263	Proposed Target KOLs for PPR Communications	PPLP00426891		Webster 6	AU; H; R; PRE; CON; CU; A; LF; T-MIL-4; J-MIL-7	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1264	GAO Prescription Drugs OxyContin Abuse and Diversion and Efforts to Address the Problem			Webster 7	H; R; PRE; CON; CU; A; LF; T-MIL-4; J-MIL-7	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2802
S-1265	Statement of United States Attorney John Brownlee on the Guilty Plea of the Purdue Frederick Company and its Executives for Illegally Misbranding OxyContin			Webster 8	AU; H; R; PRE; CON; CU; A; LF; T-MIL-4; J-MIL-7	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802

S-1266	Actig Master Plan	TEVA_OK_00094174-94234	Webster 9	AU; H; R; LF; A	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1267	Curriculum Vitae of Lynn Webster, MD	JAN-MS-00811437	Webster 10	AU; H; R	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1268	PowerPoint presentation excerpt	TEVA_OK_00039272	Webster 11	AU; H; R; INC; LF	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1269	Teva Advocacy Mapping: Identifying advocacy Partners to Enhance Patient Care	TEVA_OK_00101615	Webster 12	First Amendment; AU; H; R; F	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1270	Duragesic Disease Modeling Workshop Takeaways dated March 14, 2002	JAN-MS-00481547	Webster 13	AU; H; LF; R; PRE	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1271	PAINS Project Overview	JAN-MS-00397434-449	Webster 14	First Amendment; AU; H; R; LF; PRE	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1272	Email from Myra Christopher dated 11/6/12	JAN-MS-00264060-062	Webster 15	First Amendment; AU; H; LF; R; PRE	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1273	PAINS Project, No Longer Silent SWAT Team	FOLEY00007302	Webster 16	First Amendment; AU; H; R; LF; PRE	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1274	Email from Heather Thomson dated 2-18-2002	JAN-MS-00492412-413	Webster 17	AU; H; LF; R; PRE	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1275	United States Cancer Pain Relief Committee Request for Support	FOLEY00001071	Webster 18	First Amendment; AU; H; R; LF; PRE	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1276	Proposed Transmucosal Immediate Release Fentanyl (TIRF) Risk Evaluation and Mitigation Strategy (REMS)		Webster 19	AU; H; N/A	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1277	Article entitled Pseudoaddiction revisited: a commentary on clinical and historical considerations		Webster 20	AU; H; R; N/A	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1278	Article entitled The Economic Impact of Opioid Use in the Management of Chronic Nonmalignant Pain		Webster 21	Nuisance Statute's Safe-harbor; Preemption; H; R; N/A	12 O.S. 2401, 2402; 12 O.S. 2802

S-1279	Article entitled American Academy of Pain Medicine Response to PROP Petition to the FDA That Seeks to Limit Pain Medications for Legitimate Noncancer Pain Sufferers				Webster 22	First Amendment; Nuisance Statute's Safe-harbor; Preemption; H; R; N/A	12 O.S. 2401, 2402; 12 O.S. 2802
S-1280	Article entitled Breakthrough Pain in the Management of Chronic Persistent Pain Syndromes				Webster 23	Discovery Violations; H; N/A	12 O.S. 2802
S-1281	Article entitled Impact of Breakthrough Pain on Quality of Life in Patients with Chronic, Noncancer Pain: Pain Perceptions and Effect of Treatment with Oral Transmucosal Fentanyl Citrate				Webster 24	Discovery Violations; H; N/A	12 O.S. 2802
S-1282	Article entitled Fentanyl Buccal Tablet Compared with Immediate-Release Oxycodone for the Management of Breakthrough Pain in Opioid-Tolerant Patients with Chronic Cancer and Noncancer Pain: A randomized Double-Blind, Crossover Study Followed by a 12-week Open-Label Phase to Evaluate Patient Outcomes				Webster 25	Discovery Violations; H; N/A	12 O.S. 2802
S-1283	Review of Promotional Material	TEVA_OK_06850831-0650843			Hassler 1	AU; H; R; LF; T-MIL-1; PRE	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1284	2003 Actiq Marketing Plan	TEVA_OK_00107392-00107461			Hassler 2	AU; H; R; T-MIL-1	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1285	Directors Meeting Actiq, December 2, 2014	TEVA_OK_00044404			Hassler 3	AU; H; R; LF; T-MIL-1	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1286	OVF Commercial strategy Meeting, January 26, 2005	TEVA_OK_00039264			Hassler 4	AU; H; R; LF; T-MIL-1	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1287	Government's Memorandum for Entry of Plea and Sentencing, US/Eastern District of Pennsylvania, USA vs. Cephalon				Hassler 5	AU; R; PRE; CON; CU; H; T-MIL-1; T-MIL-5; PO	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901

S-1288	Fentora Strategic Marketing Plan, 2017	TEVA_OK_00045716		Hassler 6	AU; H; R; T-MIL-1	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1289	Fentora 2009 Brand Plan	TEVA_OK_00039513		Hassler 7	AU; H; R; LF; T-MIL-1	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1290	Responsible Opioid Prescribing, A Physician's Guide			Hassler 8	AU; H; R; J-MIL-3; T-MIL-1; PRE	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1291	Making Pain Talk Painless, A Guide to Help You Talk With Your Doctor About Pain Management	TEVA_OK_00116233-116236		Hassler 9	AU; H; R; T-MIL-1	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1292	Noramco World Wide Narcotics Franchise September 2015 presentation- JAN-OK-00149914	JAN-OK-00149914		Martin 1	J-MIL-4; AU; LF; H	
S-1293	12/05/06 - Option Agreement between Noramco and Controlled Chemicals Inc. JAN-OK-00163791 - JAN-OK-00163797	JAN-OK-00163791	JAN-OK-00163797	Martin 2	Nuisance Statute's Safe-harbor; AU; H; R; J-MIL-4; LF	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1294	Website printout titled "Our Credo". 05/07/13- Noramco, Inc. Action Authorized by Unanimous Consent of Shareholder in lieu of the 2013 Annual Meeting of Shareholder JAN-OK-00169344 - JAN-OK-00169360	JAN-OK-00169344	JAN-OK-00169360	Martin 3	AU; H; R; PRE; CON; CU; LF	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1295	Printout from Noramco's website titled "Commitment"			Martin 4	Nuisance Statute's Safe-harbor; AU; H; R; J-MIL-4; LF	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1296	05/30/03- Email from Mike Kindergan to Rick Blockinger Subject: Noramco with attachments	JAN-MS-00725218		Martin 5	Nuisance Statute's Safe-harbor; AU; H; R; J-MIL-4; LF	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1297	The Tasmanian Poppy Industry: A Case Study of the Application of Science and Technology written by A.J. Fist			Martin 6	J-MIL-4; AU; LF; H	
S-1298	02/06/08 - Federal Register Vol. 73 No. 25 Pages 6833-7186			Martin 7	Nuisance Statute's Safe-harbor; AU; H; R; J-MIL-4; LF	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1299				Martin 8	Nuisance Statute's Safe-harbor; R; J-MIL-4; AU; LF; H	12 O.S. 2401, 2402

S-1300	Charts of Rates of Opioid Sales, OD Deaths, and Treatment, 1999-2010 (CDC)				Martin 9	R; PRE; CON; CU; H; PRE; AU; LF; SUM	12 O.S. 2403; 12 O.S. 2802
S-1301	Oklahoma PCS Sales Force Total Base Compensation 2011-2017 in Response to Topic #42				Hassler 1	R; H; PRE; T-MIL-1	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1302	1-8/9-09 Fast Start Meeting	TEVA_OK_00008185			Hassler 2	AU; H; R; LF; T-MIL-1	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1303	10-17-05 Re: Pain for Dummies	TEVA_OK_03810009			Hassler 3	AU; H; R; LF; T-MIL-1	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1304	5-11-09 Email from Stanton Mohler Re: PCS Q2 2009 Bonus Plan	TEVA_OK_00641897			Hassler 4	AU; H; R; INC; LF	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1305	1-4/14-05 Welcome to Actiq Training	TEVA_OK_07228617			Hassler 5	AU; H; R; LF; T-MIL-1	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1306	2008 Pre-Module Introduction to Pain	TEVA_OK_00058933			Hassler 6	AU; H; R; T-MIL-1	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1307	Porter and Jick Letter				Hassler 7	AU; H; LF; J-MIL-12; T-MIL-1; R	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2401, 2403
S-1308	Emerging Solutions in Pain Tool Kit	TEVA_OK01551293			Hassler 8	AU; H; R; LF; T-MIL-1	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1309	The Emerging Solutions in Pain Tool Kit- Sales Training Overview	TEVA_OK_00061905			Hassler 9	AU; H; R; J-MIL-3; T-MIL-1	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1310	4-6-05 Email String	TEVA_OK_03112541			Hassler 10	AU; H; R; LF; T-MIL-1	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1311	ESP Patient Tool Kit - Print D1 9-28-07	TEVA_OK_00514801			Hassler 11	AU; H; R; LF; T-MIL-1	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1312	Implementation Guide - Emerging Solutions in Pain Tool Kit CD Rom	TEVA_OK_06536624			Hassler 12	AU; H; R; T-MIL-1	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1313	Total Bonus Payout by Position Q1 2007	TEVA_OK_08952840			Hassler 13	H; R; AU; LF; T-MIL-1; PRE	12 O.S. 2401, 2402; 12 O.S. 2802

S-1314	Fentora Total Component 1 Early View Report	TEVA-OK-08952848		Hassler 14	AU; H; R; T-MIL-1	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1315	Email String Re: Important News: New Tools Available	TEVA_OK_00785480		Hassler 15	First Amendment; AU; H; R; LF; T-MIL-1; J-MIL-3	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1316	8-15-06 Memo to Oncology Sales Force	TEVA_OK_06514598		Hassler 16	AU; H; R; LF; T-MIL-1	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1317	12-06-10 Email from Bonnie Weissfeld to David Gerould	JAN-MS-00329343		Hassler 17	AU; H; LF; T-MIL-1; J-MIL-3; R; PRE	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1318	Policy of Promotional Materials and Activities	TEVA_OK_00510530		Hassler 18	AU; H; R; T-MIL-1	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1319	Targeting & "Do Not Detail" Policy in 'connection with Promotional Activities	TEVA_OK_00510540		Hassler 19	AU; H; R; T-MIL-1	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1320	Email from Mark Reese to Robyn Kohn re "We are on the case!"	JAN-MS-00941473	474	Kohn 1	First Amendment; AU; H; J-MIL-2; LF	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1321	NAD HPAD PAIN Team Update	JAN-MS-00404402	403	Kohn 2	First Amendment; H; J-MIL-3; LF; J-MIL-2	12 O.S. 2802
S-1322	Director of Stakeholders Business Plan	JAN-MS-00408675	676	Kohn 3	First Amendment; AU; H; J-MIL-3; LF; J-MIL-2	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1323	Nucynta - A Vital Balancing Act: Recognizing Prescription Drug Abuse While Ensuring Patient Access	JAN-MS-00399829	830	Kohn 4	First Amendment; AU; H; R; J-MIL-3; LF; J-MIL-2	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1324	Pain Brief Advocacy & Policy Monthly 2011	JAN-MS-00403639	644	Kohn 5	First Amendment; PRE; CON; CU; AU; H; J-MIL-3; LF	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1325	Email from Greg Panico to Robyn Kohn re Senate panel	JAN-MS-00508279	280	Kohn 6	First Amendment; AU; H; J-MIL-3; LF	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1326	Email from Jeffrey Christensen to Robyn Kohn re Wash Post - Senate Inquiry - Duragesic	JAN-MS-00927417	420	Kohn 7	First Amendment; AU; H; J-MIL-3; LF	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1327	Janssen Update & 2013 National Advocacy Business Planning	JAN-MS-00393084	85	Kohn 8	First Amendment; PRE; CON; CU; AU; H; J-MIL-3; LF	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1328	Meeting #2 October 12, 2011 Imagine the Possibilities Pain Coalition	JAN-MS-00940011		Kohn 9	First Amendment; PRE; CON; CU; AU; H; J-MIL-3; LF	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802

S-1329	PAINS Project 2012 Annual Meeting Invitees	JAN-MS-00411906	907	Kohn 10	J-MIL-3; H; AU; LF	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1330	Email from Robyn Kohn to Myra Christopher re PAINS Policy Briefing Series	JAN-MS-00262694	695	Kohn 11	First Amendment; R; PRE; CON; CU; AU; H; R; PRE; J-MIL-3; LF	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1331	Email from Myra Christopher re PAINS & PAINS Project	JAN-MS-00405269		Kohn 12	First Amendment; AU; H; R; J-MIL-3; LF	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1332	Janse - Demonstrate Industry Leadership in Advocacy for HCPs & Patient Access 2011-12 Advocacy Launch Plan	JAN-MS-00940675	676	Kohn 13	First Amendment; R; PRE; CON; CU; AU; H; R; PRE; Privileged; J-MIL-3; LF	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1333	list of medical conditions marked for identification			Halford 1	AU; H; R	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1334	Package Insert for OxyContin			Halford 2	AU; H; R; A; LF; PRE; T-MIL-4; J-MIL-7	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1335	2001 Budget Plan (excerpt)	PDD1715030714		Halford 3	AU; H; R; PRE; CON; CU; A; LF; T-MIL-4; J-MIL-7	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1336	Durgestic Market Update	JAN-MS-00310227		Halford 4	Nuisance Statute's Safe-harbor; Preemption; AU; H; LF; R; PRE	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1337	Purdue Sales & Marketing	PDD8901061469		Halford 5	AU; H; R; PRE; CON; CU; A; LF; T-MIL-4; J-MIL-7	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1338	Purdue Marketing-Rx is highly correlated	PKY183117989		Halford 6	AU; H; R; PRE; CON; CU; A; LF; T-MIL-4; J-MIL-7	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1339	E-mail 11-6-2000 Rationale for Partners Against Pain Spinoff	PKY181998690		Halford 7	First Amendment; R; PRE; CON; CU; AU; H; R; PRE; A; LF; T-MIL-4; J-MIL-7	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1340	E-mail 10-16-2008 Purdue Business Plan	POK003625780		Halford 8	AU; H; R; PRE; CON; CU; A; LF; T-MIL-4; J-MIL-7	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1341	E-mail dated 1-9-2013 Target List	POK003625673		Halford 9	AU; H; R; PRE; CON; CU; A; LF; T-MIL-4; J-MIL-7	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1342	Oklahoma City, Ken Murphy, PainForce Start Date 5-6-13	JAN-MS-00982436		Halford 10	AU; H; A; LF; R; PRE	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802

S-1343	Purdue Call Notes	POK001852070	Halford 11	AU; H; R; PRE; CON; CU; A; LF; T-MIL-4; J-MIL-7; J-MIL-16	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1344	Janssen and J&J call notes	JAN-OK-00145255	Halford 12	AU; H; A; LF; R; PRE; J-MIL-16	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1345	E-mail dated 8-3-2009 Blitz Targets Nucynta	JAN-MS-00358879	Halford 13	A; LF; H; R; PRE	
S-1346	E-mail dated 12-10-2010	JAN-OK00134401	Halford 14	AU; H; A; LF; R; PRE	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1347	Attendees for Speaker Training Programs	PDD8800000895	Halford 15	AU; H; R; PRE; CON; CU; A; LF; T-MIL-4; J-MIL-7	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1348	E-mail dated 9-18-2010 Re Speaker Training Programs	JAN-OK-00133020	Halford 16	AU; H; A; LF; R; PRE	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1349	Contributions to Advocacy Organizations list		KDE 79	First Amendment; H; J-MIL-3; A; LF	12 O.S. 2802
S-1350	Payment History list		KDE 80	First Amendment; H; A; LF; R; PRE	12 O.S. 2802
S-1351	Continuing Medical Education list		KDE 81	First Amendment; H; A; LF; R; PRE	12 O.S. 2802
S-1352	5-28-98 Memo to Teri Cole	JAN-OK-00132723	KDE 82	AU; H; A; LF; R; PRE	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1353	Email String Re: Oklahoma DUR Recap - Nucynta	JAN-OK-00133058	KDE 83	AU; H; A; LF; R; PRE	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1354	Email String re: 2013 Convention Planning	JAN-OK-00135380	KDE 84	Inadmissible Character Evidence; R; PRE; CON; CU; H; PRE; A; LF; R	12 O.S. 2403; 12 O.S. 2802
S-1355	Document Entitled "Oklahoma City - Ken Murphy - PainForce Start Date: 05/06/13"	JAN-MS-00982436	KDE 85	AU; H; A; LF; R; PRE	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1356	7-2-09 Invoice from Beth Israel	JAN-MS-00394853	KDE 86	A; LF; H; R; PRE	
S-1357	9-15-09 Invoice from Beth Israel	JAN-MS-00395835	KDE 87	A; LF; H; R; PRE	
S-1358	Duragesic (fentanyl transdermal system) CII - 2003 Business Plan	JAN-MS-00726353	KDE 88	A; LF; H; R; PRE	
S-1359	Pediatric Assessment for D=Trans Fentanyl with Naltrexone HCI System		KDE 89	PRE; CON; CU; H; J-MIL-5; A; LF; R; SCOPE	12 O.S. 2403; 12 O.S. 2802
S-1360	Email String Re: New Pain Doc in Roland	JAN-OK-00132943	KDE 90	AU; H; A; LF; R; PRE	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1361	Email String Re: NC Speaker Programs	JAN-OK-00133020	KDE 91	AU; H; PRE; CON; CU; A; LF; R	12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802

S-1362	Call Notes	JAN-OK-00145260&61		KDE 92	Inadmissible Character Evidence; R; PRE; CON; CU; AU; H; PRE; J-MIL-16; INC; LF; R	12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1363	NewsOK Article "Doctor who worked at alleged 'pill mill' in Roland charged with murder"			KDE 93	H; R; LF; A	12 O.S. 2401, 2402; 12 O.S. 2802
S-1364	PowerPoint Presentation by Ortho McNeill Janssen	JAN-OK-00138697		KDE 94	AU; H; A; LF; R; PRE	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1365	10-22-08 Email re: Pain District Hub Meetings	JAN-MS-01126753		KDE 95	AU; H; A; LF; R; PRE	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1366	IR & ER 2010 Business Plan - July 21, 2009	JAN-MS-00454883		KDE 96	A; LF; H; R; PRE	
S-1367	Curriculum Vitae of Scott M. Fishman, M.D.	FISH000001		Fishman 1	H; R; PRE	12 O.S. 2401, 2402; 12 O.S. 2802
S-1368	Various Documents, top page Program Detail-139651, with handwriting	PPLP003465695	PPLP003465714	Fishman 2	First Amendment; R; PRE; CON; CU; AU; H; R; PRE; A; LF; T-MIL-4; J-MIL-7	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1369	E-mail chain, top dated 8/23/10, from Takeshita Takashi, to Scott Fishman	JAN-MS-00483184		Fishman 3	First Amendment; R; PRE; CON; CU; AU; H; R; PRE; A; LF	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1370	Memo, 1/25/07, from Cephalon, to Legal Department, with attached Independent Educational Program Grant Agreement	TEVA_OK_01465610		Fishman 4	First Amendment; R; PRE; CON; CU; AU; H; R; PRE; A; LF	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1371	NUCYNTA & NUCYNTA ER 2012 Business Plan, 12/12/12	JAN-MS-00010801		Fishman 5	A; LF; H; R; PRE	
S-1372	E-mail chain, top dated 1/5/07, from Haya Taitel, to Gregory Imber, with attached Janssen Duragesic KOL Mapping Analysis, 2/18/04	JAN-MS-02533808&JAN-MS-02533811		Fishman 6	Inadmissible Character Evidence; R; PRE; CON; CU; AU; H; PRE; A; LF; R	12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1373	Key Opinion Leader (KOL) Development Plan for Cephalon Pain Franchise, 2/4/05	TEVA_OK_03063698		Fishman 7	First Amendment; AU; H; R; A; LF; PRE	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1374	Purdue Guidelines for Non-Promotional Activities by Scientific and Medical Personnel-Status Update	PPLPC041000029381	PPLPC041000029381	Fishman 8	AU; H; R; PRE; CON; CU; A; LF; T-MIL-4; J-MIL-7	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1375	Purdue Pharma Corporate Reputation and Visibility Strategic Plan, 1/21/11	PPLP004282019		Fishman 9	AU; H; R; PRE; CON; CU; A; LF; T-MIL-4; J-MIL-7	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802

S-1376	Summary of Payments by Name and Year (1997-May 8, 2012)	PPLPC046000040457	PPLPC046000040457	Fishman 10	First Amendment; AU; H; R; PRE; CON; CU; A; LF; T-MIL-4; J-MIL-7; J-MIL-3	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1377	Information provided by Teva re payments made to third-party organizations	TEVA_OK_07950545		Fishman 11	First Amendment; AU; H; R; A; LF; PRE; J-MIL-3	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1378	Summary of Payments Made In Response to Senate Finance Committee dated 6/8/12	JAN-MS-0000001		Fishman 12	First Amendment; AU; H; R; A; LF; PRE; J-MIL-3	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1379	HSGAC Minority Staff Report, "Fueling an Epidemic"			Fishman 13	First Amendment; A; LF; H; R; PRE; J-MIL-3	
S-1380	E-mail chain, top dated 12/6/11, to Will Rowe, from Mary Vargas Re_Emergency Funding Update	FISH006241		Fishman 14	First Amendment; R; PRE; CON; CU; AU; H; R; PRE; A; LF; J-MIL-3	12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1381	E-mail chain, top dated 11/22/11, from Will Rowe, to Mary Vargas Re_Special Funding Update	FISH007075		Fishman 15	First Amendment; R; PRE; CON; CU; AU; H; R; PRE; A; LF; J-MIL-3	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1382	E-mail chain, top dated 1/15/12, Scott Fishman, to Mary Vargas Re_Purdue Funds	FISH006877		Fishman 16	First Amendment; R; PRE; CON; CU; H; R; PRE; A; LF; T-MIL-4; J-MIL-7; J-MIL-3	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2802
S-1383	E-mail, 8/5/10, with attached American Pain Foundation Executive Summary Re_APF - Local Media Outreach- 2009-10 Results Report	SFC00006614	SFC00006514	Fishman 17	First Amendment; AU; H; R; A; LF; PRE; J-MIL-3	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1384	E-mail chain, top dated 7/15/08, from Burt Rosen, to Kimberly Tiller Re_APF Sponsorship Opportunities	SFC00009587	SFC00009589	Fishman 18	First Amendment; AU; H; R; INC; A; LF; PRE; H	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1385	Document entitled "Exit Wounds" Book Excerpts			Fishman 19	First Amendment; AU; H; R; PRE; CON; CU; AU; H; A; LF; R; PRE; J-MIL-3	12 O.S. 2401, 2402; 12 O.S. 2901;
S-1386	Pain Brief Advocacy & Policy Monthly, 2011	JAN-MS-00403640		Fishman 20	First Amendment; PRE; CON; CU; AU; H; A; LF; R; PRE; J-MIL-3	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1387	NUCENTA Immediate Release (tepentadol) Launch Plan, Ketchum Public Relations, 7/8/09	JAN-MS-00500153		Fishman 21	AU; H; A; LF; R; PRE; J-MIL-3	12 O.S. 2602, 12 O.S. 2901;
S-1388	Partners Against Pain Magazine, Pain Matters, Issue 7	FISH008941		Fishman 22	AU; R; A; LF; H; PRE; J-MIL-3	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901
S-1389	Memorandum, 11/6/00, from Robin Hogan, to Mark Alfonso	PKY181998690		Fishman 23	First Amendment; AU; H; R; PRE; CON; CU; A; LF; T-MIL-4; J-MIL-7	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802

S-1390	2012 Individual Objectives for Burt Rosen	PPLP004273776		Fishman 24	AU; H; R; PRE; CON; CU; A; LF; T-MIL-4; J-MIL-7	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602; 12 O.S. 2901; 12 O.S. 2802
S-1391	E-mail chain, top dated 5/29/97, from Michael Friedman, to Michael Cullen Re_Oxyplms	PDD9316506216	PDD9316506218	Fishman 25	AU; H; R; PRE; CON; CU; A; LF; T-MIL-4; J-MIL-7	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602; 12 O.S. 2901; 12 O.S. 2802
S-1392	Excerpt from "Responsible Opioid Prescribing, A Physician's Guide," by Scott Fishman, M.D.			Fishman 26	AU; H; R; A; LF; PRE; T-MIL-4; J-MIL-7; J-MIL-3	12 O.S. 2401, 2402; 12 O.S. 2602; 12 O.S. 2901; 12 O.S. 2802
S-1393	Letter, 6/8/12, from Federation of State Medical Board, to Senators Baucus and Grassley	FSMB00000017		Fishman 27	AU; H; R; A; LF; PRE; T-MIL-4; J-MIL-7; J-MIL-3	12 O.S. 2401, 2402; 12 O.S. 2602; 12 O.S. 2901; 12 O.S. 2802
S-1394	E-mail, 8/27/11, from Joshua Horwitz, to Lisa A. Robin Re_J&J's new opioid approved...	FISH006765		Fishman 28	First Amendment; AU; H; R; A; LF; PRE; T-MIL-4; J-MIL-7	12 O.S. 2401, 2402; 12 O.S. 2602; 12 O.S. 2901; 12 O.S. 2802
S-1395	Government's Memorandum for Entry of Plea and sentencing, U.S. v. Cephalon			Fishman 29	AU; R; PO; T-MIL-5	12 O.S. 2401, 2402; 12 O.S. 2602; 12 O.S. 2901
S-1396	Guilty Plea Agreement, U.S. v. Cephalon	TEVA_OK_01322524		Fishman 30	R; PO; T-MIL-5	12 O.S. 2401, 2402
S-1397	Incident Report Editing of Scott Fishman Pain Book	SFC00013344	SFC00013348	Fishman 31	AU; H; R; A; LF; PRE; T-MIL-4; J-MIL-7; J-MIL-3	12 O.S. 2401, 2402; 12 O.S. 2602; 12 O.S. 2901; 12 O.S. 2802
S-1398	Notice of Deposition			Hassler 1	R; PRE	
S-1399	Excel File	TEVA_OK_00129936		Hassler 2	AU; H; R; INC; LF; J-MIL-3	12 O.S. 2401, 2402; 12 O.S. 2602; 12 O.S. 2901; 12 O.S. 2802
S-1400	March 2, 2016 E-mail from Paula Gregory to Paula Williams, Kathy Sapp, Hong Na, Kristen Minnick, and Sarah Filling Re_ updated status reprints for MED & PED - 3/22/2016			Hassler 3	AU; H; R; LF; J-MIL-3; T-MIL-1	12 O.S. 2401, 2402; 12 O.S. 2602; 12 O.S. 2901; 12 O.S. 2802
S-1401	Education Grant Draft Request	TEVA_OK_01488576		Hassler 4	AU; H; R; LF; T-MIL-1	12 O.S. 2401, 2402; 12 O.S. 2602; 12 O.S. 2901; 12 O.S. 2802
S-1402	PowerPoint labeled Appendix - Public Relations Proposed 2009 Plan-Fentora	TEVA_OK_00046295		Hassler 5	AU; H; R; LF; T-MIL-1	12 O.S. 2401, 2402; 12 O.S. 2602; 12 O.S. 2901; 12 O.S. 2802
S-1403	Marketing Document	TEVA_OK_00094820		Hassler 6	AU; H; R; LF; T-MIL-1; Scope	12 O.S. 2401, 2402; 12 O.S. 2602; 12 O.S. 2901; 12 O.S. 2802

S-1404	April 11, 2008 E-mail from Kay McGhee to Andy Pyfer Re_ FW Referral to Pinney Associates	TEVA_OK_04925772		Hassler 7	AU; H; R; LF; T-MIL-1; PRE	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1405	E-mail from David Haddock to Lang James, Sidney Scholl, James Hains, Chris Sposato, and Windell Fisher RE_ Dr. Laski being interviewed by Chanel 12 following the Newsweek article May 27, 2009 E-mail from Randy Spokane to Sales PCS East Region Managers; Jim Reilly and Bill Cunningham	PKY183405327 TEVA_OK_04366146	PKY183405328	Hassler 8 Hassler 9	PRE; CON; CU; AU; H; R; LF; J-MIL-7; T-MIL-1; T-MIL-4; Scope AU; H; R; LF; PRE	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802 12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1406	Pain Franchise Public Relation 2006 Budget Supplement	TEVA_OK_01022263		Hassler 10	AU; H; R; LF; T-MIL-1	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1407	April 21, 2006 Letter Agreement	TEVA_OK_00958538		Hassler 11	AU; H; R; LF; T-MIL-1	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1408	"Promoting Healthy Literacy"	TEVA_OK_04321297		Hassler 12	AU; H; R; J-MIL-3; T-MIL-1	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1409	Guidebook	TEVA_OK_01263193		Hassler 13	H; R; J-MIL-3; T-MIL-1	12 O.S. 2401, 2402; 12 O.S. 2802
S-1410	May 22, 2012 E-mail from Jcdougall to Matthew Day and others Re_ attachment of Cephalon - Gentrol 2011 Print Media Plan ppt, Cephalon - Fentora 2011_Digita Media and Analytic ppt and Fentora Media Brief doc	TEVA_OK_00664724		Hassler 14	AU; H; R; LF; T-MIL-1	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1411	PPT Attachment to May 22, 2012 E-mail labeled Fentora 2011 Digital Media Recommendations Feb. 16, 2011	TEVA_OK_00664724		Hassler 15	AU; H; R; LF; T-MIL-1	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1412	4/4/01 email from Kathleen Foley	PPLPC030000207179	PPLPC030000207180	Rosen 1	First Amendment; R; PRE; CON; CU; AU; H; R; PRE; LF; T-MIL-4; J-MIL-7	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1413	4/7/03 Email from Burt Rosen	PPLPC030000321036	PPLPC030000321036	Rosen 2	R; PRE; CON; CU; AU; H; PRE; LF; T-MIL-4; J-MIL-7; J-MIL-3; J-MIL-2	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802

S-1415	6/17/10 Email from Robyn Kohn	JAN-MS-00330383			Rosen 3	First Amendment; R; PRE; CON; CU; AU; H; R; PRE; LF; R; J-MIL-3; J-MIL-2	12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1416	12/2/04 Teva document	TEVA_OK_00044404			Rosen 4	First Amendment; R; PRE; CON; CU; AU; H; R; PRE; LF	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1417	7/8/04 Email from Burt Rosen	PPLPC031000199946			Rosen 5	R; PRE; CON; CU; AU; H; PRE; LF; T-MIL-4; J-MIL-7	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1418	11/29/04 Email from Burt Rosen	PPLPC030000351652		PPLPC030000351652	Rosen 6	First Amendment; AU; H; R; PRE; CON; CU; LF; T-MIL-4; J-MIL-7; J-MIL-3; J-MIL-2	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1419	1/26/05 Teva document	TEVA_OK_00039264			Rosen 7	R; PRE; CON; CU; AU; H; PRE; LF	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1420	4/10/08 Email from Lynn Leonard with Tapentadol PR Initiatives attachment	JAN-MS-00500562			Rosen 8	H; AU; LF; R; PRE	
S-1421	6/7/05 Email from Burt Rosen with 2005 Objectives attachment	PPLPC030000360459		PPLPC030000360459	Rosen 9	First Amendment; R; PRE; CON; CU; AU; H; R; PRE; LF; T-MIL-4; J-MIL-7; J-MIL-2	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1422	6/7/05 Email from Burt Rosen with Threats and Opportunities Top 12 attachment	PPLPC030000359736		PPLPC030000359736	Rosen 10	First Amendment; R; PRE; CON; CU; AU; H; R; PRE; LF; T-MIL-4; J-MIL-7; J-MIL-3; J-MIL-2	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1423	2005 Performance Appraisal	PPLPC030000364447		PPLPC030000364449	Rosen 11	R; PRE; CON; CU; AU; H; PRE; LF; T-MIL-4; J-MIL-3; J-MIL-2	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1424	The Pain Care Forum, A Proposal	PPLP004054309		PPLP004054309	Rosen 12	First Amendment; R; PRE; CON; CU; AU; H; R; PRE; LF; T-MIL-4; J-MIL-7; J-MIL-2	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1425	Application for patent for Self-Destructing Document and E-mail Messaging System & Patent for Self-Destructing Document and E-mail Messaging System				Rosen 13	R; PRE; CON; CU; H; PRE; AU; LF; T-MIL-4; J-MIL-7	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2802
S-1426	5/13/05 email from Burt Rosen with Pain Care Forum Directory attachment	PPLPC030000358837		PPLPC030000358837	Rosen 14	First Amendment; R; PRE; CON; CU; AU; H; R; PRE; LF; T-MIL-4; J-MIL-7; J-MIL-3	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1427	2/4/14 Email from Burt Rosen re Fight Club turns 5	PPLP004269996		PPLP004269997	Rosen 15	First Amendment; AU; H; R; PRE; CON; CU; LF; T-MIL-4; J-MIL-7; J-MIL-3	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802

S-1428	Rules of Fight Club				Rosen 16	AU; H; R; PRE; CON; CU; LF; T-MIL-4; J-MIL-7	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1429	3/14/08 Email from Howard Udell	PPLP004321111			Rosen 17	First Amendment; R; PRE; CON; CU; AU; H; R; PRE; LF; T-MIL-4; J-MIL-7; J-MIL-3	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1430	11/16/06 Email from Burt Rosen	POK003300493			Rosen 18	First Amendment; AU; H; R; PRE; CON; CU; LF; T-MIL-4; J-MIL-7; J-MIL-3	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1431	7/7/11 Email from Robyn Kohn with 2011 Pain Brief Advocacy & Policy Manual attachment	JAN-MS-00403639			Rosen 19	First Amendment; AU; H; R; LF; PRE; J-MIL-3	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1432	2009 individual objectives	PPLP004317984	PPLP004317989		Rosen 20	First Amendment; R; PRE; CON; CU; AU; H; R; PRE; LF; T-MIL-4; J-MIL-7; J-MIL-3; J-MIL-2	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1433	PCF Media Committee Report 7/17/09	WISPPSG00007660			Rosen 21	First Amendment; R; PRE; CON; CU; AU; H; R; PRE; LF; R; J-MIL-3	12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1434	2012 individual objectives	PPLP004273776			Rosen 22	First Amendment; AU; H; R; PRE; CON; CU; LF; T-MIL-4; J-MIL-7; J-MIL-3; J-MIL-2	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1435	Payments to front groups				Rosen 23	First Amendment; R; PRE; CON; CU; AU; H; PRE; LF; R; T-MIL-4; J-MIL-7; J-MIL-3	12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1436	7/27/11 email from Mark Reese	JAN-MS-00941473			Rosen 24	First Amendment; R; PRE; CON; CU; AU; H; PRE; LF; R; J-MIL-3; J-MIL-2	12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1437	11/1/11 Email from Robyn Kohn with 10/12/11 Pain Coalition Meeting # 2 - Imagine the Possibilities attachment	JAN-MS-00940011			Rosen 25	First Amendment; R; PRE; CON; CU; AU; H; R; PRE; LF; J-MIL-3; J-MIL-5	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1438	4/8/16 April Board Update	PPLPC031001429644	PPLPC031001429753		Rosen 26	AU; H; R; PRE; CON; CU; LF; T-MIL-4; J-MIL-7	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1439	8/5/11 Email from Robyn Kohn with Janssen 2011.1-12 Advocacy Launch Plan Draft	JAN-MS-00940675			Rosen 27	First Amendment; R; PRE; CON; CU; AU; H; R; PRE; LF; J-MIL-3; J-MIL-2	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1440	August 1, 2018 Settlement Agreement and Mutual General Release	PLTF_2804_000000450 7			Fishman 32	H; AU; LF; R; PRE	

S-1441	January 11, 2012 Letter to Scott Fishman, MD from Stacey Beckhardt	FISH003358	Fishman 33	R; H; PRE	12 O.S. 2401, 2402
S-1442	Prescription Opioid Forgery: Reporting to Law Enforcement and HIPAA	FISH000933	Fishman 34	H; R; N/A	12 O.S. 2401, 2402; 12 O.S. 2802
S-1443	Responsible Opioid Prescribing, A Physician's Guide	TEVA_OK_00514199	Fishman 35	AU; H; N/A	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1444	Unrestricted Educational Grant Agreement	TEVA_OK_01287333	Fishman 36	AU; H; R; LF	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1445	Responsible Opioid Prescribing,, A Clinician's Guide	FISH006902	Fishman 37	First Amendment; N/A	
S-1446	Medscape, Advances in Assessing and Managing Breakthrough Pain	FISH00000077	Fishman 38	Nuisance Statute's Safe-harbor; Preemption; AU; H; R; N/A	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1447	Special Article, The Opioid Contract in the Management of Chronic Pain		Fishman 39	H; N/A	12 O.S. 2802
S-1448	Duragesic Label	JAN-MS-00780844	Fishman 40	A; LF; H; R; PRE	
S-1449	August 1, 2018 Settlement Agreement and Mutual General Release	OKPURDFISH000006	Fishman 41	H; AU; LF; R; PRE	
S-1450	Dollars for Doctors, Two Leaders in Pain Treatment Have Long Ties to Drug Industry		Fishman 42	First Amendment; AU; H; R; PRE; LF	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1451	December 26, 2011 email to SMF111@gmail.com from Lonnie Zeltzer, M.D.	FISH006389	Fishman 43	H; R; PRE	
S-1452	Response to Charles Ornstein from Scott Fishman, December 15, 2011	PPLPC030000204729	Fishman 44	AU; H; R; PRE; CON; CU	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1453	Exit Wounds		Fishman 45	First Amendment; A; LF; H; R; PRE	
S-1454	Chapter 1, The Clinician's Dilemma: Under-Treated Pain Versus Prescription Drug Misuse	FISH000609	Fishman 46	N/A	
S-1455	Responsible Opioid Prescribing, A Physician's Guide		Fishman 47	First Amendment; N/A	
S-1456	February 26, 2012 email to Scott Fishman from Mary Vargas	FISH007069	Fishman 48	First Amendment; AU; H; R; N/A	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802

S-1457	June 17, 2007 email to smfishman@ucdavis.edu from Dr. J. David Haddox	PPLP004087123	PPLP004087123	Fishman 49	AU; H; R; PRE; CON; CU; A; LF; T-MIL-4; J-MIL-7; J-MIL-3	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1458	Mathew Minardi LinkedIn Profile			Minardi 1	Nuisance Statute's Safe-harbor; AU; H; R; PRE; J-MIL-4; J-MIL-12; T-MIL-1	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1459	Noramco World Wide Narcotics Franchise slide deck of September 2015	JAN-OK-00149914		Minardi 2	AU; H; LF; R; PRE; J-MIL-4; J-MIL-12; T-MIL-1	
S-1460	E-mail string	JAN-MS-02965665to666		Minardi 3	Nuisance Statute's Safe-harbor; AU; H; R; PRE; J-MIL-4; J-MIL-12; T-MIL-1	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1461	Amended Notice for 3230(C)(5) Videotaped Deposition			Hassler 1	R; PRE	
S-1462	Fentora - Pre-Modulentrroduction to Pain	TEVA_OK_00058933		Hassler 2	AU; H; R; T-MIL-1	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1463	New England Journal of Medical Document (Porter and Jick Letter) - Prognostic Value of Immunologic Markers in Adults with Acute Lymphoblastic Leukemia			Hassler 3	H; R; AU; LF; T-MIL-1	12 O.S. 2401, 2402; 12 O.S. 2802; 12 O.S. 2602, 2901
S-1464	Table of Clinical Studies	TEVA_OK_08952668		Hassler 4	H; R; T-MIL-1; J-MIL-12	12 O.S. 2401, 2402; 12 O.S. 2802
S-1465	Cephalon - ESP Patient Tool Kit	TEVA_OK_00514801		Hassler 5	H; R; T-MIL-1	12 O.S. 2401, 2402; 12 O.S. 2802
S-1466	Making Pain Talk Painless	TEVA_OK_00116233		Hassler 6	H; R; AU; LF; T-MIL-1	12 O.S. 2401, 2402; 12 O.S. 2802
S-1467	Cancer Pain Release - Tolerance			Hassler 7	AU; H; R; LF; T-MIL-1	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1468	Definitions Related to the Use of Opioids for the Treatment of Pain	JAN-MS-00618658		Hassler 8	First Amendment; AU; H; R; LF; J-MIL-3; T-MIL-1	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1469	Email String Re: Pain For Dummies	TEVA_OK_03810009		Hassler 9	H; R; AU; LF; T-MIL-1	12 O.S. 2401, 2402; 12 O.S. 2802
S-1470	Frequently Asked Questions About Actiq	TEVA_OK_07226345		Hassler 10	AU; H; R; LF; T-MIL-1	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802

S-1471	FAQ Listing Re: Actiq	TEVA_OK_00823379		Hassler 11	AU; H; R; LF; T-MIL-1	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1472	Addiction Research Report Re: Risk Factors for Drug Dependence			Hassler 12	AU; H; LF; T-MIL-1; J-MIL-12; R; PRE	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1473	PowerPoint - 2005 Actiq Training	TEVA_OK_07228617		Hassler 13	AU; H; R; T-MIL-1	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1474	Pain Management Partnership Pharmacists' Responsibilities in Managing Opioids: 2005 Update			Hassler 14	AU; H; R; LF; T-MIL-1; J-MIL-3	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1475	The Care of Patients with Severe Chronic Pain in Terminal Illness (McGivney)			Hassler 15	H; R; AU; LF; T-MIL-1; J-MIL-12; PRE	12 O.S. 2401, 2402; 12 O.S. 2802
S-1476	New England Journal of Medicine A 1980 Letter on the Risk of Opioid Addiction			Hassler 16	AU; H; R; PRE; CON; CU; LF; T-MIL-1; J-MIL-12	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1477	Article: Doctor Who Wrote 1980 Letter On Painkillers Regrets That It Fed The Opioid Crisis			Hassler 17	AU; H; PRE; CON; CU; T-MIL-1; J-MIL-12; R	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1478	Article: Barriers to Better Pain Control in Hospitalized Patients			Hassler 18	H; AU; LF; T-MIL-1; J-MIL-12; R; PRE	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1479	List of Health Conditions			Schick 1	Nuisance Statute's Safe-harbor; Preemption; H; AU; LF; CON; R; PRE; V	12 O.S. 2802
S-1480	JAMA Article "Pharmaceutical Industry Sponsored Meals and Physician Prescribing Patterns for Medicare Beneficiaries."			Schick 2	H; AU; LF; J-MIL-12; T-MIL-1; R; PRE	12 O.S. 2802
S-1481	Call Notes of M. Jones	PDD1715030714		Schick 3	AU; H; R; PRE; CON; CU; LF; J-MIL-7; J-MIL-12; T-MIL-1; T-MIL-4; Document description does not match document	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1482	Call Notes for M. Jones	POK003477669		Schick 4	AU; H; R; PRE; CON; CU; LF; J-MIL-7; J-MIL-12; T-MIL-1; T-MIL-4	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1483	Benefit/Risk Assessment of Opioid Therapy for Chronic Pain Advisory Board Meeting dated 11-14-201	JAN-MS-02296456		Schick 5	H; AU; LF; J-MIL-6, J-MIL-12; T-MIL-1	12 O.S. 2802

S-1484	Johnson & Johnson request for approval			Schick 6	AU; H; LF; J-MIL-9, J-MIL-12; T-MIL-1	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1485	Email dated 4-13-2005 from A. Dadd to D. Winkelman and others Re_Segmentation - Based on Past	TEVA_OK_02529011		Schick 7	AU; H; R; LF	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1486	Email dated 3-14-2018 from C. McGinn to L. Sidorsky RE_ 3040 Site Level Drug Diversions	TEVA_OK_09468143		Schick 8	AU; H; R; LF	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1487	Marketing Plan 2007, Confidential, Fentora (portion)	TEVA_OK_00064909		Schick 9	AU; H; R; INC; LF; J-MIL-12; T-MIL-1	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1488	Duragesic Sheet	JAN-MS-00310227		Schick 10	AU; H; LF; J-MIL-12; T-MIL-1	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1489	Duragesic Disease Modeling Workshop 2 Takeaways	JAN-MS-00481547		Schick 11	Inadmissible Character Evidence; R; PRE; CON; CU; AU; H; LF; J-MIL-12; T-MIL-1	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1490	Email dated 3-13-2010 from M. Mason to B. Karnig Re_ Updated Lists	JAN-OK-00138866		Schick 12	Inadmissible Character Evidence; R; PRE; CON; CU; H; R; AU; LF; J-MIL-12; T-MIL-1; PRE	12 O.S. 2401, 2402; 12 O.S. 2802
S-1491	Amended Notice for 3230(C)(5) Videotaped Deposition of Corporate Representative of Teva/Cephalon Defendants			Hassler 1	H; R; PRE	
S-1492	Summary of API Supplier Contracts in Response to Topic # 34			Hassler 2	Nuisance Statute's Safe-harbor; H; R	12 O.S. 2401, 2402; 12 O.S. 2802
S-1493	Email String to Burt Rosen_ Re: Pain Meeting	PPLPC032000015778	PPLPC032000015778	Hassler 3	First Amendment; AU; H; R; PRE; CON; CU; LF; J-MIL-3; J-MIL-7; T-MIL-1; T-MIL-4	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1494	1-26-05 Email from Burt Rosen to Jeannine Bender Re: Pain Care Forum	POK003317380		Hassler 4	First Amendment; AU; H; R; PRE; CON; CU; LF; J-MIL-3; J-MIL-7; T-MIL-1; T-MIL-4	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1495	3-10-05 Email from Burt Rosen Re: Follow-Up From Today's Discussion	POK00331695		Hassler 5	AU; H; R; PRE; CON; CU; LF; J-MIL-3; J-MIL-7; T-MIL-1; T-MIL-4	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1496	6-13-06 "The Epidemic of Pain in America" (portion)	APP2056		Hassler 6	First Amendment; AU; H; R; LF; J-MIL-2; J-MIL-3; J-MIL-12; T-MIL-1; T-MIL-6; T-MIL-7; T-MIL-10; R; PRE	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802

S-1497	7-16-09 Pain Care Forum Media Committee Report	WISPPSG00007660	Hassler 7	First Amendment; AU; H; R; LF; J-MIL-2, J-MIL-3; J-MIL-12; T-MIL-1; T-MIL-10, R; PRE	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1498	Email String Re: Tamper-Resistant Opioids	POK003297488	Hassler 8	AU; H; R; PRE; CON; CU; LF; J-MIL-2, J-MIL-3; J-MIL-7; J-MIL-12; T-MIL-1; T-MIL-4; T-MIL-10, R	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1499	8-16-16 Email String Re: Draft DEA Comments	TEVA_OK_04853771	Hassler 9	AU; H; R; LF; T-MIL-1	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1500	9-2-15 "Government Affairs Summit"	TEVA_OK_06445573	Hassler 10	AU; H; R; LF; J-MIL-2, T-MIL-1; T-MIL-10	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1501	8-8-14 Email to Aynne Klein from Jason Gardner Re: Oxycodone Quota	TEVA_OK_00897854	Hassler 11	AU; H; LF; J-MIL-4; T-MIL-1	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1502	6/10/2013 Email String to Colleen McGinn, Patrick Shields, Jason Garder, Michael Edwards form Keneeth Ferrantello Re: Buprenorphine API	TEVA_OK_00896166	Hassler 12	AU; H; LF; J-MIL-4; T-MIL-1	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1503	Manufacturing and Supply Agreement	TEVA_OK_05062553	Hassler 13	AU; H; LF; T-MIL-1; R; PRE	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1504	3-4-14 Letter from Teva to Dr. Sannerud	TEVA_OK_03573813	Hassler 14	Nuisance Statute's Safe-harbor; AU; H; R; LF; T-MIL-1; Scope	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1505	7/8/2004 Email String from Burt Rosen to Alan Must and others Re: Group List (Pain are Management & Policy Review)	PPLPC031000199946	Hassler 15	First Amendment; AU; H; R; PRE; CON; CU; LF; J-MIL-3; J-MIL-7; T-MIL-1; T-MIL-4	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1506	11-16-06 Email from Burt Rosen to Will Rowe and others RE_ I would like to send these the Pain Care Forum subject to your edits. Many Thanks	POK003300493	Hassler 16	First Amendment; AU; H; R; PRE; CON; CU; LF; J-MIL-2, J-MIL-3; J-MIL-7; T-MIL-1; T-MIL-4; T-MIL-10, R	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1507	Communications and External Affairs Committee April 24th Minutes/Action Items	PPLP004270640	Hassler 17	PRE; CON; CU; AU; H; R; Privileged; LF; J-MIL-2, J-MIL-3; J-MIL-7; T-MIL-1; T-MIL-4; T-MIL-10, R	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802

S-1508	2/25/2011 Email String from Stacey Beckhardt to J. Antonacci, J. Thatcher, A. Jerri, A. Brooks, J. Mattice Re: Comments Submitted on Behalf of Cephalon Regarding Breakthrough Pain	TEVA_OK_02446087		Hassler 18	AU; H; LF; J-MIL-2, J-MIL-3; T-MIL-1; T-MIL-10	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1509	5/23/2005 Email String from B. Cunningham to Joseph Caminiti Re: Oklahoma Medicaid and Actiq	TEVA_OK_00598841		Hassler 19	AU; H; R; T-MIL-10	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1510	12-11-17 PhRMA Board of Directors Meeting Prep Memo	TEVA_OK_01256889		Hassler 20	First Amendment; R; PRE; CON; CU; AU; H; R; PRE; LF; T-MIL-1; T-MIL-10; Scope	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1511	September 2013 Teva Executive Fly-In Briefing Book	TEVA_OK_07845215		Hassler 21	AU; H; R; LF; T-MIL-1; T-MIL-10	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1512	Alan Must Deposition Topics (defendant produced document)			Must 18	First Amendment; R; PRE; CON; CU; AU; H; PRE; A; LF; R; T-MIL-4; J-MIL-7; J-MIL-3; J-MIL-2	12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1513	Law 360 Article Gov't Opioid Suits Hide Attys Personal Interests			Must 19	R; PRE; CON; CU; AU; H; PRE; LF; T-MIL-4; J-MIL-7	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1514	J Heins Strategic Comm Review email w/ powerpoint	PPLPC031000075050	PPLPC031000075050	Must 20	AU; H; R; PRE; CON; CU; A; LF; T-MIL-4; J-MIL-7; J-MIL-3	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1515	Managing Purdue's Public Exposure	PDD1782006256	PDD1782006312	Must 21	First Amendment; AU; H; R; PRE; CON; CU; LF; T-MIL-4; J-MIL-7; J-MIL-3	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1516	Purdue Pharma Open Letter to the Public			Must 22	AU; H; R; LF; PRE; T-MIL-4; J-MIL-7	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1517	Partners Against Pain Compendium	PDD1502308553	PDD1502308555	Must 23	R; PRE; CON; CU; AU; H; PRE; LF; T-MIL-4; J-MIL-7; J-MIL-3	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1518	JCAHO Promotional Initiatives Powerprt	PDD1782032086		Must 24	R; PRE; CON; CU; AU; H; PRE; LF; T-MIL-4; J-MIL-7; J-MIL-3	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1519	"OxyContin Tablets"	PKY180239493	PKY180239553	Must 25	R; PRE; CON; CU; AU; H; PRE; LF; T-MIL-4; J-MIL-7	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802

S-1520	Purdue Frederick Memo re 1999 Budget Request	PKY180119834	PKY180119838	Must 26	R; PRE; CON; CU; AU; H; PRE; LF; T-MIL-4; J-MIL-7	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1521	Summary of Payments by Name and Year (Response to Request 1) SFC	PPLPC046000040467	PPLPC046000040467	Must 27	R; PRE; CON; CU; AU; H; PRE; LF; T-MIL-4; J-MIL-7; J-MIL-3	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1522	PainAdvocacyCommunity	PKY180149565	PKY180149571	Must 28	First Amendment; R; PRE; CON; CU; AU; H; R; PRE; LF; T-MIL-4; J-MIL-7; J-MIL-3	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1523	Purdue Marketign Tips Spt. Is Pain Awareness Month	PKY181214277	PKY181214281	Must 29	R; PRE; CON; CU; AU; H; PRE; LF; T-MIL-4; J-MIL-7; J-MIL-3	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1524	Latest on Feb 7 and 9 FDA Contracts	PPLPC031001015817	PPLPC031001015817	Must 30	First Amendment; R; PRE; CON; CU; AU; H; R; PRE; LF; T-MIL-4; J-MIL-7; J-MIL-3	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1525	FDA 2/8-8 Speakers Email - Contac Attachment, response to PROP pet.	PPLP004272003	PPLP004272003	Must 31	First Amendment; R; PRE; CON; CU; AU; H; R; PRE; LF; T-MIL-4; J-MIL-7; J-MIL-2	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1526	External Affairs Group Pwrpt 2006 Accomplishments 2007 Objectives	PPLP004302663	PPLP004298120	Must 32	First Amendment; R; PRE; CON; CU; AU; H; R; PRE; LF; T-MIL-4; J-MIL-7; J-MIL-2	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1527	External Affairs Planning Tool	PPLP004298120	PPLP004298120	Must 33	First Amendment; R; PRE; CON; CU; AU; H; R; PRE; LF; T-MIL-4; J-MIL-7; J-MIL-2	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1528	Association and HAD Primary Contact	PPLP004299093	PPLP004299097	Must 34	First Amendment; R; PRE; CON; CU; AU; H; R; PRE; LF; T-MIL-4; J-MIL-7; J-MIL-3	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1529	KT Reports	PPLP004270552	PPLP004270553	Must 35	Nuisance Statute's Safe-harbor; Preemption; R; PRE; CON; CU; AU; H; R; PRE; LF; T-MIL-4; J-MIL-7; J-MIL-3	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1530	Purdue Corporate Reputation and Visibility Strategic Plan	PPLP004281019		Must 36	R; PRE; CON; CU; AU; H; PRE; LF; T-MIL-4; J-MIL-7; J-MIL-3	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1531	Project Tango Powerpoint	PPLP004305140	PPLP004305171	Must 37	R; PRE; CON; CU; AU; H; PRE; LF; T-MIL-4; J-MIL-7; J-MIL-3; J-MIL-2	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1532	"@Purdue" Quarterly Magazine - 4th Quarter 2002	PKY181695465	PKY181695480	Must 38	First Amendment; R; PRE; CON; CU; AU; H; R; PRE; LF; T-MIL-4; J-MIL-7	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802

S-1533	New Mexico News SB 159 DEAD	PPLPC039000752730	PPLPC039000752731	Must 39	First Amendment; R; PRE; CON; CU; AU; H; R; PRE; LF; T-MIL-4; J-MIL-7; J-MIL-2	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1534	BCBS of Oklahoma	PDD8806344356		Must 40	AU; H; R; PRE; CON; CU; LF; T-MIL-4; J-MIL-7	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1535	Oklahoma ADP Hearing - Pill Crush Hearing - Sn Griffin	POK003300759		Must 41	First Amendment; AU; H; R; PRE; CON; CU; LF; T-MIL-4; J-MIL-7; J-MIL-2	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1536	Communications of External Affairs Committee	PPLP004313704	PPLP004313709	Must 42	First Amendment; R; PRE; CON; CU; AU; H; R; PRE; LF; T-MIL-4; J-MIL-7; J-MIL-3; J-MIL-2	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1537	Triplicate Kit prescribing Laws	PKY180370287	PKY180370287	Must 43	Nuisance Statute's Safe-harbor; Preemption; R; PRE; CON; CU; AU; H; R; PRE; LF; T-MIL-4; J-MIL-7; J-MIL-2	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1538	Purdue Election Contribution Spreadsheet			Must 44	First Amendment; R; PRE; CON; CU; AU; H; R; PRE; LF; T-MIL-4; J-MIL-7; J-MIL-2	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1539	Detailed Transaction List for Gary Huddleston			Must 45	First Amendment; R; PRE; CON; CU; AU; H; R; PRE; LF; T-MIL-4; J-MIL-7; J-MIL-2	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1540	Detailed Transaction List for Gary Huddleston			Must 46	First Amendment; AU; H; R; LF; PRE; T-MIL-4; J-MIL-7; J-MIL-2	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1541	New resources for OADP State Efforts	POK003333115		Must 47	First Amendment; AU; H; R; PRE; CON; CU; LF; T-MIL-4; J-MIL-7; J-MIL-2	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1542	15 Oct 17 Model Language	POK003343236		Must 48	First Amendment; R; PRE; CON; CU; AU; H; R; PRE; LF; T-MIL-4; J-MIL-7; J-MIL-2	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1543	Bill Draft for Approval	POK003348539		Must 49	First Amendment; AU; H; R; PRE; CON; CU; LF; T-MIL-4; J-MIL-7; J-MIL-2	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1544	IWG Meeting Minutes May 19, 2010	POK003339702		Must 50	First Amendment; AU; H; R; PRE; CON; CU; LF; T-MIL-4; J-MIL-7; J-MIL-2	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1545	OU DUR Memo 11/4/2004	OKAG-00012703		Must 51	H; AU; LF; T-MIL-4; J-MIL-7; J-MIL-2	
S-1546	DUR Board Meeting Minutes - 4/12/2005	OKAG-00006122		Must 52	H; AU; LF; T-MIL-4; J-MIL-7; J-MIL-2	

S-1547	Medical Liason Monthly Report Nov 2002	PPLPC034000108143	PPLPC034000108158	Must 53	First Amendment; AU; H; R; PRE; CON; CU; LF; T-MIL-4; J-MIL-7; J-MIL-2	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1548	Medical Liason Monthly Report March 2003	PPLPC036000022099	PPLPC036000022122	Must 54	First Amendment; AU; H; R; PRE; CON; CU; LF; T-MIL-4; J-MIL-7; J-MIL-2	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1549	State Groups w/ Thought Leaders	PPLPC031000182131	PPLPC031000182240	Must 55	First Amendment; AU; H; R; PRE; CON; CU; LF; T-MIL-4; J-MIL-7; J-MIL-2	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1550	Purdue PDMP Grant of \$1 million from Joe Biden	PPLPC019000512544	PPLPC019000512544	Must 56	R; PRE; CON; CU; AU; H; PRE; LF; T-MIL-4; J-MIL-7; J-MIL #2	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1551	Report on Abuse Deterrent opioids			Must 57	First Amendment; AU; H; LF; T-MIL-4; J-MIL-7; J-MIL-2	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1552	Purdue Actions to Abate the Opioid Crisis Chart			Must 58	R; PRE; CON; CU; AU; H; PRE; LF; T-MIL-4; J-MIL-7	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1553	Purdue Pharma Re-Launches Partners Against Pain website			Must 59	R; PRE; CON; CU; AU; H; PRE; LF; T-MIL-4; J-MIL-7; J-MIL-3	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1554	SDT to Thomas Mosley			Mosley 1	H; R; PRE	12 O.S. 2802
S-1555	Thomas Mosley Performance Summary	TEVA_OK_00637346		Mosley 2	AU; H	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1556	Field Contact Report	TEVA_OK_00535492		Mosley 3	AU; H	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1557	Mosley Office Visits w/ Jenkins	TEVA_OK_00099767		Mosley 4	AU; H; LF	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1558	MD's prescriptions of Fentora	TEVA_OK_00099770		Mosley 5	H; INC; AU; LF; Document description does not match document	12 O.S. 2802
S-1559	Rx List	TEVA_OK_0153990		Mosley 6	AU; H; INC; LF	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1560	Pam Costa Transcript Excerpt			Mosley 7	H; IC; LF; S; PRE	12 O.S. 2802
S-1561	Johnson & Johnson Code of Business Conduct - Live Our Credo, Know Our Code			Mashett 1	AU; H; R; PRE; CON; CU	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1562	Chart of Rates of Opioid Sales, OD Deaths, and Treatment, 1999-2010 by the CDC			Mashett 2	AU; H; R; PRE; CON; CU; INC; LF; J-MIL-12; T-MIL-1	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802

S-1563	October 2015 Noramco World Wide Narcotics Franchise PowerPoint Slide Deck	JAN-OK-00149992	JAN-OK-00150068	Mashett 5	AU; H; LF; J-MIL-4; J-MIL-12; R; PRE	
S-1564	Business Dealing with Other Opioid Manufacturers Prepared Based on a Reasonable Investigation Conducted as of the Deposition of Frnak Mashett on January 30, 2019			Mashett 26	AU; H; R; PRE; CON; CU; T-MIL-1	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1565	Ron Kuntz (G01-340) Project Rose Open PowerPoint	JAN-MS-01002292		Mashett 30	R; PRE; CON; CU; AU; H; LF	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1566	Janssen Excel Spreadsheet	JAN-MS-011-5572		Mashett 31	AU; H; LF	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1567	Janssen Excel Spreadsheet	JAN-MS-01996743		Mashett 32	AU; H; LF	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1568	Ortho-McNeil/Pricara 2005 Actual/2006 FBP Slide Deck	JAN-MS-00596156	JAN-MS-00596157	Mashett 33	AU; H; LF	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1569	"Increase in Unintentional Medication Overdose Deaths, Oklahoma, 1994-2006" by Emily Piercefield, MD, DVM, Pam Archert, MPH, Philip Kemp, Ph.D., and Sue Mallonee, RN, MPH			Mashett 34	AU; H; LF; T-MIL-7	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1570	Supply Agreement Between Noramco, Inc., and Purdue Pharma L.P.	JAN-OK-00152231	JAN-OK-00152261	Mashett 35	H; J-MIL-4; J-MIL-7; T-MIL-4; R; PRE	
S-1571	8/15/16 Brand Name OxyContin Preferred Over Generic Letter to Pharmacist from Oklahoma Health Care Authority Pharma Services	OKAG-00001669		Mashett 36	AU; H; LF; J-MIL-7; T-MIL-4; R; PRE	
S-1572	Notice			Cramer 1	AU; H; R	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1573	Excerpt of Sales Call Notes from D. McIntyre	POK003477669		Cramer 2	AU; H; R; PRE; CON; CU; J-MIL-7; T-MIL-4; J-MIL-16; INC	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1574	White House Comm. Report Full Version			Cramer 3	First Amendment; R; PRE; CON; CU; H; PRE; T-MIL-1	12 O.S. 2403; 12 O.S. 2802
S-1575	Call Notes (excerpt)	POK003477669		Cramer 4	AU; H; R; PRE; CON; CU; J-MIL-7; T-MIL-4; J-MIL-16; INC	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802

S-1576	Myths About Opioids	PKY180120983			Cramer 5	First Amendment; AU; H; R; PRE; CON; CU; T-MIL-4; J-MIL-7; LF	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1577	Excerpt of Sales Call Notes from Amie Gardiner (excerpt)	POK003477669			Cramer 6	AU; H; R; PRE; CON; CU; J-MIL-7; T-MIL-4; J-MIL-16; INC	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1578	Counseling Your Patients and Their Families Regardign the Use of Opioids	PKY180112565			Cramer 7	Discovery Violations; Nuisance Statute's Safe-harbor; Preemption; AU; H; R; PRE; CON; CU; T-MIL-4; J-MIL-7; LF	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1579	American Academy of Pain Medicine Response to PROP Petition to the FDA That Seeks to Limit Pain Medications for Legitimate Noncancer Pain Sufferers Article				Cramer 8	First Amendment; H; R; AU; LF	12 O.S. 2401, 2402; 12 O.S. 2802
S-1580	Cochrane Review				Cramer 9	Nuisance Statute's Safe-harbor; Preemption; H; R; AU; LF	12 O.S. 2401, 2402; 12 O.S. 2802
S-1581	Sales Call Notes from Mitchell Jones (excerpt)	POK003477669			Cramer 10	Judicial Estoppel; R; PRE; CON; CU; AU; H; R; PRE; J-MIL-7; T-MIL-4; J-MIL-16; INC	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1582	Transcript of I Got My Life Back P1	PKY180145193			Cramer 11	Judicial Estoppel; R; PRE; CON; CU; AU; H; R; PRE; T-MIL-4; J-MIL-7; LF	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1583	Transcript of I Got My Life Back P2	PKY180989476	PKY180989494		Cramer 12	Judicial Estoppel; R; PRE; CON; CU; AU; H; R; PRE; T-MIL-4; J-MIL-7; LF	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1584	GAO Report	POK000273432			Cramer 13	Judicial Estoppel; R; PRE; CON; CU; AU; H; R; PRE; T-MIL-4; J-MIL-7; LF	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1585	Purdue News Summary	PP LPC001000113149	PP LPC001000113165		Cramer 14	Judicial Estoppel; R; PRE; CON; CU; AU; H; R; PRE; T-MIL-4; J-MIL-7; LF	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1586	Deposition Transcript of Lauren Cambra				Cramer 15	Judicial Estoppel; R; PRE; CON; CU; AU; H; R; PRE; LF	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1587	Call Notes in OKC (excerpt)	POK003477669			Cramer 16	AU; H; R; PRE; CON; CU; J-MIL-7; T-MIL-4; J-MIL-16; INC	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802

S-1588	AAPM/APS Consensus Statement	PKY180816034	PKY180816037	Cramer 17	First Amendment; Nuisance Statute's Safe-harbor; Preemption; AU; H; R; PRE; CON; CU; T-MIL-4; J- MIL-7; LF	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1589	Principles of Analgesic Use in the Treatment of Pain - APS	PKY180227566	PKY180227633	Cramer 18	AU; H; R; PRE; CON; CU; T-MIL-4; J- MIL-7; LF	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1590	PR Program Pain is the 5th Vital Sign	PKY183052626		Cramer 19	First Amendment; R; PRE; CON; CU; AU; H; R; PRE; T-MIL-4; J-MIL-7; LF	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1591	Call Notes in OKC (excerpt)	POK003477659		Cramer 20	AU; H; R; PRE; CON; CU; J-MIL-7; T- MIL-4; J-MIL-16; INC	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1592	2012 10 Year Plan	PPLPC034000636268	PPLPC034000636268	Cramer 21	AU; H; R; PRE; CON; CU; T-MIL-4; J- MIL-7; LF	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1593	2012 OxyContin Tablets Budget Submission	PPLP004244463	PPLP004244493	Cramer 22	AU; H; R; PRE; CON; CU; T-MIL-4; J- MIL-7; LF	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1594	Creative Services Copy Clearance	PKY180383234	PKY180383238	Cramer 23	First Amendment; Nuisance Statute's Safe-harbor; Preemption; AU; H; R; PRE; CON; CU; T-MIL-4; J- MIL-7; LF	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1595	Creative Services Copy Clearance	PKY180339368	PKY180339377	Cramer 24	Judicial Estoppel; R; PRE; CON; CU; AU; H; R; PRE; T-MIL-4; J-MIL-7; LF	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1596	Physician Request Form	PKY180780836	PKY180780836	Cramer 25	AU; H; R; PRE; CON; CU; T-MIL-4; J- MIL-7; LF	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1597	Benefit Risk Assessment of Opioid Therapy for Chronic Pain Advisory Board Meeting	JAN-MS-02296456		Cramer 26	First Amendment; Nuisance Statute's Safe-harbor; Preemption; AU; H; R; PRE; LF	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1598	WHO Cancer Pain Relief	8100237248		Cramer 27	H; AU; LF	12 O.S. 2802
S-1599	Cancer Pain Relief and palliative care - Who Expert Report			Cramer 28	Discovery Violations; H; R; AU; LF	12 O.S. 2401, 2402; 12 O.S. 2802
S-1600	The Management of Pain - Bonia Book Excerpt			Cramer 29	H; AU; LF	12 O.S. 2802
S-1601	New Drug Application for Oxycontin	PPLP000602339		Cramer 30	Inadmissible Character Evidence; R; PRE; CON; CU; AU; H; R; PRE; T-MIL- 4; J-MIL-7; LF	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802

S-1602	OxyContin Package Insert				Cramer 31	H; R; T-MIL-4; J-MIL-7; AU; LF; PRE	12 O.S. 2401, 2402; 12 O.S. 2802
S-1603	Nat'l Institute on Drug Abuse Poster				Cramer 32	Nuisance Statute's Safe-harbor; Preemption; AU; H; R; LF	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1604	NIH Archives Website screenshot				Cramer 33	H; AU; LF	12 O.S. 2802
S-1605	The Economic Impact of Opioid Use in the Management of Chronic Nonmalignant Pain - Lipman				Cramer 34	H; AU; LF	12 O.S. 2802
S-1606	What Percentage of Chronic Nonmalignant Pain Patients Exposed to Chronic Opioid Analgesic Therapy Develop Abuse/Addiction and/or Aberrant Drug-Related Behaviors? A Structured Evidence-Based Review - Fishbain				Cramer 35	R; PRE; CON; CU; H; PRE; AU; LF	12 O.S. 2403; 12 O.S. 2802
S-1607	OxyContin Package Insert				Cramer 36	H; R; T-MIL-4; J-MIL-7; AU; LF; PRE	12 O.S. 2401, 2402; 12 O.S. 2802
S-1608	Key promotional initiatives to ensure product promotion	PKY181656389		PKY181656390	Cramer 37	AU; H; R; PRE; CON; CU; T-MIL-4; J-MIL-7; LF	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1609	Purdue Health Care Compliance Policies	PKY1813004415			Cramer 38	AU; H; R; PRE; CON; CU; T-MIL-4; J-MIL-7; LF	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1610	Purdue Incentive Bonus Program	PDD1503491351		PDD1503491360	Cramer 39	AU; H; R; PRE; CON; CU; T-MIL-4; J-MIL-7; LF	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1611	RADARS System Field Research Results	PPLPC025000074612		PPLPC025000074616	Cramer 40	AU; H; R; PRE; CON; CU; T-MIL-4; J-MIL-7; LF	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1612	Purdue Pharma Grant Review Committee Summary Report	PPLPC018000439136		PPLPC018000439217	Cramer 41	AU; H; R; PRE; CON; CU; T-MIL-4; J-MIL-7; LF	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1613	SoonerCare Medicare/Medicaid	POK003531640			Cramer 42	AU; H; R; PRE; CON; CU; T-MIL-4; J-MIL-7; LF	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1614	Co-Promotion Topic 33	PKY181021847		PKY181021851	Cramer 43	R; PRE; CON; CU; AU; H; PRE; T-MIL-4; J-MIL-7; LF	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802

S-1615	Call Notes from Sheryl Brimberry (excerpt)	POK003477669		Cramer 44	AU; H; R; PRE; CON; CU; J-MIL-7; T-MIL-4; J-MIL-16; INC	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602; 12 O.S. 2901; 12 O.S. 2802
S-1616	2006 Update	PDD8901791203		Cramer 45	Nuisance Statute's Safe-harbor; AU; H; R; PRE; CON; CU; T-MIL-4; J-MIL-7; LF	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602; 12 O.S. 2901; 12 O.S. 2802
S-1617	Purdue Letter to Physicians regarding negative media	PKY181424022	PKY181424022	Cramer 46	R; PRE; CON; CU; AU; H; PRE; T-MIL-4; J-MIL-7; LF	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602; 12 O.S. 2901; 12 O.S. 2802
S-1618	Analgesia Sales Force letter	PPLP003444878	PPLP003444879	Cramer 47	AU; H; R; PRE; CON; CU; T-MIL-4; J-MIL-7; LF	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602; 12 O.S. 2901; 12 O.S. 2802
S-1619	Purdue Quarterly Report To The Board	PDD8901530511	PDD8901530538	Cramer 48	Nuisance Statute's Safe-harbor; AU; H; R; PRE; CON; CU; T-MIL-4; J-MIL-7; LF	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602; 12 O.S. 2901; 12 O.S. 2802
S-1620	OxyContin 2012 ACAM Part 2	PKY183117966		Cramer 49	AU; H; R; PRE; CON; CU; T-MIL-4; J-MIL-7; LF	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602; 12 O.S. 2901; 12 O.S. 2802
S-1621	Abbott Purdue Sales Bulletin	PKY180241316		Cramer 50	AU; H; R; PRE; CON; CU; T-MIL-4; J-MIL-7; LF	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602; 12 O.S. 2901; 12 O.S. 2802
S-1622	News Story About Oxycontin video email J. heins	PPLP004158474		Cramer 51	Judicial Estoppel; R; PRE; CON; CU; AU; H; R; PRE; T-MIL-4; J-MIL-7; LF	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602; 12 O.S. 2901; 12 O.S. 2802
S-1623	Tonya Ratcliff LinkedIn Profile			Ratcliff 1	Judicial Estoppel; R; PRE; CON; CU; AU; H; R; PRE	12 O.S. 2401, 2402; 12 O.S. 2602; 12 O.S. 2901; 12 O.S. 2802
S-1624	Notice to take Videotaped Deposition			Ratcliff 2	Judicial Estoppel; R; PRE; CON; CU; AU; R; H; PRE	12 O.S. 2401, 2402; 12 O.S. 2602; 12 O.S. 2901
S-1625	State's Second Amended Disclosure of Individuals likely to have Discoverable Information that may be used to support the claims or defenses			Ratcliff 3	Judicial Estoppel; R; PRE; CON; CU; H; R; PRE	12 O.S. 2401, 2402; 12 O.S. 2802
S-1626	Oklahoma Healthcare Authority, Drug Utilization Review Board Meeting, Minutes of Meeting of September 9, 2015			Ratcliff 4	AU; H; R; LF; PRE; T-MIL-7	12 O.S. 2401, 2402; 12 O.S. 2602; 12 O.S. 2901; 12 O.S. 2802
S-1627	OxyContin Launch Plan	PKY180111098		Cramer 52	AU; H; R; PRE; CON; CU; T-MIL-4; J-MIL-7; LF	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602; 12 O.S. 2901; 12 O.S. 2802

S-1628	Email dated 6-3-1997 from M. Cullen	PDD9316506202	PDD9316506202			Cramer 53	AU; H; R; PRE; CON; CU; T-MIL-4; J-MIL-7; LF	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1629	Email dated 5-28-1997 from M. Friedman to R. Sackler and others	PDD9316506236				Cramer 54	AU; H; R; PRE; CON; CU; T-MIL-4; J-MIL-7; LF	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1630	"Titration" by Mary Beth Miller	PKY181215519	PKY181215519			Cramer 55	AU; H; R; PRE; CON; CU; T-MIL-4; J-MIL-7; LF	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1631	Memo dated 1-19-1999 by P. Cramer	PKY180239263	PKY180239263			Cramer 56	AU; H; R; PRE; CON; CU; T-MIL-4; J-MIL-7; LF	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1632	Call Notes for Thomas Ashcraft (excerpt)	POK003477669				Cramer 57	AU; H; R; PRE; CON; CU; J-MIL-7; T-MIL-4; J-MIL-16; INC	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1633	Team Link Newsletter, Volume 13, Number 5	PDD9316711985	PDD9316712004			Cramer 58	AU; H; R; PRE; CON; CU; T-MIL-4; J-MIL-7; LF	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1634	Call Notes for C. Brimberry (excerpt)	POK003477669				Cramer 59	AU; H; R; PRE; CON; CU; J-MIL-7; T-MIL-4; J-MIL-16; INC	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1635	PowerPoint Presentation	PPLPC03000265308	PPLPC03000265308			Cramer 60	AU; H; R; PRE; CON; CU; T-MIL-4; J-MIL-7; LF	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1636	Call Notes for C. Brimberry, 2000, 2001 (excerpt)	POK003477669				Cramer 61	AU; H; R; PRE; CON; CU; J-MIL-7; T-MIL-4; J-MIL-16; INC	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1637	Email chain dated 11-2012 Involving Purdue Employees	POK003581455				Cramer 62	AU; H; R; PRE; CON; CU; T-MIL-4; J-MIL-7; LF	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1638	Advertisement for the Leadership Summit on Pain Management dated 7-31-2000	PKY180129816	PKY180129816			Cramer 63	AU; H; R; PRE; CON; CU; T-MIL-4; J-MIL-7; LF	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1639	Email Chain dated 3-29-2013 between D. McIntyre and L. Butler	POK003545793				Cramer 64	AU; H; R; PRE; CON; CU; T-MIL-4; J-MIL-7; LF	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1640	"Authority to Sell" PowerPoint	PKY151502297				Cramer 65	AU; H; R; PRE; CON; CU; T-MIL-4; J-MIL-7; LF	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802

S-1641	"The Resistance Model of Selling" PowerPoint	PKY181530125	PKY181530173	Cramer 66	AU; H; R; PRE; CON; CU; T-MIL-4; J-MIL-7; LF	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1642	Excerpts from Call Notes (excerpt)	POX003477669		Cramer 67	AU; H; R; PRE; CON; CU; J-MIL-7; T-MIL-4; J-MIL-16; INC	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1643	"Keys to the Compliance Kindgon" PowerPoint	PPLPC032000223825	PPLPC032000223825	Cramer 68	AU; H; R; PRE; CON; CU; T-MIL-4; J-MIL-7; LF	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1644	LBD Budget Presentation PowerPoint	PPLPC001000029707	PPLPC001000029707	Cramer 69	AU; H; R; PRE; CON; CU; T-MIL-4; J-MIL-7; LF	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1645	2013 OxyContin Annual Marketing Plan	PPLP003428932	PPLP003428965	Cramer 70	AU; H; R; PRE; CON; CU; T-MIL-4; J-MIL-7; LF	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1646	"Identifying Granular Growth Opportunities for OxyContin. First Board Update"	PPLPC029000533172	PPLPC029000533190	Cramer 71	AU; H; R; PRE; CON; CU; T-MIL-4; J-MIL-7; LF	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1647	"Identifying Granular Growth Opportunities for OxyContin. Addendum to July 18th and August 5th Updates."	PPLPC028000498476	PPLPC028000498482	Cramer 72	AU; H; R; PRE; CON; CU; T-MIL-4; J-MIL-7; LF	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1648	"EZE: Evolve to Excellence" PowerPoint	PPLPC035000198773		Cramer 73	AU; H; R; PRE; CON; CU; T-MIL-4; J-MIL-7; LF	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1649	Action Plan for 2014 First Quarter	PMA000196209		Cramer 74	AU; H; R; T-MIL-4; J-MIL-7; LF; PRE	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1650	"Maximizing Benefits from Opioid Surveillance" PowerPoint	PDD8901541892	PDD8901541893	Cramer 75	AU; H; R; PRE; CON; CU; T-MIL-4; J-MIL-7; LF	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1651	"Evolve 2 Excellence 2013 Program"	PPLPC034000830891	PPLPC034000830891	Cramer 76	AU; H; R; PRE; CON; CU; T-MIL-4; J-MIL-7; LF	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1652	USA oxycodone consumption (mg/capita) 1980-2015 chart from World Health Organization			Cramer 77	AU; H; R; T-MIL-4; J-MIL-7; LF; PRE	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1653	1987 MS Contin Label	PDD8023012065		Cramer 78	AU; H; R; PRE; CON; CU; T-MIL-4; J-MIL-7; LF	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802

S-1654	Purdue's Ten-Point Plan	PPLPC02800004009		Cramer 79	AU; H; R; PRE; CON; CU; T-MIL-4; J-MIL-7; LF	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1655	Notice to take Videotaped Deposition			Hoos 1	R	12 O.S. 2401, 2402
S-1656	Proposed Target Key Opinion Leaders PPR Communications	PPLP004268991		Cramer 55	AU; H; R; PRE; CON; CU; T-MIL-4; J-MIL-7; LF	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1657	Medical Affairs Analgesia Medical Science Liaison Report (July 2004)	JAN-MS-01203019		Cramer 56	T-MIL-4; J-MIL-7; AU; LF; H; R; PRE	
S-1658	PAINS Project	JAN-MS-00397451		Cramer 57	A; LF; H	
S-1659	PAINS Project - 2012 Annual Meeting Invitees	JAN-MS-00411906		Cramer 58	A; LF; H	
S-1660	9-27-11 Email from Burt Rosen re : IOM Task Force	PPLP004285947	PPLP004285949	Cramer 59	AU; H; R; PRE; CON; CU; T-MIL-4; J-MIL-7; LF	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1661	Pain Care Forum Participating Organizations	JAN-MS00992093		Cramer 60	R; H; AU; LF	
S-1662	Purdue Lecture Program Group Check	PKY18050606543		Cramer 61	AU; H; R; PRE; CON; CU; T-MIL-4; J-MIL-7; LF	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1663	List Oklahoma Speaker Program Data			Cramer 62	T-MIL-4; J-MIL-7; AU; LF; H; R; PRE	
S-1664	OxyContin 2010 ACAM May 2009	PPLP003421596	PPLP003421744	Cramer 63	AU; H; R; PRE; CON; CU; T-MIL-4; J-MIL-7; LF	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1665	Purdue - Sales & Marketing Budget Meeting	PDD8901061469		Cramer 64	AU; H; R; PRE; CON; CU; T-MIL-4; J-MIL-7; LF	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1666	Cover Sheet (Metadata) with Call Notes Attached	POK003477669		Cramer 65	AU; H; R; PRE; CON; CU; J-MIL-7; T-MIL-4; J-MIL-16; INC	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1667	OxyContin Launch Plan	PDD1502302206		Cramer 66	AU; H; R; PRE; CON; CU; T-MIL-4; J-MIL-7; LF	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1668	Email from James Lang re Educational Grant	PKY180245078	PKY180245078	Cramer 67	AU; H; R; PRE; CON; CU; T-MIL-4; J-MIL-7; LF	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1669	Groundhog - Top 5 Customers	JAN-OK-00150475		Cramer 68	AU; H; R; PRE; LF	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802

S-1670	Partners Against Pain - Making a Difference in the Treatment of Pain	PKY180109015	PKY180109029	Cramer 69	AU; H; R; PRE; CON; CU; T-MIL-4; J-MIL-7; LF	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1671	9-15-17 Email String re: Statement for Monday's Meeting in Trenton	PPLPC032000400431	PPLPC032000400432	Cramer 70	AU; H; R; PRE; CON; CU; T-MIL-4; J-MIL-7; LF	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1672	Cancer Pain Relief Article 1986			Cramer 71	H	12 O.S. 2802
S-1673	Cancer Pain Relief and Palliative Care Report of a WHO Expert Committee			Cramer 72	H	12 O.S. 2802
S-1674	The Management of Pain - John J. Bonica			Cramer 73	H	12 O.S. 2802
S-1675	New Drug Application - Volume 105 OxyContin	PPLP000602339		Cramer 74	AU; H; R; PRE; CON; CU; T-MIL-4; J-MIL-7; LF	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1676	OxyContin Prescribing Information National Institute on Drug Abuse Research Report - Prescription Drugs Abuse and Addiction	PDD1501602953		Cramer 75	AU; H; R; PRE; CON; CU; T-MIL-4; J-MIL-7; LF	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1677	NIH Archives			Cramer 76	H	12 O.S. 2802
S-1678	Technical Operations and Non-Clinical Research & Development Communication Meeting February 6, 2006			Cramer 77	AU; H	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1679	Original Petition	PDDD8901755166		Cramer 78	AU; H; R; PRE; CON; CU; T-MIL-4; J-MIL-7; LF	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1680	Plaintiff's Amended Disclosure of Individuals			Box 1	R; N/A	12 O.S. 2401, 2402
S-1681	Medical examiner's report			Box 2	AU; H; R; PRE; CON; CU	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1682	Article in Oklahoman entitled "Prescription painkiller blamed in OU linebacker's death"			Box 3	Judicial Estoppel; R; PRE; CON; CU; AU; H; R; PRE; N/A	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1683	News article entitled "Sooners, family search for answers to Austin Box's death"			Box 4	Judicial Estoppel; R; PRE; CON; CU; AU; H; R; PRE; N/A	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1684				Box 5	Judicial Estoppel; R; PRE; CON; CU; AU; H; R; PRE; N/A	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802

S-1685	News article entitled "Gail Box inspires as opioid crisis that gripped her son Austin rages"				Box 6	Judicial Estoppel; R; PRE; CON; CU; AU; H; R; PRE; N/A	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1686	Article entitled "Austin Box's Parents Speak Out Two Years After Son's Death"				Box 7	Judicial Estoppel; R; PRE; CON; CU; AU; H; R; PRE; N/A	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1687	Petition filed in State of Oklahoma v. Purdue Pharma, et. Al.				McGregor 1	N/A	
S-1688	The State's Expert Witness Disclosures in State of Oklahoma v Purdue Pharma, et al.				McGregor 2	R	
S-1689	Email re RFP06181	JAN-OK-00147447				AU; H; R; LF; J-MIL-9	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1690	Email re RFP Coming soon with verbiage for website	JAN-OK-00147288				H; R; AU; LF; J-MIL-9	12 O.S. 2401, 2402; 12 O.S. 2802
S-1691	Email re New Johnson & Johnson Request for Proposal Now Posted	JAN-OK-00147327				AU; H; R; LF; J-MIL-9	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1692	Email re Duragesic Proposal	JAN-MS-00311528				AU; H	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1693	Janssen Product News Update - re Abuse Potential of Opioids	JAN-MS-01192118				AU; H; R	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1694	Redline of Pain Community Briefing Meeting Notes	JAN-MS-00393725				AU; H; R	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1695	Burden of Pain PowerPoint	JAN-MS-00667427				AU; H	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1696	Pain Coalition Meeting	JAN-MS-00403041				First Amendment; AU; H; R	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1697	Duragesic - Market Research: Trends in Promotion and Message Delivery PowerPoint	JAN-MS-00305673&JAN-MS-00305674				AU; H; R	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1698	Duragesic - Positioning/Message/Campaign Evolution Overview	JAN-MS-00306326&JAN-MS-00306327				AU; H; R	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1699	Janssen - Pain Review PowerPoint	JAN-MS-00484882				AU; H	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802

S-1700	Duragesic - Grow and Defend to Build for the Future 2005 Business Plan	JAN-MS-02771548				AU; H; R	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1701	Letter to Thomas Abrams, Director of Division of Drug Marketing re NDA 19-813 Duragesic II	JAN-MS-00480561				AU; H	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1702	Janssen - Imagine the Possibilities: Building the Pain Coalition - Member Recommendations	JAN-MS-00402599&JAN-MS-00402600				First Amendment; AU; H; R	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1703	Email from Christine DeVries re Message refinement	JAN-MS-00246886				AU; H; R	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1704	Email from Steve Zollo to Chupa and Fitzsimons re ALZA	JAN-MS-00247144				AU; H; R	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1705	Duragesic Learning System - The Chronic Pain Marketplace Optimizing Chronic Pain Management with Duragesic, An educational resource provided by Janssen Pharmaceutica Products, LP	JAN-MS-00302831				AU; H	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1706	Email from Susan Jones re Non Branded Campaign Research - Logistics	JAN-MS-00310474				AU; H; PRE; CON; INC; R	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1707	Reactions to A Non-Branded Campaign Regarding the Acute Use of Opioid Analgesics Physician Discussion Guide	JAN-MS-00322887				AU; H; R	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1708	PriCara Tapentadol Professional Education Acute Pain Management Message Platform - Health Science Communications	JAN-MS-00322889				AU; H; R	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1709	Tapentadol Professional Education Message Platform - Health Science Communications	JAN-MS-00323382				AU; H	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1710	Letter to Director of Office of Generic Drugs re NDA 19-183 Duragesic (fentanyl transdermal system) with attached Application to Market a New Drug	JAN-MS-00339425				AU; H; R	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1711		JAN-MS-00412269				AU; H	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802

S-1712	Duragesic Clinical Overview by Gary J. Vorsanger	JAN-MS-00598224				Discovery Violations; R; PRE; CON; CU; AU; H; R; PRE	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1713	Substance Abuse Issues in Chronic Pain by Steven Passik	JAN-MS-00776171				Discovery Violations; AU; H	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1714	Psychological Dependence with Opioids: Focus on Duragesic (fentanyl transdermal system) CII by Janssen	JAN-MS-00786435				AU; H; PRE; CON; INC; R	
S-1715	Instructus - The RJO Healthcare Group - Johnson & Johnson Services, Inc. - Tapentadol eLearning Proposal	JAN-MS-00810115				AU; H	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1716	American Cancer Society Pain Management Pocket Tool - Commonly Used Non-Opioid Analgesics	JAN-MS-00862339				AU; H; R	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1717	Duragesic - Expert Statement	JAN-MS-00901275				R; PRE; CON; CU; AU; H; PRE	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1718	Iatrogenic addiction	JAN-MS-02132710				First Amendment; Judicial Estoppel; Nuisance Statute's Safe-harbor; Preemption; R; PRE; CON; CU; AU; H; R; PRE	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1719	2002 Janssen Pain Franchise Review Executive Summary from Jennifer McElheeron & Mike Lee re Advisory Board Evaluations	JAN-MS-03065657				Nuisance Statute's Safe-harbor; Preemption; PRE; CON; CU; AU; H; R; PRE; LF; J-MIL-3	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1720	Johnson & Johnson Partner of Choice in Pharmaceuticals PowerPoint (Project Tappas Presentation) with cover email	JAN-MS-00306640				AU; H	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1721	Duragesic Sample Voucher Program Regional Redemptions (01/01/03 to 05/03/03) Excel	JAN-MS-01002291&JAN-MS-01002292				R; PRE; CON; CU; AU; H	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1722	Imagine the Possibilities - Pain Coalition - Launch Meeting and cover email	JAN-MS-00939605&JAN-MS-00939606				Inadmissible Character Evidence; Nuisance Statute's Safe-harbor; Preemption; R; PRE; CON; CU; AU; H; R; PRE	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1723						First Amendment; AU; H; R	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802

S-1724	PPSG Meeting Notes	PKY180298669	PKY180298670			AU; H; R; PRE; CON; CU; LF; V; J-MIL-7; T-MIL-4; J-MIL-3	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1725	Agenda - Meeting Between Members of Purdue Pharma, LP and the Pain & Policy Studies Group	PKY180298668	PKY180298668			First Amendment; R; PRE; CON; CU; AU; H; R; PRE; LF; J-MIL-7; T-MIL-4; J-MIL-3	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1726	Letter to Brenda Marques, Reviewer of Drugs of Abuse Division of Drug Marketing re NDA 19-813 Duragesic II	JAN-MS-00779363				AU; H; R	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1727	Janssen Pharmaceutica - 1998 Sales Representative Personnel Review of Tone Jones	JAN-OK-00132730				AU; H; R	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1728	Nucynta Partnering Initiative between PriCara Pain, AI/GI and CV Institutional	JAN-OK-00137744				H; R	12 O.S. 2401, 2402; 12 O.S. 2802
S-1729	Master Advocate Listing & cover email	JAN-MS-02533808	JAN-MS-02533814			CON; CU; SUM	
S-1730	Email from Bo Boson re OK 1Q 2012 Strategy includes Rxper day to meet quota	JAN-OK-00134650				AU; H	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1731	PainForce Targeted HCP Demographics - Southwest District - PowerPoint Presentation	JAN-MS-00670266				R; PRE; CON; CU; AU; H; PRE	12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1732	Pain Non-Branded Campaign Market Research "Round 2" Findings & Recommendations Final Report	JAN-MS-02565606				Nuisance Statute's Safe-harbor; Preemption; R; PRE; CON; CU; AU; H; R; PRE	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1733	American Academy of Pain Medicine Annual Meeting - Business Intelligence Presentation to Nucynta Team	JAN-MS-02948683				First Amendment; Nuisance Statute's Safe-harbor; Preemption; R; PRE; CON; CU; AU; H; R; PRE	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1734	Sales Representative Advisory Council Meeting Notes March 14, 2002, Hyatt Regency Baltimore	JAN-MS-00304197				AU; H; R	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1735	Field Coach Report - Work With Letter	JAN-OK-00133238				AU; H	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1736	Retail Rep Calibration Form 2012	JAN-OK-00135560				AU; H	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802

S-1737	Email from James Lang re Neighborhood Update	PKY181271694	PKY181271695			First Amendment; R; PRE; CON; CU; AU; H; R; PRE; LF; J-MIL-7; T-MIL-4; J-MIL-3	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602; 12 O.S. 2901; 12 O.S. 2802
S-1738	Email from Yong Yue re A report from AHRQ on long term opioid treatment of pain	JAN-MS-00246480				Nuisance Statute's Safe-harbor; Preemption; AU; H; R	12 O.S. 2401, 2402; 12 O.S. 2602; 12 O.S. 2901; 12 O.S. 2802
S-1739	Local Market Selling Certification Parameters	JAN-MS-00063128				AU; H; R; PRE; CON; CU	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602; 12 O.S. 2901; 12 O.S. 2802
S-1740	Nucynta Metrics That Matter - Week 52 Ending June 18, 2010	JAN-MS-00358318				AU; H	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1741	Email from Timothy Ferencik re Boston South Voucher Allocation	JAN-MS-00358629				AU; H; R	12 O.S. 2401, 2402; 12 O.S. 2602; 12 O.S. 2901; 12 O.S. 2802
S-1742	Janssen Individual Goals & Objectives - Gary Vorsanger	JAN-MS-00489888				AU; H; R	12 O.S. 2401, 2402; 12 O.S. 2602; 12 O.S. 2901; 12 O.S. 2802
S-1743	Durogesic/Duragesic/Duratep Strategy Project, Status Dec 26, 2001 Project Scope & Plan with cover email	JAN-MS-00902068				R; PRE; CON; CU; AU; H; PRE	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602; 12 O.S. 2901; 12 O.S. 2802
S-1744	Email to Burt Rosen re McNeil Monitoring - Consumer Reports - 'Special Report: The dangers of pain killers'	JAN-MS-00996775				First Amendment; Nuisance Statute's Safe-harbor; Preemption; R; PRE; CON; CU; H; R; PRE	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2802
S-1745	Institutional Incentive Compensation Goals Jul - Sep 2011 Methodology & Goals & cover email	JAN-OK-00137461&JAN-OK-00137462				AU; H	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1746	Johnson & Johnson Achieving Pull Through Excellence: Driving Demand by Leveraging Access PowerPoint and cover email	JAN-OK-00137525&JAN-OK-00137527				AU; H	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1747	Email from Peter Moore re Mid Atlantic Ad Board Conference Call Agenda with Richmond Pain District Article Review - Trends in Medical Use and Abuse of Opioid Analgesics	JAN-MS-03069724				AU; H; R; LF; J-MIL-3	12 O.S. 2401, 2402; 12 O.S. 2602; 12 O.S. 2901; 12 O.S. 2802

S-1748	Janssen - Evolving Medicaid and Medicare Markets - Duragesic Medicaid Fact Base, May 22, 2003 with cover email	JAN-MS-00299274				R; PRE; CON; CU; AU; H; PRE	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1749	Janssen Important Correction of Drug Information - Letter to Health Care Professionals with Duragesic warning	JAN-MS-00776286				First Amendment; J-MIL #10; PRE; CON; LF	
S-1750	Janssen - Tapentadol work Session October 7, 2010	JAN-MS-02947989				Nuisance Statute's Safe-harbor; R	12 O.S. 2401, 2402
S-1751	Beth Israel Letter to Robyn Kohn re Pricara	JAN-MS-00929463				AU; H; R	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1752	2011 Institutional Specialist PDM Mid-Year Review: Kelly VanBurkleo	JAN-OK-00137781				AU; H; R	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1753	Incentive Compensation Scorecard - April 2011	JAN-OK-00137822				AU; H; R; PRE; CON; CU	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1754	2011 Jason Day PDM Sales Results	JAN-OK-00137844				AU; H	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1755	Incentive Compensation Scorecard - September 2011	JAN-OK-00137850				AU; H; R; PRE; CON; CU	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1756	Incentive Compensation - December 2011	JAN-OK-00138072				AU; H; R; PRE; CON; CU	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1757	Medical Development Project Statement, Status: June 26, 2001	JAN-MS-00491921				Nuisance Statute's Safe-harbor; Preemption; AU; H; R	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1758	Email from Kellie McLaughlin re The New York Times Article - Duragesic Letter from Daniel Donovan III to the Honorable Max Baucus, Chairman and the Honorable Charles E. Grassley in response to May 8, 2012 letter	JAN-MS-02379476				AU; H	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1759		JAN-OK-00144156				First Amendment; AU; H	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802

S-1760	Letter from Daniel Donovan III to the Honorable Max Baucus, Chairman and the Honorable Charles E. Grassley in response to Request 7 of May 8, 2012 letter	JAN-OK-00144159				First Amendment; AU; H	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1761	Email from Bob Twillman re Your CDC opioid guideline article	TWILLMAN 017921	TWILLMAN 017923			AU; H; PRE; CON; CU; LF; J-MIL-3	12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1762	Email from Bob Twillman to Burt Rosen re planting a question to DEA on access	TWILLMAN 036943	TWILLMAN 036944			First Amendment; AU; H; R; J-MIL-7; T-MIL-4; PRE; J-MIL-3	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1763	Email from Peter Christ re experts Meeting F/U	JAN-MS-00305231				First Amendment; AU; H; R	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1764	Noramco Letter to DEA re 2009 Morphine and Oxycodone Quota	JAN-OK-00168239				AU; H; R	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1765	Email from Alyson Lewis re Pain Language	JAN-MS-00263558				First Amendment; AU; H; R	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1766	Work Order - Project: Laying the Foundation to Drive Nucynta Growth	JAN-MS-00659270				AU; H; R	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1767	Opioid Company Revenue Received Jan 2007 - Jun 2013	AIPM00000005	AIPM000000005			First Amendment; AU; H; R; LF; J-MIL-7; PRE; J-MIL-3	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1768	Johnson & Johnson Tapentadol Hydrochloride Pediatric Investigational Plan and Staged Deferral Request Module 1.9.2	JAN-MS-00230430				PRE; CON; CU; AU; H; R	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1769	Email from Richarz Ute to Bruce Moskovitz re Durogesic Slide Kit	JAN-MS-00495427				AU; H	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1770	Redline of Abuse and Diversion of Immediate-Release Prescription Opioids: 30 Months of Data from the RADARS system with cover email	JAN-MS-00636529&JAN-MS-00636531				First Amendment; AU; H; R	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1771	NEO Website - The Impact of Undertreated Pain	JAN-MS-00819667				First Amendment; AU; H; R	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802

S-1772	Email from Brigitte Kuperwasser re Fentanyl	JAN-MS-00896200				R; PRE; CON; CU; AU; H; PRE	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602; 12 O.S. 2901; 12 O.S. 2802
S-1773	Email to Gary Vorsanger re Surge in Fentanyl abuse	JAN-MS-02310050				R; PRE; CON; CU; AU; H; PRE	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602; 12 O.S. 2901; 12 O.S. 2802
S-1774	Email from Russell Wilson re Week 66 - Nycynta Hotsheet 9/24/10	JAN-OK-00137307				AU; H	12 O.S. 2602; 12 O.S. 2901; 12 O.S. 2802
S-1775	2010 PDM Year End Template for: Kelly VanBurkelo	JAN-OK-00137734				AU; H; R	12 O.S. 2401, 2402; 12 O.S. 2602; 12 O.S. 2901; 12 O.S. 2802
S-1776	Meeting Feedback from other members on Media Outreach on October 12th	JAN-MS-01453905				PRE; CON; CU; AU; H; R	12 O.S. 2401, 2402; 12 O.S. 2602; 12 O.S. 2901; 12 O.S. 2802
S-1777	Email from Lisa Ferguson to Robyn Konn and Jeffrey Christensen re Advocacy Opportunities	JAN-MS-00263347				First Amendment; AU; H	12 O.S. 2602; 12 O.S. 2901; 12 O.S. 2802
S-1778	Email from Tricia Haertlein to Burce Moskowitz re 7-Day Duragesic Patch	JAN-MS-00284719				AU; H; R	12 O.S. 2401, 2402; 12 O.S. 2602; 12 O.S. 2901; 12 O.S. 2802
S-1779	Performance and Coaching Report Spreadsheet with cover email	JAN-MS-00861174&JAN-MS-00861175				First Amendment; R; PRE; CON; CU; AU; H; R	12 O.S. 2401, 2402; 12 O.S. 2602; 12 O.S. 2901; 12 O.S. 2802
S-1780	Janssen Tapentadol IR and ER 2008 Strategic Plan with cover email	JAN-MS-01128760&JAN-MS-01128761				Nuisance Statute's Safe-harbor; Preemption; AU; H; R	12 O.S. 2401, 2402; 12 O.S. 2602; 12 O.S. 2901; 12 O.S. 2802
S-1781	Bruce Moskowitz edited Janssen Tapentadol IR and ER 2008 Strategic Plan	JAN-MS-02572996				AU; H	12 O.S. 2602; 12 O.S. 2901; 12 O.S. 2802
S-1782	Testimony on behalf of the Pharmaceutical Research Manufacturers Association (PhRMA) before the Committee on Government Reform Subcommittee on Criminal Justice, Drug Policy and Human Resources	PPLPC031000171908	PPLPC031000171920			First Amendment; AU; H; R; PRE; CON; CU; LF; J-MIL-3; J-MIL-7; T-MIL-4	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602; 12 O.S. 2901; 12 O.S. 2802
S-1783	Emails with Mmo re Wall Street Journal Article on Opium Demand	PPLPC031000049260	PPLPC031000049261			Nuisance Statute's Safe-harbor; AU; H; R; PRE; CON; CU; LF; J-MIL-3; J-MIL-7; T-MIL-4	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602; 12 O.S. 2901; 12 O.S. 2802

S-1784	Email from Jonathan Sackler re Ortho - J&J, possible business transactions with Janssen	PPLPC045000002403	PPLPC045000002405		AU; H; R; PRE; CON; CU; LF; J-MIL-3; J-MIL-7; T-MIL-4	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1785	Email from Bruce Colligen to Ron Kuntz re DEC 2 ADF Model Language	JAN-MS-00430125			First Amendment; AU; H	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1786	Email from Richard Silverman re Janssen sponsored meeting	POK003499665			AU; H; R; PRE; CON; CU; LF; J-MIL-3; J-MIL-7; T-MIL-4	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1787	Duragesic Summary Attachment 1	JAN-MS-00780114			AU; H	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1788	1998 Noramco & PF Labs Supply Agreement	POK003479626			Nuisance Statute's Safe-harbor; AU; H; R; PRE; CON; CU; LF; T-MIL-4	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1789	1999 Amendment to Supply Agreement	POK003479662			Nuisance Statute's Safe-harbor; AU; H; R; PRE; CON; CU; LF; T-MIL-4	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1790	2002 Amendement to Supply Agreement	POK003479653			Nuisance Statute's Safe-harbor; AU; H; R; PRE; CON; CU; LF; T-MIL-4	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1791	Email to LaDonna Steiner from James Lang re Janssen's Remark to Dr. Richard Dom Sky	PPLPC053000002497	PPLPC053000002498		R; PRE; CON; CU; AU; H; PRE; LF; J-MIL-7; T-MIL-4; J-MIL-3	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1792	Johnson & Johnsons Pediatric Plan for Tapentadol in Chronic Pain	JAN-MS-00214418			PRE; CON; CU; AU; H; R	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1793	Email from Ron Kuntz re Market Analysis for tapentadol Performance and Development Plan Summary Final Review - 2005 Performance and Development Plan Summary for Steven Butterfield	JAN-MS-00267799			PRE; CON; CU; AU; H; R	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1794	Impact of Nucynta Co-Pay Cards on PCPs - Epocrates MedInsight Q&A Summary June 2010 with cover email	JAN-OK-001328698&JAN-OK-00132871			AU; H; R	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1795	Speaker Events Locations with cover email	JAN-MS-00358879&JAN-MS-00358880			First Amendment; R; PRE; CON; CU; AU; H; R; PRE	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802

S-1797	Email from Eric Anderson re Q1'11 Dallas PAIN Nucynta H3 Exception List for Goals	JAN-OK-00134401				PRE; R; CON	12 O.S. 2401, 2402; 12 O.S. 2802
S-1798	Email from Dominic Lazzaro re Q3 Speaker Program Budget	JAN-MS-01067380				H; R	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1799	Email from Paula Smykili re Q3 Dinner Programs	JAN-MS-00997188				AU; H; R	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1800	Duragesic Speaker Bureau 9-23	JAN-MS-00786422				R; PRE; CON; CU; AU; H; PRE	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1801	Final Overall List - Speakers	JAN-MS-02914372				First Amendment; AU; H; R	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1802	Kansas City East Team - November 2000 Team Meeting PowerPoint	POK003636882				AU; H; R; PRE; CON; CU; LF; J-MIL-7; T-MIL-4	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1803	Email from Russell Gasdia re GAO Purdue Sales & Marketing - Oklahoma District Meeting 10/5 - 6/2011	PPLPC057000001984	PPLPC0570000001985			AU; H; R; PRE; CON; CU; LF; J-MIL-7; T-MIL-4; J-MIL-3	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1804	Letter to Yusef Mosuro re article on OxyConton and Duragesic	POK003656199				AU; H; R; PRE; CON; CU; LF; J-MIL-7; T-MIL-4	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1805	Email from Ricahrd Silbert re Janssen Promotion	PPLPC051000006789	PPLPC0510000006791			R; PRE; CON; CU; AU; H; PRE; LF; J-MIL-7; T-MIL-4; J-MIL-3	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1806	Email from Monica Kwarcinsky re Retired DEA Agent's Talk	PPLPC053000005865	PPLPC053000005865			R; PRE; CON; CU; AU; H; PRE; LF; J-MIL-7; T-MIL-4	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1807	NEO Welcome and Introductions - Sunil Panchal, MD, National Institute of Pain, Tampa Florida PowerPoint	PPLPC0530000014752	PPLPC0530000014754			First Amendment; AU; H	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1808	Purdue Quarterly Report To The Board	JAN-MS-011137595				AU; LF; J-MIL-7; T-MIL-4; R; PRE	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1809	Quality Agreement Between Purdue Pharma LP and Actavis Totowa LLC	PDD8901724434	PDD8901724461	Acquired_Actavis_001 99961	Acquired_Actavis_001 99982	AU; H; R; LF; J-MIL-7; T-MIL-4; PRE	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802

S-1811	Johnson & Johnson - Buprenorphine TDS Moderate to Moderately Severe Pain - Decision Required - Co-develop/Co-promote with Purdue in US	JAN-MS-04211163				AU; H; R	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1812	Email from Michael Friedman to Jonathan & Richard Sackler re things to do	PDD1715232609	PDD1715232610			AU; H; R; PRE; CON; CU; LF; J-MIL-7; T-MIL-4; J-MIL-3	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1813	Distribution and Supply Agreement between Purdue Pharma and Actavis Totowa LLC	POK003478567				AU; H; R; PRE; CON; CU; LF; T-MIL-4	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1814	Distribution and Supply Agreement between Purdue Pharma LP and Watson Pharma, Inc	POK003478620				AU; H; R; PRE; CON; CU; LF; T-MIL-4	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1815	Distribution and Supply Agreement by and between Purdue Pharma LP and Watson Pharma, Inc.	POK003478888				AU; H; R; PRE; CON; CU; LF; T-MIL-4	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1816	Acceptance of Purchase Orders from Endo Ventures Limited to Purdue Pharma LP	POK003479534				AU; H; R; PRE; CON; CU; LF; J-MIL-7; T-MIL-4	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1817	Confidential Disclosure Agreement between Purdue and Janssen	POK003479589				AU; H; R; PRE; CON; CU; LF; J-MIL-7; T-MIL-4	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1818	Settlement Agreement between Purdue and Teva	TEVA_OK_05039942				AU; LF; J-MIL-7; T-MIL-4; R; PRE	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1819	Settlement Agreement between Purdue and Actavis	TEVA_OK_05056898				AU; LF; J-MIL-7; T-MIL-4; R; PRE	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1820	Email from Dawne McClendon re Speakers Training Mtg. Analysis	JAN-MS-00786421				AU; H	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1821	Email from Patricia Yap re 2013 Final Speaker Bureau Determination 4-0-13	JAN-MS-02914371				AU; H; R	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1822	Reformulated OxyContin (ORF) R&D Operating Committee Project Update	PDD8901467696	PDD8901467725			Nuisance Statute's Safe-harbor; AU; H; R; PRE; CON; CU; LF; J-MIL-7; T-MIL-4	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1823	Pediatric Research Programs by Brianne Weingarten, CEAC Meeting	PPLPC002000094487	PPLPC002000094487			PRE; CON; CU; AU; H; R; LF; J-MIL-7; T-MIL-4	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802

S-1824	Assessment of the Pediatric Chronic Pain Market Prepared for Janssen Pharmaceutica	JAN-MS-00385608					PRE; CON; CU; AU; H; R	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1825	Imagine the Possibilities Pain Coalition - Next Steps - Key Slides 7.11	JAN-MS-00402812					First Amendment; PRE; CON; CU; AU; H; R	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1826	American Chronic Pain Association Projected Projects 2009	JAN-MS-00325853					First Amendment; AU; H; R; Incomplete Document	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1827	American Chronic Pain Association Letter to Robyn Kohn	JAN-MS-00396372					First Amendment; PRE; CON; CU; AU; H; R	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1828	Email from Penney Cowan re Growing Pains	JAN-MS-00396535					J-MIL-3; First Amendment; H; PRE	
S-1829	Email from amy Levinson re 2003 Duragesic Media Planning & Input	JAN-MS-00306238					AU; H; R	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1830	Ortho-McNeil Janssen Chronic Pain 2007 Medical Education Business	JAN-MS-00264570					First Amendment; R; PRE; CON; CU; AU; H; R; PRE	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1831	Email from Gary Vorsanger re Follow up question on RADAR data with Oxy	JAN-MS-00283698					R; PRE; CON; CU; AU; H; PRE	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1832	Tapentadol Budget 2010 spreadsheet	JAN-MS-00325962					AU; H; R	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1833	Email from Felice Sweeney re Successfully submitted Military manuscript	JAN-MS-01460092					AU; H; R	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1834	Email from Gary Baker re Successfully submitted Military manuscript	JAN-MS-00283571					AU; H; R	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1835	Chronic Pain Management Strategies and Lessons From the Military: A Narrative Review	JAN-MS-01460093					AU; H; R	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1836	Email re Draft of manuscript on chronic pain in returning veterans (55598)	JAN-MS-00403057					AU; H; R	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1837	Key Point Summary - Chronic Pain Management Strategies: Lessons from the Military	JAN-MS-00403058					AU; H; R	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802

S-1838	Ortho-cNeil Analgesic Franchise Plan	JAN-MS-02555351				Nuisance Statute's Safe-harbor; AU; H	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1839	Noramco Sales Report December 2010	NORAMCO0000011				Nuisance Statute's Safe-harbor; AU; H; R; LF; J-MIL-7; T-MIL-4; PRE	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1840	Purdue Quarterly Report To The Board	PDD9316101002	PDD9316101031			Nuisance Statute's Safe-harbor; AU; H; R; PRE; CON; CU; LF; J-MIL-7; T-MIL-4	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1841	Purdue Quarterly Report To The Board	PDD8901733974	PDD8901734003			Nuisance Statute's Safe-harbor; AU; H; R; PRE; CON; CU; LF; J-MIL-7; T-MIL-4	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1842	Email from Joseph Cannavo re Purdue Pharma Execs Plead Guilty in OxyContin Risk Case	JAN-MS-00782059				First Amendment; H; R; PRE; CON; CU	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2802
S-1843	Email from Greg Panico re Purdue Pharma Execs Plead Guilty in OxyContin Risk Case	JAN-MS-00928071				AU; H; R	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1844	Duragesic Coupon Program Study Guide & FAQs	JAN-MS-00311338				Nuisance Statute's Safe-harbor; Preemption; AU; H; R	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1845	Nucynta Pharmacy Stocking National Manager's Meeting	JAN-MS-00024239				AU; H; R	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1846	Pharmacy Target List & Viewpoint Assessment	JAN-MS-00272870				AU; H	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1847	Nucynta RBD Meeting December 2010	JAN-MS-00827303				AU; H	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1848	Email from Malcom Monaghan re FDA petition regarding opioid labeling	JAN-MS-00455268				First Amendment; H; R	12 O.S. 2401, 2402; 12 O.S. 2802
S-1849	Email from Pamela Bennett re FDA petition regarding opioid labeling	PPLP004272941	PPLP004272941			First Amendment; AU; H; R; PRE; CON; CU; LF; J-MIL-7; T-MIL-4	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1850	REMS Task Force Meeting (PCF)	JAN-MS-00483507				First Amendment; AU; H; R	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1851	Pain Care Forum REMS Task Force - Points for FDA Inforation Gathering Stakeholder Sessions	JAN-MS-00488347				First Amendment; AU; H; R	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802

S-1852	Pain Care Forum REMS Take Force Class Opioid REMS Recommendations to FDA	JAN-MS-00491392				First Amendment; AU; H; R	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1853	Pain Care Forum Agenda - April 15 Email from Robyn Kohn re Urgent: AAPM/SCSCAn Sign on letter opposing federal hydrocodone rescheduling amendment	JAN-MS-00934444				First Amendment; AU; H; R	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1854	Email from Lauryl Jackson re Draft Letter to HHS on Hydrocodone Rescheduling	JAN-MS-00926821				First Amendment; R; PRE; CON; CU; H; R; PRE	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2802
S-1855	Email from Tom O'Donnell re Hydrocodone rescheduling Letter	JAN-MS-00984138				First Amendment; AU; H; R	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1856	Letter to the Secretary of the US Department of Health & Human Services re Opposition to Rescheduling Hydrocodone Combination Medications	JAN-MS-00992083				First Amendment; R; PRE; CON; CU; AU; H; R; PRE	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1857	Pain Care Forum Meeting Agenda - January 10, 2013	JAN-MS-00992085				First Amendment; AU; H; R	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1858	Email from Robyn Kohn re Today's Meeting of the Pain Care Forum - Consensus Statements CDC summary	JAN-MS-00992107				First Amendment; AU; H; R	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1859	Pain Care Forum - 2012 Meetings Schedule	JAN-MS-00948075				First Amendment; AU; H; R	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1860	State Metrics data: week ending 7/17/09	JAN-MS-00926749				First Amendment; AU; H; R	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1861	Week 76 - Nucynta Hotsheet - 12/3/2010	JAN-MS-00327422				AU; H; R	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1862	76) Nucynta Hotsheet 120310.pdf	JAN-MS-00327428				AU; H	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1863	76) Nucynta Hotsheet Deep Dive 120310.pdf	JAN-MS-00327430				AU; H	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1864	76) Nucynta Hotsheet Deep Dive 120310.pdf	JAN-MS-00327434				AU; H	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802

S-1865	Week 79 - Nucynta Hotsheet - 12/24/2010	JAN-MS-00327442				AU; H; R	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1866	79) Nucynta Hotsheet 122410.pdf	JAN-MS-00327444				AU; H	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1867	79) Nucynta Hotsheet Deep Dive 122410.pdf	JAN-MS-00327448				AU; H	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1868	FW: NUCYNTA Hotsheet: Week ending 7/3/09	JAN-MS-00358108				AU; H; R	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1869	1) Nucynta Weekly HS Binder 070309.pdf	JAN-MS-00358110				AU; H	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1870	FW: NUCYNTA HOTSHEET: Week ending 7/10/09	JAN-MS-00358114				AU; H; R	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1871	2) Nucynta HS Binder 071009.pdf	JAN-MS-00358116				R; PRE; CON; CU; AU; H; PRE	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1872	FW: NUCYNTA Weekly Hotsheet: week ending 7/24/09	JAN-MS-00358120				AU; H	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1873	4) NUCYNTA Weekly HS Binder 072409.pdf	JAN-MS-00358121				AU; H	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1874	FW: NUCYNTA Weekly Hotsheet: week ending 7/31/09	JAN-MS-00358130				AU; H	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1875	NUCYNTA Weekly HS Binder 073109.pdf	JAN-MS-00358131				AU; H	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1876	FW: Q re: NUCYNTA Weekly Hotsheet: week ending 7/24/09	JAN-MS-00358140				R; PRE; CON; CU; AU; H; PRE	12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1877	FW: NUCYNTA Weekly Hotsheet: week ending 9/11/09	JAN-MS-00358165				AU; H	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1878	NUCYNTA Weekly HS Binder (091109).pdf	JAN-MS-00358167				AU; H; R	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1879	FW: NUCYNTA Weekly Hotsheet: week ending 9/18/09	JAN-MS-00358173				AU; H; R	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1880	NUCYNTA Weekly HS Binder (091809).pdf	JAN-MS-00358175				R; PRE; CON; CU; AU; H; PRE	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802

S-1881	FW: NUCYN TA Weekly Hotsheet:	JAN-MS-00358191				R; PRE; CON; CU; AU; H; PRE	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1882	NUCYN TA Weekly HS Binder (100209).pdf	JAN-MS-00358193				R; PRE; CON; CU; AU; H; PRE	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1883	FW: NUCYN TA Hotsheet: Week ending 10/9/09	JAN-MS-00358201				AU; H; R	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1884	NUCYN TA Weekly HS Binder (100909).pdf	JAN-MS-00358202				R; PRE; CON; CU; AU; H; PRE	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1885	FW: Week 34 - Nucyn ta Hotsheet - 2/12/2010	JAN-MS-00358273				R; PRE; CON; CU; AU; H; PRE	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1886	34) Nucyn ta Hotsheet 02.12.10.pdf	JAN-MS-00358275				AU; H; R	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1887	FW: Week 35 - Nucyn ta Hotsheet - 2/19/2010	JAN-MS-00358283				AU; H; R	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1888	35) Nucyn ta Hotsheet 02.19.10.pdf	JAN-MS-00358285				AU; H; R	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1889	FW: Week 37 - Nucyn ta Hotsheet - 3/5/2010	JAN-MS-00358299				R; PRE; CON; CU; AU; H; PRE	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1890	37) Nucyn ta Hotsheet 03.05.10.pdf	JAN-MS-00358301				AU; H; R	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1891	FW: Week 38 - Nucyn ta Hotsheet - 3/12/2010	JAN-MS-00358305				R; PRE; CON; CU; AU; H; PRE	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1892	38) Nucyn ta Hotsheet 03.12.10.pdf	JAN-MS-00358307				AU; H; R	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1893	Week 52 - Nucyn ta Hotsheet - 6/18/2010	JAN-MS-00358316				AU; H; R	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802

S-1894	52) Nucynta Hotsheet 061810.pdf	JAN-MS-00358318				R; PRE; CON; CU; AU; H; PRE	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1895	52) Nucynta Hotsheet Deep Dive 061810.pdf	JAN-MS-00358321				AU; H; R	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1896	RE: NUCYNATA Weekly Hotsheet: week ending 9/11/09	JAN-MS-00362285				AU; H	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2901; 12 O.S. 2802
S-1897	RE: NUCYNATA Weekly Hotsheet:	JAN-MS-00362289				AU; H; R	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1898	Aetna Weekly Hotsheet - The Week that Texas Eight the Competition	JAN-MS-00366916				AU; H; R	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1899	Nucynta weekly by key market tabbed by week.xls	JAN-MS-00366917				AU; H; R	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1900	Bradley EOY Year 2009 PDM Comments.docx	JAN-MS-00370326				R; PRE; CON; CU; AU; H; PRE	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1901	79) Nucynta Hotsheet Deep Dive 122410.pdf	JAN-MS-00403778				AU; H; R	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1902	FW: 2P HOT SHEET for ticket	JAN-MS-00748308				AU; H; R	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1903	NUCYNATA Weekly Hotsheet: week ending 7/31/09	JAN-MS-00792934				AU; H; R	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1904	NUCYNATA Weekly HS Binder 073109.pdf	JAN-MS-00792935				AU; H; R	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1905	NUCYNATA Weekly Hotsheet: week ending 8/7/09	JAN-MS-00792941				AU; H; R	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1906	NUCYNATA Weekly HS Binder 080709.pdf	JAN-MS-00792942				AU; H; R	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1907	NUCYNATA Weekly Hotsheet: week ending 8/14/09	JAN-MS-00792948				AU; H; R	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802

S-1908	NUCYNTA Weekly HS Binder {081409}.pdf	JAN-MS-00792949				AU; H; R	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1909	RESEND: NUCYNTA Weekly Hotsheet: week ending 8/21/09	JAN-MS-00792955				AU; H; R	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1910	NUCYNTA Weekly HS Binder {082109}.pdf	JAN-MS-00792956				AU; H; R	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1911	NUCYNTA Weekly Hotsheet: week ending 8/28/09	JAN-MS-00792962				AU; H; R	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1912	NUCYNTA Weekly HS Binder {082809}.pdf	JAN-MS-00792963				AU; H; R	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1913	NUCYNTA Weekly Hotsheet: week ending 9/4/09	JAN-MS-00792969				AU; H; R	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1914	NUCYNTA Weekly HS Binder {090409}.pdf	JAN-MS-00792970				AU; H; R	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1915	NUCYNTA Weekly Hotsheet: week ending 9/18/09	JAN-MS-00792976				AU; H; R	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1916	NUCYNTA Weekly HS Binder {091809}.pdf	JAN-MS-00792977				R; PRE; CON; CU; AU; H; PRE	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1917	NUCYNTA Weekly Hotsheet: week ending 9/18/09	JAN-MS-00792983				AU; H; R	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1918	NUCYNTA Weekly HS Binder {092509}.pdf	JAN-MS-00792984				AU; H; R	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1919	NUCYNTA Hotsheet: Week ending 10/9/09	JAN-MS-00792990				AU; H; R	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1920	NUCYNTA Weekly HS Binder {100909}.pdf	JAN-MS-00792991				AU; H; R	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802

S-1921	NUCYNTA Hotsheet: Week ending 10/16/09	JAN-MS-00792997				AU; H; R	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1922	NUCYNTA Weekly HS Binder (101609).pdf	JAN-MS-00792998				AU; H; R	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1923	NUCYNTA Hotsheet for the week ending 10/23/09	JAN-MS-00793004				AU; H; R	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1924	NUCYNTA Weekly HS Binder (102309).pdf	JAN-MS-00793005				AU; H; R	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1925	NUCYNTA Hotsheet for the week ending 10/30/09	JAN-MS-00793011				AU; H; R	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1926	NUCYNTA Weekly HS Binder (103009).pdf	JAN-MS-00793012				R; PRE; CON; CU; AU; H; PRE	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1927	NUCYNTA Hotsheet for the week ending 11/6/09	JAN-MS-00793018				AU; H; R	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1928	NUCYNTA Weekly HS Binder (110609).pdf	JAN-MS-00793019				R; PRE; CON; CU; AU; H; PRE	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1929	NUCYNTA Hotsheet for the week ending 11/20/09	JAN-MS-00793025				AU; H; R	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1930	21) HS Binder 11.20.09.pdf	JAN-MS-00793026				AU; H; R	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1931	NUCYNTA Hotsheet for the week ending 11/27/09	JAN-MS-00793032				AU; H; R	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1932	23) HS Binder 11.27.09.pdf	JAN-MS-00793033				AU; H; R	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1933	NUCYNTA Hotsheet for the week ending 12/04/09	JAN-MS-00793039				AU; H; R	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802

S-1934	24) Nucynta Hotsheet 12.04.09.pdf	JAN-MS-00793041				AU; H; R	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1935	NUCYN TA Hotsheet for Week 26 - week ending 12/18/09	JAN-MS-00793045				AU; H; R	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1936	26) Nucynta Hotsheet 12.18.09.pdf	JAN-MS-00793046				AU; H	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1937	NUCYN TA Hotsheet for Week 25 - week ending 12/11/09	JAN-MS-00793050				AU; H	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1938	25) Nucynta Hotsheet 12.11.09.pdf	JAN-MS-00793051				AU; H	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1939	Nucynta Hotsheet Week 28 - week ending 1/1/2010	JAN-MS-00793055				AU; H	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1940	28) Nucynta Hotsheet 01.01.10.pdf	JAN-MS-00793056				AU; H	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1941	Nucynta Hotsheet WE 1/8/2010	JAN-MS-00793060				AU; H	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1942	29) Nucynta Hotsheet 01.08.10.pdf	JAN-MS-00793061				AU; H	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1943	Week 30 - Nucynta Hotsheet	JAN-MS-00793065				AU; H	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1944	30) Nucynta Hotsheet 01.15.10.pdf	JAN-MS-00793066				AU; H	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1945	Nucynta Hotsheet - Week 31 - 1/22/2010	JAN-MS-00793070				AU; H	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1946	31) Nucynta Hotsheet 01.22.10.pdf	JAN-MS-00793071				AU; H	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1947	Week 33 - Nucynta Hotsheet - 2/5/2010	JAN-MS-00793075				AU; H	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1948	33) Nucynta Hotsheet 02.05.10.pdf	JAN-MS-00793076				AU; H	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1949	Week 34 - Nucynta Hotsheet - 2/12/2010	JAN-MS-00793080				AU; H	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1950	34) Nucynta Hotsheet 02.12.10.pdf	JAN-MS-00793081				AU; H; R	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1951	Week 35 - Nucynta Hotsheet - 2/19/2010	JAN-MS-00793085				AU; H	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1952	35) Nucynta Hotsheet 02.19.10.pdf	JAN-MS-00793086				AU; H	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802

S-1953	Week 36 - Nucynty Hotsheet - 2/26/2010	JAN-MS-00793090			AU; H	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1954	36) Nucynty Hotsheet 02.26.10.pdf	JAN-MS-00793091			AU; H	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1955	Week 37 - Nucynty Hotsheet - 3/5/2010	JAN-MS-00793095			AU; H	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1956	37) Nucynty Hotsheet 03.05.10.pdf	JAN-MS-00793096			AU; H	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1957	Week 38 - Nucynty Hotsheet - 3/12/2010	JAN-MS-00793100			AU; H	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1958	38) Nucynty Hotsheet 03.12.10.pdf	JAN-MS-00793101			AU; H	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1959	Week 39 - Nucynty Hotsheet - 3/19/2010	JAN-MS-00793105			AU; H	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1960	39) Nucynty Hotsheet 03.19.10.pdf	JAN-MS-00793106			AU; H	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1961	Week 40 - Nucynty Hotsheet - 3/26/2010	JAN-MS-00793110			AU; H	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1962	40) Nucynty Hotsheet 03.26.10.pdf	JAN-MS-00793111			AU; H	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1963	Week 41 - Nucynty Hotsheet - 4/2/2010	JAN-MS-00793115			AU; H	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1964	41) Nucynty Hotsheet 04.02.10.pdf	JAN-MS-00793117			AU; H	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1965	41) Nucynty Hotsheet Deep Dive 04.02.10.pdf	JAN-MS-00793120			AU; H	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1966	Week 42 - Nucynty Hotsheet - 4/9/10	JAN-MS-00793127			AU; H; R	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1967	42) Nucynty Hotsheet 04.09.10.pdf	JAN-MS-00793129			AU; H	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1968	42) Nucynty Hotsheet Deep Dive 04.09.10.pdf	JAN-MS-00793132			AU; H	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1969	Week 43 - Nucynty Hotsheet - 4/16/2010	JAN-MS-00793139			AU; H	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1970	43) Nucynty Hotsheet 04.16.10.pdf	JAN-MS-00793141			AU; H	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1971	43) Nucynty Hotsheet Deep Dive 04.16.10.pdf	JAN-MS-00793144			AU; H	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1972	Week 44 - Nucynty Hotsheet - 4/23/10	JAN-MS-00793151			AU; H	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802

S-1973	44) Nucynta Hotsheet 04.23.10.pdf	JAN-MS-00793153				AU; H	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1974	44) Nucynta Hotsheet Deep Dive 04.23.10.pdf	JAN-MS-00793156				AU; H	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1975	Week 45 - Nucynta Hotsheet - 4/30/2010	JAN-MS-00793163				AU; H	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1976	45) Nucynta Hotsheet 04.30.10.pdf	JAN-MS-00793165				AU; H	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1977	45) Nucynta Hotsheet Deep Dive 04.30.10.pdf	JAN-MS-00793168				AU; H	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1978	Week 46 - Nucynta Hotsheet - 5/7/2010	JAN-MS-00793175				AU; H	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1979	46) Nucynta Hotsheet 05.07.10.pdf	JAN-MS-00793177				AU; H	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1980	46) Nucynta Hotsheet Deep Dive 05.07.10.pdf	JAN-MS-00793180				AU; H	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1981	RE: Week 47 - Nucynta Hotsheet - 5/14/2010 - Hotsheet Deep Dive	JAN-MS-00793187				AU; H	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1982	47) Nucynta Hotsheet Deep Dive 051410.pdf	JAN-MS-00793188				AU; H	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1983	Week 47 - Nucynta Hotsheet - 5/14/2010	JAN-MS-00793195				AU; H	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1984	47) Nucynta Hotsheet 051410.pdf	JAN-MS-00793196				AU; H; R	12 O.S. 2401, 2402, 12 O.S. 2602, 12 O.S. 2901, 12 O.S. 2802
S-1985	Week 48 - Nucynta Hotsheet - 5/21/2010	JAN-MS-00793199				AU; H	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1986	48) Nucynta Hotsheet 052110.pdf	JAN-MS-00793201				AU; H	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1987	48) Nucynta Hotsheet Deep Dive 052110.pdf	JAN-MS-00793204				AU; H	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1988	Week 49 - Nucynta Hotsheet - 5/28/2010	JAN-MS-00793211				AU; H	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1989	49) Nucynta Hotsheet 052810.pdf	JAN-MS-00793213				AU; H	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1990	49) Nucynta Hotsheet Deep Dive 052810.pdf	JAN-MS-00793216				AU; H	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1991	Week 49 - Nucynta Hotsheet - 5/28/2010 - UPDATED	JAN-MS-00793223				AU; H	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1992	49) Nucynta Hotsheet 052810.pdf	JAN-MS-00793225				AU; H	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802

S-1993	49) Nucynta Hotsheet Deep Dive 052810.pdf	JAN-MS-00793228			AU; H	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1994	Week 50 - Nucynta Hotsheet - 6/4/2010	JAN-MS-00793235			AU; H	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1995	50) Nucynta Hotsheet: 060410.pdf	JAN-MS-00793237			AU; H	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1996	50) Nucynta Hotsheet Deep Dive 060410.pdf	JAN-MS-00793240			AU; H	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1997	Week 51 - Nucynta Hotsheet - 6/11/2010	JAN-MS-00793247			AU; H	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1998	51) Nucynta Hotsheet: 061110.pdf	JAN-MS-00793249			AU; H	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-1999	51) Nucynta Hotsheet Deep Dive 061110.pdf	JAN-MS-00793252			AU; H	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2000	Week 53 - Nucynta Hotsheet - 6/25/2010	JAN-MS-00793259			AU; H	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2001	53) Nucynta Hotsheet: 062510.pdf	JAN-MS-00793261			AU; H	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2002	53) Nucynta Hotsheet Deep Dive 062510.pdf	JAN-MS-00793264			AU; H	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2003	Week 55 - Nucynta Hotsheet - 7/9/2010	JAN-MS-00793271			AU; H	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2004	55) Nucynta Hotsheet: 070910.pdf	JAN-MS-00793273			AU; H	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2005	55) Nucynta Hotsheet Deep Dive 070910.pdf	JAN-MS-00793277			AU; H	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2006	Nucynta Weekly Launch Readiness Update minutes 6-8.doc	JAN-MS-00808691			AU; H	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2007	Nucynta Weekly Launch Readiness Update minutes 6-15.doc	JAN-MS-00808694			AU; H; R	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2008	Nucynta Monthly Performance Update_June2010.pptx	JAN-MS-00811303			AU; H	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2009	Nucynta Monthly Performance Update_Aug 2010.pptx	JAN-MS-00811321			AU; H	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2010	IMPORTANT FIELD REPORTING UPDATE: Nucynta Hotsheet	JAN-MS-00812982			AU; H	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2011	IMPORTANT FIELD REPORTING UPDATE: Nucynta Hotsheet	JAN-MS-00812983			AU; H; R	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802

S-2012	IMPORTANT FIELD REPORTING UPDATE: Nucynta Hotsheet	JAN-MS-00812984				AU; H; R	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2013	FW: NUCYNTA Weekly Hotsheet: week ending 7/31/09	JAN-MS-00859051				AU; H; R	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2014	NUCYNTA Weekly HS Binder 073109.pdf	JAN-MS-00859052				AU; H; R	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2015	RE: NUCYNTA Hotsheet: Week ending 10/9/09	JAN-MS-00859117				R; PRE; CON; CU; AU; H; PRE	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2016	HotSheet and Early View weekending 10-16	JAN-MS-00859122				R; PRE; CON; CU; AU; H; PRE	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2017	NE Region Earlyview 10-16-09.xlsx	JAN-MS-00859123				AU; H; R	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2018	Northeast Pain Region 10-16-09.ppt	JAN-MS-00859124				R; PRE; CON; CU; AU; H; PRE	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2019	NUCYNTA Weekly HS Binder (101609).pdf	JAN-MS-00859125				AU; H; R	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2020	Hot Sheet and EV weekending Nov 27	JAN-MS-00859175				AU; H; R	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2021	23) HS Binder 11.27.09.pdf	JAN-MS-00859176				AU; H; R	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2022	FW: Week 39 - Nucynta Hotsheet - 3/19/2010	JAN-MS-00859285				R; PRE; CON; CU; AU; H; PRE	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2023	39) Nucynta Hotsheet 03.19.10.pdf	JAN-MS-00859287				AU; H; R	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2024	Action Needed:FW: Nucynta Monthly Performance Update	JAN-MS-00859305				AU; H; R	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802

S-2025	Nucynta Monthly Performance Update_May2010_2.pdf	JAN-MS-00859307				AU; H; R	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2026	47) Nucynta Hotsheet Deep Dive 051410.pdf	JAN-MS-00859349				AU; H; R	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2027	RE: NUCYNITA Weekly Hotsheet: week ending 9/18/09	JAN-MS-00864197				AU; H; R	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2028	RE: NUCYNITA Hotsheet for the week ending 11/6/09	JAN-MS-00864203				AU; H; R	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2029	Week 55 - Nucynta Hotsheet - 7/9/2010	JAN-MS-00865923				AU; H; R	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2030	56) Nucynta Hotsheet 071610.pdf	JAN-MS-00865925				AU; H; R	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2031	56) Nucynta Hotsheet Deep Dive 071610.pdf	JAN-MS-00865929				AU; H; R	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2032	Week 58 - Nucynta Hotsheet - 7/30/2010	JAN-MS-00865941				AU; H; R	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2033	58) Nucynta Hotsheet 073010.pdf	JAN-MS-00865943				AU; H; R	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2034	58) Nucynta Hotsheet Deep Dive 073010.pdf	JAN-MS-00865947				AU; H; R	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2035	Week 59 - Nucynta Hotsheet - 8/6/2010	JAN-MS-00865959				AU; H; R	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2036	59) Nucynta Hotsheet 080610.pdf	JAN-MS-00865961				AU; H; R	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2037	59) Nucynta Hotsheet Deep Dive 080610.pdf	JAN-MS-00865965				AU; H; R	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802

S-2038	Week 61 - Nucynty Hotsheet - 8/20/2010	JAN-MS-00865975				AU; H; R	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2039	61) Nucynty Hotsheet 082010.pdf	JAN-MS-00865977				AU; H; R	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2040	61) Nucynty Hotsheet Deep Dive 082010.pdf	JAN-MS-00865981				AU; H; R	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2041	Week 62 - Nucynty Hotsheet - 8/27/2010	JAN-MS-00865989				AU; H; R	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2042	62) Nucynty Hotsheet 082710.pdf	JAN-MS-00865991				AU; H; R	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2043	62) Nucynty Hotsheet Deep Dive 082710.pdf	JAN-MS-00865995				AU; H; R	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2044	Week 63 - Nucynty Hotsheet - 9/3/2010	JAN-MS-00866003				AU; H; R	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2045	63) Nucynty Hotsheet 090310.pdf	JAN-MS-00866005				AU; H; R	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2046	63) Nucynty Hotsheet Deep Dive 090310.pdf	JAN-MS-00866009				AU; H; R	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2047	Week 64 - Nucynty Hotsheet - 9/10/2010	JAN-MS-00866019				AU; H; R	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2048	64) Nucynty Hotsheet 091010.pdf	JAN-MS-00866021				AU; H; R	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2049	64) Nucynty Hotsheet Deep Dive 091010.pdf	JAN-MS-00866025				AU; H; R	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2050	Week 65 - Nucynty Hotsheet - 9/17/2010	JAN-MS-00866037				AU; H; R	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802

S-2051	65) Nucynta Hotsheet 091710.pdf	JAN-MS-00866039				AU; H; R	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2052	65) Nucynta Hotsheet Deep Dive 091710.pdf	JAN-MS-00866043				AU; H; R	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2053	Week 68 - Nucynta Hotsheet - 10/15/2010	JAN-MS-00866057				AU; H; R	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2054	69) Nucynta Hotsheet 101510.pdf	JAN-MS-00866059				AU; H; R	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2055	69) Nucynta Hotsheet Deep Dive 101510.pdf	JAN-MS-00866063				AU; H; R	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2056	PriCara Pain Nucynta National Sales Report	JAN-MS-00866071				AU; H; R	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2057	Week 70 - Nucynta Hotsheet - 10/22/2010	JAN-MS-00866074				AU; H; R	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2058	70) Nucynta Hotsheet 102210.pdf	JAN-MS-00866076				AU; H; R	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2059	70) Nucynta Hotsheet Deep Dive 102210.pdf	JAN-MS-00866080				AU; H; R	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2060	PriCara Pain Nucynta National Sales Report	JAN-MS-00866088				AU; H; R	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2061	PriCara Pain Nucynta National Sales Report	JAN-MS-00866091				AU; H; R	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2062	Week 77 - Nucynta Hotsheet - 12/10/2010	JAN-MS-00866112				AU; H; R	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2063	77) Nucynta Hotsheet 121010.pdf	JAN-MS-00866114				AU; H; R	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802

S-2064	77) Nucynta Hotsheet Deep Dive 121010.pdf	JAN-MS-00866118				AU; H; R	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2065	PriCara Pain Nucynta National Sales Report	JAN-MS-00866126				AU; H; R	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2066	RE: PriCara Pain Nucynta National Sales Report - 12/17/2010	JAN-MS-00866128				AU; H; R	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2067	PriCara Pain Nucynta National Sales Report - Week Ending 12/31/10	JAN-MS-00866130				AU; H; R	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2068	RE: Nucynta Monthly Performance Update	JAN-MS-01037291				AU; H; R	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2069	Nucynta Monthly Performance Update_May2010_2.pdf	JAN-MS-01037292				AU; H; R	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2070	47) Nucynta Hotsheet Deep Dive 051410.pdf	JAN-MS-01037334				AU; H; R	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2071	NUCYNTA Weekly HS Binder 080709.pdf	JAN-MS-01129365				R; PRE; CON; CU; AU; H; PRE	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2072	Week 32 Nucynta Hotsheet - 1/29/2010	JAN-MS-01131612				AU; H; R	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2073	32) Nucynta Hotsheet 01.29.10.pdf	JAN-MS-01131613				AU; H; R	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2074	RE: J&J Weekly Status Report	JAN-MS-02385584				AU; H; R	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2075	Nucynta Monthly Performance Update_Aug 2010.pptx	JAN-MS-02409305				AU; H; R	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2076	44) Nucynta Hotsheet Deep Dive 04.23.10.pdf	JAN-MS-02470256				AU; H; R	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802

S-2077	45) Nucynta Hotsheet Deep Dive 04.30.10.pdf	JAN-MS-02470274				AU; H; R	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2078	NUC Monthly Update March 052510.pptx	JAN-MS-02946657				AU; H; R	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2079	September Update 092810.ppt	JAN-MS-02946679				AU; H; R	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2080	Nucynta Monthly Performance Update_Sept 2010.pptx	JAN-MS-02946680				R; PRE; CON; CU; AU; H; PRE	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2081	Nucynta Monthly Performance Update_May2010_2.pdf	JAN-MS-02962646				AU; H; R	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2082	Nucynta Monthly Performance Update_June2010.pptx	JAN-MS-02962688				AU; H; R	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2083	FW: NUCYNTA Hotsheet: Week ending 7/3/09	JAN-MS-03868139				AU; H; R	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2084	1) Nucynta Weekly HS Binder 070309.pdf	JAN-MS-03868140				AU; H; R	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2085	RE: NUCYNTA Hotsheet: Week ending 7/3/09	JAN-MS-03868144				AU; H; R	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2086	Re: NUCYNTA HOTSHEET: Week ending 7/10/09	JAN-MS-03868370				AU; H; R	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2087	RE: NUCYNTA HOTSHEET: Week ending 7/10/09	JAN-MS-03868372				AU; H; R	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2088	FW: NUCYNTA Weekly Hotsheet: week ending 8/7/09	JAN-MS-03868581				AU; H; R	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2089	NUCYNTA Weekly HS Binder 080709.pdf	JAN-MS-03868583				AU; H; R	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802

S-2090	RE: NUCYNTA Weekly Hotsheet: week ending 8/7/09	JAN-MS-03868593				AU; H; R	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2091	Ultram ER Hotsheet - June 2009 data w/ commentary	JAN-MS-03868623				AU; H; R	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2092	PriCara UER Hotsheet Commentary_June 09 data_082609.docx	JAN-MS-03868625				AU; H; R	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2093	FW: RESEND: NUCYNTA Weekly Hotsheet: week ending 8/21/09	JAN-MS-03868663				AU; H; R	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2094	NUCYNTA Weekly HS Binder (082109).pdf	JAN-MS-03868665				AU; H; R	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2095	RE: RESEND: NUCYNTA Weekly Hotsheet: week ending 8/21/09	JAN-MS-03868686				AU; H; R	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2096	FW: NUCYNTA Weekly Hotsheet: week ending 8/28/09	JAN-MS-03868897				AU; H; R	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2097	NUCYNTA Weekly HS Binder (082809).pdf	JAN-MS-03868899				AU; H; R	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2098	FW: NUCYNTA Weekly Hotsheet: week ending 8/28/09	JAN-MS-03868905				AU; H; R	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2099	NUCYNTA Weekly HS Binder (082809).pdf	JAN-MS-03868906				AU; H; R	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2100	Re: NUCYNTA Weekly Hotsheet: week ending 8/28/09	JAN-MS-03868912				AU; H; R	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2101	FW: NUCYNTA Weekly Hotsheet: week ending 9/4/09	JAN-MS-03868962				AU; H; R	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2102	NUCYNTA Weekly HS Binder (090409).pdf	JAN-MS-03868963				AU; H; R	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802

S-2103	RE: NUCYNTA Weekly Hotsheet: week ending 8/28/09	JAN-MS-03868983				R; PRE; CON; CU; AU; H; PRE	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2104	Ultram ER Hotsheet - July 2009 data w/ commentary	JAN-MS-03869113				AU; H; R	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2105	PriCara UER Hotsheet Commentary Jul 09 data_100109.pdf	JAN-MS-03869114				AU; H; R	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2106	PriCara UER Hotsheet July09.xlsm	JAN-MS-03869116				AU; H; R	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2107	Re: NUCYNTA Weekly Hot sheet: week ending 9/18/09	JAN-MS-03869145				AU; H; R	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2108	Re: NUCYNTA Hotsheet for the week ending 11/6/09	JAN-MS-03869475				AU; H; R	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2109	RE: NUCYNTA Hotsheet for the week ending 11/27/09	JAN-MS-03869556				AU; H; R	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2110	Re: NUCYNTA Hotsheet for the week ending 12/04/09	JAN-MS-03869606				AU; H; R	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2111	FW: Week 55 - Nucynta Hotsheet - 7/9/2010	JAN-MS-03871207				AU; H; R	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2112	55) Nucynta Hotsheet 070910.pdf	JAN-MS-03871209				AU; H; R	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2113	55) Nucynta Hotsheet Deep Dive 070910.pdf	JAN-MS-03871213				AU; H; R	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2114	RE: Week 55 - Nucynta Hotsheet - 7/9/2010	JAN-MS-03871221				AU; H; R	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2115	FW: Week 60 - Nucynta Hotsheet - 8/13/2010	JAN-MS-03871807				AU; H; R	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802

S-2116	60) Nucynta Hotsheet 081310.pdf	JAN-MS-03871810				AU; H; R	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2117	60) Nucynta Hotsheet Deep Dive 081310.pdf	JAN-MS-03871814				AU; H; R	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2118	FW: Week 62 - Nucynta Hotsheet - 8/27/2010	JAN-MS-03872018				AU; H; R	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2119	62) Nucynta Hotsheet 082710.pdf	JAN-MS-03872020				AU; H; R	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2120	62) Nucynta Hotsheet Deep Dive 082710.pdf	JAN-MS-03872024				AU; H; R	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2121	RE: Week 62 - Nucynta Hotsheet - 8/27/2010	JAN-MS-03872044				AU; H; R	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2122	Re: Week 62 - Nucynta Hot sheet - 8/27/2010	JAN-MS-03872049				AU; H; R	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2123	RE: Week 63 - Nucynta Hotsheet - 9/3/2010	JAN-MS-03872212				AU; H; R	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2124	RE: Week 63 - Nucynta Hotsheet - 9/3/2010	JAN-MS-03872214				AU; H; R	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2125	RE: Week 63 - Nucynta Hotsheet - 9/3/2010	JAN-MS-03872229				AU; H; R	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2126	FW: Week 67 - Nucynta Hotsheet - 10/1/2010	JAN-MS-03872738				AU; H; R	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2127	67) Nucynta Hotsheet 100110.pdf	JAN-MS-03872740				AU; H; R	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2128	67) Nucynta Hotsheet Deep Dive 100110.pdf	JAN-MS-03872744				AU; H; R	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802

S-2129	Re: Week 67 - Nucynta Hotsheet - 10/1/2010	JAN-MS-03872765				AU; H; R	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2130	FW: Week 68 - Nucynta Hotsheet - 10/8/2010	JAN-MS-03872803				AU; H; R	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2131	68) Nucynta Hotsheet 100810.pdf	JAN-MS-03872805				AU; H; R	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2132	68) Nucynta Hotsheet Deep Dive 100810.pdf	JAN-MS-03872809				AU; H; R	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2133	71) Nucynta Hotsheet 102910.pdf	JAN-MS-03873296				AU; H; R	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2134	FW: Week 71 - Nucynta Hotsheet - 10/29/2010	JAN-MS-03873300				AU; H; R	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2135	71) Nucynta Hotsheet 102910.pdf	JAN-MS-03873302				AU; H; R	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2136	71) Nucynta Hotsheet Deep Dive 102910.pdf	JAN-MS-03873306				AU; H; R	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2137	2011 Metrics.pptx	JAN-MS-03873889				AU; H; R	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2138	FW: Week 79 - Nucynta Hotsheet - 12/24/2010	JAN-MS-03874186				AU; H; R	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2139	79) Nucynta Hotsheet 122410.pdf	JAN-MS-03874188				AU; H; R	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2140	79) Nucynta Hotsheet Deep Dive 122410.pdf	JAN-MS-03874192				AU; H; R	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2141	Re: Nucynta Hotsheet	JAN-MS-03874716				AU; H; R	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802

S-2142	RE: Nucynta Hot sheet	JAN-MS-03874727				AU; H; R	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2143	RE: Aetna Weekly Hotsheet - The Week that Texas Eight the Competition	JAN-MS-03874908				AU; H; R	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2144	Week 57 - Nucynta Hotsheet - 7/23/2010	JAN-MS-04227184				AU; H; R	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2145	57) Nucynta Hotsheet 072310.pdf	JAN-MS-04227186				AU; H; R	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2146	57) Nucynta Hotsheet Deep Dive 072310.pdf	JAN-MS-04227190				AU; H; R	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2147	Week 60 - Nucynta Hotsheet - 8/13/2010	JAN-MS-04227198				AU; H; R	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2148	60) Nucynta Hotsheet 081310.pdf	JAN-MS-04227200				AU; H; R	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2149	60) Nucynta Hotsheet Deep Dive 081310.pdf	JAN-MS-04227204				AU; H; R	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2150	Week 66 - Nucynta Hotsheet - 9/24/2010	JAN-MS-04227212				AU; H; R	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2151	66) Nucynta Hotsheet 092410.pdf	JAN-MS-04227214				AU; H; R	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2152	66) Nucynta Hotsheet Deep Dive 092410.pdf	JAN-MS-04227218				AU; H; R	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2153	Week 67 - Nucynta Hotsheet - 10/1/2010	JAN-MS-04227226				AU; H; R	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2154	67) Nucynta Hotsheet 100110.pdf	JAN-MS-04227228				AU; H; R	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802

S-2155	67) Nucynta Hotsheet Deep Dive 100110.pdf	JAN-MS-04227232				AU; H; R	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2156	Week 68 - Nucynta Hotsheet - 10/8/2010	JAN-MS-04227240				AU; H; R	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2157	68) Nucynta Hotsheet 100810.pdf	JAN-MS-04227242				AU; H; R	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2158	68) Nucynta Hotsheet Deep Dive 100810.pdf	JAN-MS-04227246				AU; H; R	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2159	Nucynta Hotsheet	JAN-MS-04238528				AU; H; R	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2160	Nucynta Hotsheet.xlsb	JAN-MS-04238529				AU; H; R	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2161	Nucynta Hotsheet.xlsb	JAN-MS-04238794				AU; H	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2162	RE: Week 32 Nucynta Hotsheet - 1/29/2010	JAN-MS-04296643				AU; H	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2163	32) Nucynta Hotsheet 01.29.10.pdf	JAN-MS-04296645				AU; H	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2164	Nucynta Weekly Launch Minutes 11-2.doc	JAN-MS-05435817				AU; H	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2165	FW: NUCYNTA Weekly Hotsheet: week ending 8/7/09	JAN-OK-00133671				AU; H	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2166	NUCYNTA Weekly HS Binder 080709.pdf	JAN-OK-00133672				AU; H	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2167	FW: NUCYNTA Weekly Hotsheet: week ending 8/14/09	JAN-OK-00133681				AU; H	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2168	NUCYNTA Weekly HS Binder (081409).pdf	JAN-OK-00133683				AU; H	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2169	Hotsheet 1-8-10.pdf	JAN-OK-00135807				AU; H	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2170	Hotsheet 10-1-10.pdf	JAN-OK-00135811				AU; H	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2171	Hotsheet 10-15-10.pdf	JAN-OK-00135819				AU; H	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802

S-2172	Hotsheet 10-22-10.pdf	JAN-OK-00135827			AU; H	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2173	Hotsheet 10-8-10.pdf	JAN-OK-00135835			AU; H	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2174	Hotsheet 12-10-10.pdf	JAN-OK-00135843			AU; H	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2175	Hotsheet 12-24-10.pdf	JAN-OK-00135847			AU; H	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2176	Hotsheet 12-3-10.pdf	JAN-OK-00135851			AU; H	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2177	Hotsheet 2-12-10.pdf	JAN-OK-00135855			AU; H; R	12 O.S. 2401, 2402; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2178	Hotsheet 2-26-10.pdf	JAN-OK-00135859			AU; H	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2179	Hotsheet 2-5-10.pdf	JAN-OK-00135863			AU; H	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2180	Hotsheet 3-19-10.pdf	JAN-OK-00135867			AU; H	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2181	Hotsheet 4-16-10.pdf	JAN-OK-00135871			AU; H	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2182	Hotsheet 4-2-10.pdf	JAN-OK-00135878			AU; H	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2183	Hotsheet 4-9-10.pdf	JAN-OK-00135881			AU; H	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2184	Hotsheet 5-14-10.pdf	JAN-OK-00135888			AU; H	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2185	Hotsheet 5-21-10.pdf	JAN-OK-00135891			AU; H	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2186	Hotsheet 5-28-10.pdf	JAN-OK-00135898			AU; H	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2187	Hotsheet 5-7-10.pdf	JAN-OK-00135905			AU; H	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2188	Hotsheet 6-25-10.pdf	JAN-OK-00135912			AU; H	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2189	Hotsheet 9-10-10.pdf	JAN-OK-00135919			AU; H	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2190	FW: Week 55 - Nucynta Hotsheet - 7/9/2010	JAN-OK-00136746			AU; H	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2191	55) Nucynta Hotsheet 070910.pdf	JAN-OK-00136748			AU; H	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802

S-2192	55) Nucynta Hotsheet Deep Dive 070910.pdf	JAN-OK-00136752				AU; H	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2193	FW: Week 55 - Nucynta Hotsheet - 7/9/2010	JAN-OK-00136785				AU; H	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2194	56) Nucynta Hotsheet 071610.pdf	JAN-OK-00136787				AU; H	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2195	56) Nucynta Hotsheet Deep Dive 071610.pdf	JAN-OK-00136791				AU; H	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2196	Hotsheet april 30.pdf	JAN-OK-00137217				AU; H	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2197	FW: Week 66 - Nucynta Hotsheet - 9/24/2010	JAN-OK-00137307				AU; H	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2198	66) Nucynta Hotsheet 092410.pdf	JAN-OK-00137310				AU; H	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2199	66) Nucynta Hotsheet Deep Dive 092410.pdf	JAN-OK-00137314				AU; H	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2200	Hotsheet april 30.pdf	JAN-OK-00141380				AU; H	12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2201	Cephalon - Tamper Resistant Strategy	TEVA_OK_00600827				AU; LF	
S-2202	Pharmacovigilance Agreement Between Purdue Pharma, L.P. and Teva Branded Pharmaceutical Products R&D, Inc.	TEVA_OK_01996235				AU; LF; J-MIL-7; T-MIL-4; R; PRE	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2203	Quality Agreement Between Purdue Pharma L.P. and Teva Pharmaceuticals USA, Inc.	TEVA_OK_02777512				AU; LF; J-MIL-7; T-MIL-4; R; PRE	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2204	Distribution Agreement by and between Purdue Pharma L.P. and Teva Pharmaceuticals USA, Inc.	TEVA_OK_03321424				AU; LF; J-MIL-7; T-MIL-4; R; PRE	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2205	Cephalon - Chronic Pain Overview and Buying Process	TEVA_OK_00048420				AU; LF	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2206	Draft Meeting Minutes from Actiq DDMAC Meeting	TEVA_OK_00107329				AU; LF; J-MIL-10	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2207	Fentora - Safe Opioid Prescribing Today and Tomorrow	TEVA_OK_00120631				AU; LF	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802

S-2208	Cephalon Letter to Thomas Abrams, Director of Division of Drug Marketing re Actiq & Cephalon's Acknowledgment of DDMAC Meeting Minutes	TEVA_OK_00350820				AU; LF; J-MIL-10	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2209	American Pain Foundation - Pain Care Bill of Rights	TEVA_OK_00518164				AU; LF	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2210	Cephalon - Fentora sNDA Support Data - US Commercial Plans for Fentora Advisory Committee PowerPoint	TEVA_OK_03147486				AU; LF	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2211	Caring for Patients with Persistent and Breakthrough Pain - A Case-Based Dialogue for Nurses	TEVA_OK_01474118				AU; LF; R; PRE	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2212	Cephalon - Pain Management: Understanding Opioids and Managing Their Risks, Overview of Responsible Prescribing PowerPoint	TEVA_OK_02511810				AU; LF	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2213	Fentora 90 Day Plan "Growth from the Inside Out" September 8-10, 2008, Phoenix, CA	TEVA_OK_00050167				AU; LF	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2214	Fentora - Marketing Plan 2007	TEVA_OK_00064909				AU; LF	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2215	2004-2007 Incident log and cover email	TEVA_OK_04848110 & TEVA_OK_04848112				AU; LF; R; PRE	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2216	Transmittal of Advertisements and Promotional Labeling for Drugs and Biologics for Human Use	TEVA_OK_00010858				AU; LF	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2217	Pain Products Learning System Actiq Regional Consultants Meeting, October 24-October 26, 2003, Faculty Panel Discussion, Windsor Court Hotel, New Orleans, Louisiana Prepared by Pallio Communications	TEVA_OK_00026735				AU; LF; R; PRE	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2218		TEVA_OK_01289565				AU; LF; R; PRE	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802

S-2219	rpt FAQ List excel sheet	TEVA_OK_02761679			AU; LF	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2220	A Pain Primer - pain assessment	TEVA_OK_03810011			AU; LF; R; PRE; 2701; PR	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2221	Email from Denis Connelly re letstalkpain website	TEVA_OK_04717258			AU; LF; R; PRE	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2222	Abuse-Deterrent State Media Plan	TEVA_OK_07846236			AU; LF; R; PRE	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2223	Email from Timothy Bannon to Burt Rosen re Israeli Maker of Oxycotin May Buy Rival	PPLPC032000034989	PPLPC0320000034991		AU; H; R; PRE; CON; CU; LF; J-MIL-7; T-MIL-4	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2224	Actiq SWOT Analysis Managed Care Perspective	TEVA_OK_05507082			AU; LF; R; PRE	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2225	Cephalon - FEBT 2005-2006 Marketing Plan	TEVA_OK_00039664			AU; LF	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2226	Teva Unbranded Education Initiative on Pain Management - Readiness & Launceh Recommendation	TEVA_OK_08262919			AU; LF	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2227	Email from Dean Robinson re ACTIQ Opioid Glossary	TEVA_OK_01515753			AU; LF; J-MIL-12; R; PRE	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2228	Cephalon, Inc. Compliances Investigations and Disciplinary Actions Report	TEVA_OK_04848111			AU; LF; J-MIL-12; R; PRE	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2229	Sales Operations - Pain myCP Results	TEVA_OK_00100238			AU; LF; J-MIL-12; R; PRE	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2230	Decision Resources Group - Market Overview, Oklahoma City	TEVA_OK_00956835			AU; LF; R; PRE	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2231	Email from Deborah Bearer re Fentora exception - question	TEVA_OK_01933816			AU; LF; T-MIL-6	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802

S-2232	2004 Actiq Marketing, POA Meeting	TEVA_OK_01876775				AU; LF; INC; R; PRE; CON	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2233	Employee Self Appraisal - Robert A Host	TEVA_OK_06692815				AU; LF; J-MIL-12; R; PRE	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2234	Email from Penny Levin re Slides on behalf of Purdue Pharma to FDA for Palladone RMP	TEVA_OK_07854792				AU; LF; J-MIL-7; T-MIL-4; R; PRE	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2235	Fentora Program Spreadsheet	TEVA_OK_00017421				AU; LF; J-MIL-12; R; PRE	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2236	Email from Margaret Lagarde re APS Grant Request and APS CME Scientific Symposium Grant Request	TEVA_OK_00517066				AU; LF; J-MIL-12; R; PRE	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2237	372 Fentora Targeting Spreadsheet Redline letter re Fentora and a recent report received by Cephalon re a suspected prescribing error	TEVA_OK_01222473				AU; LF; J-MIL-12; R; PRE	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2238	Draft letter re a report received by Cephalon concerning the use of ACTIQ outside of its FDA- approved indication	TEVA_OK_09348497				AU; LF; INC	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2239		TEVA_OK_09348495				AU; LF; INC	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2240	Email from Arvind Narayana re Fentora Intervention Letter	TEVA_OK_09348462				AU; LF	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2241	Email from James Stephens re ACTIQ RMP Repeat (RPT) Off-Label Prescriber List	TEVA_OK_06842243				AU; LF; J-MIL-12; R; PRE	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2242	ACTIQ RMP Repeat (RPT) Off-Label Prescribers - Parexel	TEVA_OK_06842245				AU; LF; J-MIL-12; R; PRE	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2243	Corporate Views - Oxycontin by Theme	PKY183219207	PKY183219250			R; PRE; CON; CU; AU; H; PRE; LF; J-MIL-7; T-MIL-4	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2244	OxyContin Budget Plans	PKY183222319	PKY183222498			R; PRE; CON; CU; AU; H; PRE; LF; J-MIL-7; T-MIL-4	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802

S-2245	Statement of United States Attorney John Brownlee on the Guilty Plea of the Purdue Frederick Company and its Executives for Illegally Misbranding Oxycontin					AU; H; R; PRE; CON; CU; LF; J-MIL-7; T-MIL-4	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2246	Letter to Ami Patterson re February 13 & 16, 2001 Work Session	PKY181944411		PKY181944411		R; PRE; CON; CU; AU; H; PRE; LF; J-MIL-7; T-MIL-4	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2247	OxyContin 2012 ACAM Part II	PKY183117966				R; PRE; CON; CU; AU; H; PRE; LF; J-MIL-7; T-MIL-4	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2248	Email fro mCraig Landau re FDA Meeting Request - Draft	PDD8901705096		PDD8901705098		AU; H; R; PRE; CON; CU; LF; J-MIL-7; T-MIL-4	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2249	Letter to Dr. Sample from Purdue representative re opioid addiction	PKY180116784		PKY180116784		R; PRE; CON; CU; AU; H; PRE; LF; J-MIL-7; T-MIL-4	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2250	Memorandum to Friedman, Raymond & Mortimer Sackler, and Udell re Blowing the whistle on Purdue Pharma's crimes against humanity	PDD9316317899		PDD9316317935		AU; H; R; PRE; CON; CU; LF; J-MIL-7; T-MIL-4	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2251	Warning Letter to Michael Friedman re dissemination of promotional materials for the marketing of OxyContin	PKY181434198		PKY181434205		First Amendment; AU; H; R; PRE; CON; CU; LF; J-MIL-7; J-MIL-12; T-MIL-1; T-MIL-4	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2252	Texas Medical Association slides on pain, opioids and addiciton, with notes	PKY180932965		PKY180932974		AU; H; R; PRE; CON; CU; LF; J-MIL-7; J-MIL-12; T-MIL-1; T-MIL-4	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2253	Expert Report of Donald Marks	PKY183254864		PKY183254877		R; PRE; CON; CU; AU; H; PRE; LF; J-MIL-7; J-MIL-12; T-MIL-1; T-MIL-4; T-MIL-9	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2254	Expert Report of Leonard G. Schifrin, Ph.D.	PKY183225270		PKY183225304		AU; H; R; PRE; CON; CU; LF; J-MIL-7; J-MIL-12; T-MIL-1; T-MIL-4; T-MIL-9	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2255	Expert Report of Seymour Ehrenpreis, Ph.D.	PKY183263272		PKY183263303		AU; H; R; PRE; CON; CU; LF; J-MIL-7; J-MIL-12; T-MIL-1; T-MIL-4; T-MIL-9	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2256	New Drug Application Documents for OxyContin	PKY183238359		PKY183238428		AU; H; R; PRE; CON; CU; LF; J-MIL-7; J-MIL-12; T-MIL-1; T-MIL-4; T-MIL-9	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802

S-2257	Memo: June Sales Review, "It's Bonus Time in the Neighborhood"	PKY181707388	PKY181707389		R; PRE; CON; CU; AU; H; PRE; LF; J-MIL-7; J-MIL-12; T-MIL-1; T-MIL-4	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2258	Deposition Transcript of Richard Sackler in Endo Pharmaceuticals case	PKY183395881	PKY183396033		AU; H; R; PRE; CON; CU; LF; J-MIL-7; J-MIL-12; T-MIL-1; T-MIL-4	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2259	Email from Mortimer Sackler, Jr. re Rhodes Presentation Draft	PDD99316305345	PDD99316305348		AU; H; R; PRE; CON; CU; LF; J-MIL-4; J-MIL-7; T-MIL-1; T-MIL-4	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2260	Sales Bulletins to Sales Force re Bonuses	PDD99316727523	PDD99316727526		AU; H; R; PRE; CON; CU; LF; J-MIL-7; J-MIL-12; T-MIL-1; T-MIL-4	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2261	OKC District Meeting	PKY182731998	PKY182732002		AU; H; R; PRE; CON; CU; LF; J-MIL-7; J-MIL-12; T-MIL-1; T-MIL-4	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2262	Criticisms and Allegations Potentially Requiring a Response in Connection with the Senate Finance Committee Inquiry	PPLP004096920	PPLP004096974		First Amendment; Nuisance Statute's Safe-harbor; Preemption; R; PRE; CON; CU; AU; H; R; PRE; LF; J-MIL-7; J-MIL-12; T-MIL-1; T-MIL-4	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2263	Email from Robert Kaiiko to Richard Sackler re Oxycontin	PDD99316706209	PDD99316706213		R; PRE; CON; CU; AU; H; PRE; LF; J-MIL-7; J-MIL-12; T-MIL-1; T-MIL-4	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2264	Purdue's summary of teleconference with FDA to discuss an upcoming (May 30-31, 2012) sponsored public workshop on the analgesic treatment of chronic pain	PPLPC001000104972	PPLPC001000104972		AU; H; R; PRE; CON; CU; LF; J-MIL-7; J-MIL-12; T-MIL-1; T-MIL-4	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2265	Notes by Sales Rep John Walters re oxy for patients of Don Choi after visit	PKY182172557	PKY182172557		AU; H; R; PRE; CON; CU; LF; J-MIL-7; J-MIL-12; T-MIL-1; T-MIL-4	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2266	Notes by Sales Rep John Walters re oxy discussion with Dr. Nancy Kravant Gornish	PKY182232578	PKY182232578		AU; H; R; PRE; CON; CU; LF; J-MIL-7; J-MIL-12; T-MIL-1; T-MIL-4	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2267	Notes by Sales Rep Kathryn Florance re oxy after visit with Dr. John McDonald	PKY182249160	PKY182249160		AU; H; R; PRE; CON; CU; LF; J-MIL-7; J-MIL-12; T-MIL-1; T-MIL-4	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2268	Notes by Sales Rep Jennifer Astorino-Bozzo re oxy after visit with Diptika Patel	PKY182309787	PKY182309787		Judicial Estoppel; R; PRE; CON; CU; AU; H; R; PRE; LF; J-MIL-7; J-MIL-12; T-MIL-1; T-MIL-4; T-MIL-6	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802

S-2269	Notes by Sales Rep Brett Cooper re opioids after visit with Dr. Michael Jung	PKY182223880	PKY182223880	PKY182223880	AU; H; R; PRE; CON; CU; LF; J-MIL-7; J-MIL-12; T-MIL-1; T-MIL-4	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2270	2001 Budget Plan (full)	PKY181678793	PKY181678793	PKY181678846	R; PRE; CON; CU; AU; H; PRE; LF; J-MIL-7; J-MIL-12; T-MIL-1; T-MIL-4	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2271	Purdue Quarterly Magazine: The Road Ahead - "Foundaers Reflect on a Record Year and Future Prospects"	PKY181103962	PKY181103962	PKY181103973	AU; H; R; PRE; CON; CU; LF; J-MIL-7; J-MIL-12; T-MIL-1; T-MIL-4	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2272	"Protecting Purdue, Providers, and Patients" - Managing Purdue's Public Exposure	PKY182000431	PKY182000431		R; PRE; CON; CU; AU; H; PRE; LF; J-MIL-7; J-MIL-12; T-MIL-1; T-MIL-4	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2273	Purdue Memorandum to Tim Richards re Kansas/Oklahoma Update	PPLPC028000074980	PPLPC028000074980	PPLPC028000074981	First Amendment; AU; H; R; PRE; CON; CU; LF; J-MIL-7; T-MIL-1; T-MIL-4	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2274	Purdue 10-Year Plan	PKY180019174	PKY180019174	PKY180019212	AU; H; R; PRE; CON; CU; LF; J-MIL-7; J-MIL-12; T-MIL-1; T-MIL-4	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2275	Oxycodone 2008 breakdown by state	PPLPC041000011901	PPLPC041000011901	PPLPC041000011901	AU; H; R; PRE; CON; CU; LF; J-MIL-7; J-MIL-12; T-MIL-1; T-MIL-4	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2276	The Abuse and Diversion Detection Program ("ADD Program") Presentation	PPLPC041000011886	PPLPC041000011886	PPLPC041000011886	AU; H; R; PRE; CON; CU; LF; J-MIL-7; J-MIL-12; T-MIL-1; T-MIL-4	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2277	IMS Curbing Prescription Drug Abuse, One State at a Time PowerPoint	PPLPC041000011900	PPLPC041000011900	PPLPC041000011900	AU; H; R; PRE; CON; CU; LF; J-MIL-7; J-MIL-12; T-MIL-1; T-MIL-4	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2278	Butrans - Commercial Strategy Plan Board Presentation July 22, 2010 PowerPoint	PPLPC041000011173	PPLPC041000011173	PPLPC041000011173	AU; H; R; PRE; CON; CU; LF; J-MIL-7; J-MIL-12; T-MIL-1; T-MIL-4	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2279	Slides FDA and SAMHSA	PPLPC041000008183	PPLPC041000008183	PPLPC041000008197	AU; H; R; PRE; CON; CU; LF; J-MIL-7; J-MIL-12; T-MIL-1; T-MIL-4	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2280	Purdue Medical Affairs: Opioid Use in Chronic Pain - Medical Research Publication Plan	PPLPC039000855685	PPLPC039000855685	PPLPC039000855685	AU; H; R; PRE; CON; CU; LF; J-MIL-7; J-MIL-12; T-MIL-1; T-MIL-4; T-MIL-10, R	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2281	Healthcare Grant Review Committee Summary Report (Grants for period: Between Jan 1, 2009 and Dec 31, 2009)	PPLPC041000012553	PPLPC041000012553	PPLPC041000012634	First Amendment; R; PRE; CON; CU; AU; H; R; PRE; LF; J-MIL-7; J-MIL-12; T-MIL-1; T-MIL-4	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802

S-2282	Healthcare Grant Review Committee Summary Report (Grants for period: Between Jan 1, 2010 and Sep 30, 2010)	PPLPC041000012635	PPLPC041000012705			First Amendment; R; PRE; CON; CU; AU; H; R; PRE; LF; J-MIL-7; J-MIL-12; T-MIL-1; T-MIL-4	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2283	Purdue - Communicator & External Affairs Committee (CEAC) PowerPoint	PPLPC041000014689	PPLPC041000014689			First Amendment; AU; H; R; PRE; CON; CU; LF; J-MIL-3; J-MIL-7; J-MIL- 12; T-MIL-1; T-MIL-4	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2284	Weekly Total Prescriptions of Branded OxyContin: Original Formulation and Reformulated OxyContin charts (IMS Health)	PPLPC041000016947	PPLPC041000016947			AU; H; R; PRE; CON; CU; LF; J-MIL-7; J-MIL-12; T-MIL-1; T-MIL-4	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2285	Draft for Discussion by PCF - Pain Care Forum Priority Recommendations to: IOM Advancing Pain Research, Care, and Education Committee	PPLPC041000017396	PPLPC041000017401			First Amendment; AU; H; R; PRE; CON; CU; LF; J-MIL-3; J-MIL-7; J-MIL- 12; T-MIL-1; T-MIL-4	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2286	Letter to John Stewart of Purdue Pharma from Grassley and Baucus re marketing and epidemic	PPLPC041000022154	PPLPC041000022158			AU; H; R; PRE; CON; CU; LF; J-MIL-7; J-MIL-12; T-MIL-1; T-MIL-4	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2287	Communications and External Affairs Committee May 29th, Minutes/Action Items Pending	PPLPC041000022328	PPLPC041000022333			First Amendment; AU; H; R; PRE; CON; CU; LF; J-MIL-3; J-MIL-7; J-MIL- 12; T-MIL-1; T-MIL-4	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2288	Tables Produced with Purdue's 12-21- 18 Interrogatory Response					AU; H; R; PRE; CON; CU; Not Produced / Cannot Be Located	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2289	OxyContin Pediatric Program Chronology	PPLPC041000025431	PPLPC041000025431			AU; H; R; PRE; CON; CU; LF; J-MIL-7; J-MIL-12; T-MIL-1; T-MIL-4	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2290	Opioids and Chronic Pain Treatment by Steven d. Feinberg, D of the American Board of Pain Medicine	PPLPC041000025604	PPLPC041000025611			First Amendment; AU; H; R; PRE; CON; CU; IC; INC; LF; J-MIL-3; J-MIL- 7; J-MIL-12; T-MIL-1; T-MIL-4; T-MIL- 9	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2291	Total OxyContin Accounts in COT 13 (VA Hospitals & Outpatient Facilities) and COT 18 (State Veterans' Homes) in Descending Order of # of Pills; Annual Totals 2008-2012 Full Year, 2013 YTD November	PPLPC041000032914	PPLPC041000032914			AU; H; R; PRE; CON; CU; LF; J-MIL-7; J-MIL-12; T-MIL-1; T-MIL-4	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802

S-2292	Email from David Haddox re Public session comments - another approach	PPLPC041000055744	PPLPC041000055747			AU; H; R; PRE; CON; CU; LF; J-MIL-7; J-MIL-12; T-MIL-1; T-MIL-4	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2293	"Purdue Pharma LP Conducting childrne's trial of OxyContin" - CBS News					AU; H; R; PRE; CON; CU; J-MIL-7; T-MIL-1; T-MIL-4	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2294	ClinicalTrials.gov "Safety of Twice Daily Oxycodone Hydrochloride Controlled-release Tablets in Children with Moderate to Severe Malignant and/or Nonmalignant Pain Requiring Opioids"					AU; H; R; PRE; CON; CU; J-MIL-5 J-MIL-7; J-MIL-12; T-MIL-1; T-MIL-4; T-MIL-9	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2295	Phase IV OxyContin Tablets Team Memo to Distribution from E. Ingber/L. Harrison re Phase IV OxyContin Tables Team Meeting	PDD9316706342	PDD9316706343			First Amendment; AU; H; R; PRE; CON; CU; LF; J-MIL-7; J-MIL-12; T-MIL-1; T-MIL-4	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2296	Email from Richard Sackler re Oxycontin - Meeting with DEA/FDA	PDD9316706404	PDD9316706410			First Amendment; AU; H; R; PRE; CON; CU; LF; J-MIL-7; J-MIL-12; T-MIL-1; T-MIL-4	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2297	Memo to Field Sales re Abbott and Oxycontin co-promotion agreement	PKY180244877	PKY180244878			AU; H; R; PRE; CON; CU; LF; J-MIL-7; J-MIL-12; T-MIL-1; T-MIL-4	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2298	Memo to Entire Field Force from Jim Lang re Abbott and Oxycontin co-promotion agreement (redacted)	PKY180244891	PKY180244894			AU; H; R; PRE; CON; CU; LF; J-MIL-7; J-MIL-12; T-MIL-1; T-MIL-4	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2299	1996 National Sales Meeting Video-Conference Discussion May 11, 1995	PKY180256484	PKY180256496			AU; H; R; PRE; CON; CU; LF; J-MIL-7; J-MIL-12; T-MIL-1; T-MIL-4	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2300	Letter to Senator Dodd from Howard Udell re OxyContin tablets	PKY181046067	PKY181046072			AU; H; R; PRE; CON; CU; LF; J-MIL-7; J-MIL-12; T-MIL-1; T-MIL-4; T-MIL-10, R	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2301	East Central Region - DM Tip from Lynn Sipe, Pittsburgh District Manager - "Leading with Your Chin?"	PKY181944620	PKY181944620			AU; H; R; PRE; CON; CU; LF; J-MIL-7; J-MIL-12; T-MIL-1; T-MIL-4	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2302	Email from Mary Myers re PEI Performance	PKY181979083	PKY181979083			AU; H; R; PRE; CON; CU; LF; J-MIL-7; J-MIL-12; T-MIL-1; T-MIL-4	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802

S-2303	Email from Russell Gadia re OxyContin touted as virtually nonaddictive, newly released state records show	PKY182569175	PKY182569178			R; PRE; CON; CU; AU; H; PRE; LF; J-MIL-7; J-MIL-12; T-MIL-1; T-MIL-4	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2304	Purdue - OxyContin 2014 ACAM presentation	PPLP003420643	PPLP003420729			AU; H; R; PRE; CON; CU; LF; J-MIL-7; J-MIL-12; T-MIL-1; T-MIL-4	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2305	I Got My Life Back Part II - a Two Year Follow-up of Patients in Pain	PKY180121478	PKY180121481			R; PRE; CON; CU; AU; H; PRE; LF; J-MIL-7; J-MIL-12; T-MIL-1; T-MIL-4	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2306	Sales Bulletin to Entire Field Force from Jim Lang re Purdue Pharma's Position on Abuse and Diversion of OxyContin Tablets	PKY180144872	PKY180144879			AU; H; R; PRE; CON; CU; LF; J-MIL-7; J-MIL-12; T-MIL-1; T-MIL-4; T-MIL-6	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2307	Dispelling the Myths, Counseling Your Patients, I Got My Life Back brochure (together)	PKY183219112	PKY183219131			Judicial Estoppel; R; PRE; CON; CU; AU; H; R; PRE; IC; INC; LF; J-MIL-7; J-MIL-12; T-MIL-1; T-MIL-4; T-MIL-6	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2308	Salis Letter to Connelly re NDA 20-553 Oxy Contin, in response to Purdue Pharma's submission dated April 20, 2000	PKY180297176	PKY180297180			AU; H; R; PRE; CON; CU; LF; J-MIL-7; J-MIL-12; T-MIL-1; T-MIL-4	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2309	Between Comfort and Addiction slides by Sherry Siegel, MD Purdue Pharma LP	PKY180932744	PKY180932751			AU; H; R; PRE; CON; CU; LF; J-MIL-7; J-MIL-12; T-MIL-1; T-MIL-4	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2310	OxyContin 160mg Tablet Workshop - For Training Purposes	PKY182642341	PKY182642378			AU; H; R; PRE; CON; CU; LF; J-MIL-7; J-MIL-12; T-MIL-1; T-MIL-4	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2311	Dr. Gottlieb's Remarks Delivered Before FDA's Scientific Meeting on Opioids	PPLPC032000398468	PPLPC032000398471			AU; H; R; PRE; CON; CU; LF; J-MIL-7; J-MIL-12; T-MIL-1; T-MIL-4; T-MIL-9	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2312	Speech by Scott Gottlieb, MD Commissioner of Food and Drugs, National Rx Drug Abuse and Heroin Summit, Atlanta, Georgia	PPLPC032000403670	PPLPC032000403675			AU; H; R; PRE; CON; CU; LF; J-MIL-7; J-MIL-12; T-MIL-1; T-MIL-4; T-MIL-9	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2313	Email to Craig Landau from Burt Rosen re Ohio MDL Transcript	PPLPC036000268402	PPLPC036000268402			AU; H; R; PRE; CON; CU; LF; J-MIL-7; J-MIL-12; T-MIL-1; T-MIL-4	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802

S-2314	Email from Don Kyle re Update on the Opioid Crisis Partnership Efforts	PPLPC036000271583	PPLPC036000271585			First Amendment; AU; H; R; PRE; CON; CU; LF; J-MIL-2; J-MIL-7; J-MIL-12; T-MIL-1; T-MIL-4; T-MIL-10, R	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2315	Email from Burt Rosen re Pediatric Clinical Trial Q and A	PPLPC001000216261	PPLPC001000216270			PRE; CON; CU; AU; H; R; INC; LF; J-MIL-5 J-MIL-7; J-MIL-12; T-MIL-1; T-MIL-4	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2316	Email from Burt Rosen re Senator Manchin Letter 8.24.15 & Letter to Senator Manchin from Purdue re pediatric safety and dosing information for OxyContin	PPLPC001000216982	PPLPC001000216982			First Amendment; AU; H; R; PRE; CON; CU; LF; J-MIL-3; J-MIL-7; J-MIL-12; T-MIL-1; T-MIL-4; T-MIL-10, R	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2317	Email from Burt Rosen re 2005 Objectives -Public Affairs with 2005 External Affairs Objectives	PPLPC030000351653	PPLPC030000351655			AU; H; R; PRE; CON; CU; LF; J-MIL-3; J-MIL-7; J-MIL-12; T-MIL-1; T-MIL-4; T-MIL-10, R	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2318	Purdue Pharma LP Budget Presentation 2010 - November 2nd and 3rd, 2009 Notes and Actions figure 1: top 10 drugs plus selected other prescription drugs mentioned in ED drug abuse episodes by frequency, 2001 continued	PPLPC030000506140	PPLPC030000506149			Nuisance Statute's Safe-harbor; AU; H; R; PRE; CON; CU; LF; J-MIL-7; J-MIL-12; T-MIL-1; T-MIL-4	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2319		PPLPC031000130154	PPLPC031000130154			AU; H; R; PRE; CON; CU; LF; J-MIL-7; J-MIL-12; T-MIL-1; T-MIL-4	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2320	Email from Burt Rosen to Jonathan Sackler re pulling down webiste	PPLP004300427	PPLP004300431			First Amendment; AU; H; R; PRE; CON; CU; LF; J-MIL-3; J-MIL-7; J-MIL-12; T-MIL-1; T-MIL-4	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2321	Email from Burt Rosen re Pain Care Forum Payment	POK003317326				First Amendment; AU; H; R; PRE; CON; CU; LF; J-MIL-2; J-MIL-3; J-MIL-7; J-MIL-12; T-MIL-1; T-MIL-4; T-MIL-10, R	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2322	Email from Burt Rosen re IMT Slides 4-11 with powerpoint attachment	PPLPC030000321037	PPLPC030000321037			AU; H; R; PRE; CON; CU; LF; J-MIL-3; J-MIL-7; J-MIL-12; T-MIL-1; T-MIL-4; T-MIL-10, R	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2323	Purdue - An Update on the Extended Release Oxycodone Market	PPLPC041000002795	PPLPC041000002797			AU; H; R; PRE; CON; CU; LF; J-MIL-7; J-MIL-12; T-MIL-1; T-MIL-4	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802
S-2324	Endo, Impax, Teva Timeline	PPLPC041000003206	PPLPC041000003206			AU; H; R; PRE; CON; CU; Privileged; LF; P, J-MIL-7; J-MIL-12; T-MIL-1; T-MIL-4	12 O.S. 2401, 2402; 12 O.S. 2403; 12 O.S. 2602, 12 O.S. 2901; 12 O.S. 2802